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THE ROLE OF MICROGLIA IN ALZHEIMER'S DISEASE AND FOLLOWING
A42 IMMUNISATION
by Elina Zotova
Inammation is recognised as an important contributor to Alzheimer's disease (AD)
pathogenesis alongside extracellular deposits of amyloid  protein (A) and intraneu-
ronal deposits of hyper-phosphorylated tau protein. Microglia are the key component of
innate immunity within the central nervous system, and the source of inammation in
the brain. The amyloid cascade hypothesis places A at a key point in the pathogenesis
of AD. Consequently, immunisation against A is a promising experimental treatment
for AD. The current study presents a neuropathological follow-up of a unique cohort
of AD patients who took part in the active A42 immunisation clinical trial (AN1792,
Elan) and in whom reduction in A load had been observed. The hypothesis of the study
is that A42 immunisation aects the microglial activation level and prole associated
with the reduction in A.
Levels of the microglial markers indicative of specic microglial functions, the mi-
croglial receptors involved in antigen recognition and uptake, complement component
C1q, IgG, A42 and phospho-tau in the brain tissue (frontal, temporal and parietal
lobes) of immunised (n=11) and non-immunised (n=28) AD patients were analysed us-
ing immunohistochemistry. In immunised brain, a two-fold reduction in Fc receptor I
(P=0.001) and Fc receptor II (P=0.002), a ten-fold reduction in macrophage scavenger
receptor A (P <0.001), and a 40% reduction in lysosomal glycoprotein CD68 (P=0.018)
compared to non-immunised brain were observed. Similarly, A42 and phospho-tau
levels were also decreased by 80% and 40% respectively. No changes in the microglial
activation and antigen-presentation receptor HLA-DR, calcium-adapter channel Iba-1,
or the levels of IgG and C1q were detected. The load of all microglial markers, IgG and
C1q correlated with the phospho-tau load in non-immunised cases. In addition, Iba-
1 and Fc RII load inversely correlated with A42 load in the non-immunised group.
These correlations no longer held in the immunised group. Instead, a positive correlation
between the number of MSR-A positive microglial clusters and A42, and an inverse
correlation between C1q and A42 were noted in immunised AD cases.
The current study is the rst of its kind in presenting a detailed immunohistochemical
prole of microglia in human AD and following active A42 immunisation treatment.
In addition, a consistent and reproducible method for automated microscopy image
analysis was developed as part of this project contributing to research methodologies.
The results support the changes in the level and prole of microglial activation implied
by the hypothesis. The data also suggest a link between immune system activation and
the tau pathology in AD. The ability of microglia to change their prole and switch
targets following stimulation by active immunisation is demonstrated in human brain.Contents
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Introduction
Alzheimer's Disease (AD) is a complex neurodegenerative disease. Currently, there are
no established early diagnosis or successful intervention methods. Through over 100
years of research, it has emerged that the immune system plays an important role in
the initiation and the progression of AD, and immunotherapy is currently considered
as the most promising approach towards combating the disease. In this thesis, the
rst detailed immunohistochemical prole of microglia (the immune cells within the
brain) is described in the context of human AD pathology and following the active
A42 immunisation (clinical trial AN1792, Elan Pharmaceuticals).
1.1 The history of Alzheimer's Disease
The 37th Conference of South-West German Psychiatrists in Tubingen, November 1906,
gave the ocial start to the history of and research into AD (Maurer et al., 1997).
Doctor Alois Alzheimer from the Munich Royal Psychiatric Clinic presented clinical and
neuropathological observations on one of his patients, Auguste Deter, from the Hospital
for the Mentally Ill and Epileptics, Frankfurt am Main. The full version of the lecture
was published the next year under the title \A characteristic serious disease of the
cerebral cortex" (Alzheimer, 1907). A more detailed article with illustrations based on
the rst Alzheimer's patient was published by Perusini upon Alzheimer's suggestion in
1909 (Perusini, 1909). Although two other cases with similar observations were known
at the time (Bonglio, 1908; Fischer, 1907), the disease was named after Alzheimer by
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Professor Emil Kraepelin, the director of the Clinic in Munich, in the 8th edition of his
Handbook of Psychiatry (Kraipelin, 1910).
Following Alzheimer's identication of the disease, several scientists (Fuller, Klopp
and Barrett) continued his research with numerous brain examinations and autopsies,
but found it dicult to distinguish AD from other forms of senile dementia. Despite
this, AD was separated from the older category of senile dementia and accepted as a
diagnostic category (Holstein, 1997; Beach, 1987).
Despite this, senility and dementia continued to be considered as part of the aging
process. The percentage of elderly population in the early 1900s was much lower than
today, the occurrence of cases was relatively rare and the diculty of separating AD
from general dementia meant that the interest in the disease was limited to a handful
of scientists. The nineteenth century faced diseases with higher death rates. Infec-
tious diseases pneumonia, tuberculosis, diaorrhea and enteritis were the leading cause
of death at the time (Centers for Disease Control and Prevention, Morbidity and Mor-
tality Weekly Report \Achievements in Public Health, 1900-1999: Control of Infectious
Diseases", 1999). Finding cures for these diseases took priority. It was not until the
late 1940s that the interest in mental health started to grow again. Life expectancy was
rising, the proportion of the elderly population in the developed world was increasing,
and standards of health services improved. By the 1970s AD started to raise concerns.
Gradually, AD was accepted as a disorder rather than a natural function of aging. In
1980 the Alzheimer's Association was founded, followed by the Alzheimer's Research
Trust in the early 1990s (Alzheimer's Research UK from 2010). Age is no longer viewed
as the only and inevitable reason for the development of dementia. The growing costs
of long-term patient care contribute to the increased demand for nding a cure from, or
ways to slow down the development of dementia (Olesen et al., 2012). To date, AD has
become recognised as a leading cause of dementia and disability among the elderly.
The disease aects as many as 12 million individuals worldwide and accounts for 50-
80% of all dementia cases (Alzheimer's Association, http://www.alz.org/alzheimers_
disease_what_is_alzheimers.asp). In UK alone 820,000 individuals are aected,
costing UK economy 23 billion per year (Alzheimer's Research UK Dementia statistics
report, http://www.alzheimersresearchuk.org/siteFiles/resources/documents/
ARUK_Dementia_statistics.pdf). Although research into AD greatly improved ourChapter 1. Introduction 3
knowledge of the disease and continues to stimulate the development of dierent treat-
ment approaches with many clinical trials currently underway, to date there is still no
cure against AD.
1.2 Clinical features of AD
The le of Auguste Deter, found 90 years after her death in the archives of the Hospital
in Frankfurt, presented the rst documented record of clinical and pathological signs
of the disease identied by Alzheimer, and the methods of assessment he used (Maurer
et al., 1997).
The rst symptoms exhibited by 51 year old Auguste were an unfounded jealousy
directed at her husband and problems with memory. This progressed to disorientation
and confusion in familiar surroundings, and diculty in reading and writing (Maurer
et al., 1997). Auguste was able to recognise objects she was given, but could not recall
them a moment later. She showed indierence to her surroundings most of the time,
with unfounded episodes of sudden extreme agitation. She was unable to answer simple
questions about herself, or write her own name. \I have lost myself" is the phrase she
used and it is often quoted from her le when perception of the disease by the patient
is summarised. Hallucinations appeared at the later stage and, eventually, Auguste lost
ability and incentive to care for herself. She died in 1906, of overwhelming infections
from bedsores and pneumonia.
The clinical features observed in Auguste match the signs that are commonly ob-
served in the patients, who are given the diagnosis of Alzheimer's disease based on
cognitive assessment today. The clinical diagnostic criteria (McKhann et al., 2011)
and the warning signs advised by the Alzheimer's Association (http://www.alz.org/
alzheimers_disease_what_is_alzheimers.asp#symptoms) include the following:
 Memory loss
 Diculty performing familiar tasks
 Problems with language
 Disorientation to time and place4 Chapter 1. Introduction
 Poor or decreased judgment and physical impairment
 Problems with abstract thinking
 Misplacing objects
 Extreme and unfounded changes in mood or behaviour (agitation, depression,
anger)
 Changes in personality
 Loss of initiative
Alzheimer's disease is dicult to diagnose precisely based on cognitive assessment,
as a number of conditions can cause these symptoms. Diagnostic criteria have been
developed by dierent organisations to aid the diagnosis. The National Institute of
Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease
and Related Disorders Association (NINCDS-ADRDA) criteria are the most widely ac-
cepted and used in practice. These criteria identify eight cognitive domains (memory,
language, perceptual skills, attention, constructive abilities, orientation, problem solv-
ing and functional abilities) that may be aected by AD. Based on information about
the patient regarding history of systemic disorders, cerebro-vascular disease, parkinson-
ism, depression, and following the neuropsychological assessment asking the patient to
perform simple calculations, clock and language tests, and physical examination, a clin-
ical diagnosis of possible or probable AD is assigned. Mini Mental State Examination
(MMSE, (Folstein et al., 1975)) is a basic neuropsychological assessment used for this
purpose. Consortium to Establish a Registry for Alzheimer's Disease (CERAD) also has
guidelines for both clinical/neropsychological and neuropathological assessments (Mor-
ris et al., 1989). Following a clinical assessment, the dementia rating scale is used and a
diagnostic impression of either AD alone, AD associated with other disorders or non-AD
dementia is proposed. In the most recent version of Diagnostic and Statistical Manual
of Mental Disorders (DSM-V), the American Psychiatric Association places AD into the
category of major neurocognitive disorders (Jeste et al., 2010). Two other categories
include delirium and minor neurocognitive disorder (also known as mild cognitive im-
pairment, MCI). Each category is identied based on the assessment of six cognitive
domains: complex attention, executive ability, learning and memory, language, visuo-
constructional perceptual ability, and social cognition. The DSM-V provides details ofChapter 1. Introduction 5
examples of assessments and symptoms to aid the diagnosis. The recognition of MCI
as a separate category demonstrates an improvement in understanding of the progres-
sion of AD. It has been suggested that MCI precedes the clinical manifestation of AD,
being a prodromal stage, during which the short-term memory may be impaired, but
the ability to maintain day-to-day independent functioning remains intact. Although
approximately 12-15% of MCI subjects progress to AD per year (Jeste et al., 2010), the
mechanism of conversion from MCI to AD is currently unknown.
The clinical diagnosis of AD has to be conrmed by the neuropathological assessment
post-mortem using brain autopsy guidelines (Hyman and Trojanowski, 1997; Hyman
et al., 2012).
1.3 Pathological features of AD
After Auguste Deter's death, Alzheimer performed histopathology of her brain using
techniques available to him at the time: Bielschowsky (silver), Nissl, Weigert (glia),
Herxheimer and Mann staining (Graeber et al., 1998). The features he identied are
still used in diagnostic criteria of the disease when performing post-mortem assessment.
Pathological features observed in the brain of patients with AD include the following:
 Senile plaques, described by Alzheimer as
\Numerous small miliary foci [are] found in the superior layers. They
are determined by the storage of a peculiar material in the cortex"
(Maurer et al., 1997), Figure 1.1.
This \peculiar material" has since been identied as solid aggregates of 4kDa
amyloid peptide, A, 40-42 amino acids in length derived from the transmem-
brane amyloid precursor protein (APP) (Glenner and Wong, 1984a,b; Masters
et al., 1985; Kang et al., 1987; Roher et al., 1993). APP is cleaved by enzymes
  and   secretases producing soluble APP species and carboxyl-terminus in-
tramembrane fragments. The carboxyl fragment of the   secretase cleavage can
be further cut by   secretase, generating brils of carboxyl-terminal fragments of
A40-42 (Walter et al., 2001). Production of A brils via endosomal-lysosomal6 Chapter 1. Introduction
Figure 1.1: Bielschowsky-stained example of an amyloid plaque from the cerebral
cortex of Auguste D, magnication 63 (Graeber et al., 1998).
recycling pathway has also been suggested (Koo and Squazzo, 1994). APP pro-
cessing independent of - and -secretases generating 17-18 kDa N-terminal APP
fragments regulated by protein kinase C has also been recently proposed (Vella
and Cappai, 2012).
APP has been suggested to play a role in the broad spectrum of neuronal processes
(Muller et al., 2012). Its suggested functions include acting as a cholesterol sensor
and transporter (Beel et al., 2008), and being involved in synaptic vesicles turnover
(Kohli et al., 2012) and axonal cytoskeleton organisation (Song and Pimplikar,
2012).
The plaques are classied as either neuritic or diuse (D'Andrea and Nagele, 2002).
Neuritic plaques are characterised by a dense amyloid core surrounded by dys-
trophic neurites, microglia and astrocytes. Diuse plaques are more amorphous,Chapter 1. Introduction 7
lack neurites and cores. Plaques are found primarily in frontal, temporal and
parietal areas of the brain, but not so much in motor-sensory cortex (CERAD,
2003).
 Neurobrillary tangles (NFTs). These are intracellular structures of paired helical
laments of tau protein, found mainly in the cell body and apical dendrites of
neurons. Alzheimer gave a very detailed and precise description to tangles, both
in words and in drawings (Figure 1.2) (Maurer et al., 1997):
\In the centre of an otherwise almost normal cell there stands out
one or several brils due to their characteristic thickness and peculiar
impregnability."
Figure 1.2: Bielschowsky-stained example of a neurobrillary tangle from the cerebral
cortex of Auguste D, magnication 63 (Graeber et al., 1998).
It is now established that tau protein that composes the tangles is in its hyper-
phosphorylated form, i.e. irreversibly phosphorylated in contrast to being in dy-
namic changing state (Roher et al., 1988; Homann et al., 1997). This aects the
main physiological function of tau (molecular transport along axons and dendrites
through binding to microtubules) and results in formation of tangles (Drechsel8 Chapter 1. Introduction
et al., 1992). Abnormal phosphorylation of tau weakens its anity for micro-
tubules, potentially leading to its detachment from them and formation of intra-
cellular aggregates.
NFTs are not specic to AD. Some areas of the brain (e.g. hippocampus) of
normal aged individuals often contain NFTs. NFTs are also a feature of a variety
of other conditions, e.g. progressive supranuclear palsy (PSP) and frontotemporal
dementia (FTD). However, they are an important marker of the AD pathology as
their density parallels the duration of AD and the severity of dementia (Arriagada
et al., 1992; Bierer et al., 1995; Nagy et al., 1995; Braak and Braak, 1998). Six
stages have been distinguished by Braak & Braak according to the location and
the severity of the neurobrillary pathology, with stages I-II assigned to \clinically
silent cases", stages III-IV - to AD at early stages of development, and stages V-
VI demonstrating the fully-developed AD (Braak and Braak, 1998). This staging
approach (referred to as \Braak stage") has been adopted and is now used routinely
for post-mortem diagnosis of AD.
The recently updated National Institute on Aging-Reagan criteria, originally pro-
posed in 1997, now advise to take into account the Braak staging of NFTs along
with A deposits and neuritic plaque score (set out by CERAD) when conrming
the diagnosis of AD at autopsy (Montine et al., 2012).
 Neuropil threads - thread-like structures in neuropil of grey matter that stain
positively for tau and are often associated with dendrites and axons of NFT-
positive neurons.
 Cerebral amyloid angiopathy (CAA) - A deposition in the walls of arteries and
arterioles of the cortex and leptomeninges. A variable degree of CAA is present in
virtually all AD cases.
 Gliosis and signs of elevated inammation characterised by the presence of acti-
vated cells of immune system within the central nervous system (CNS), microglia,
and inammatory signalling proteins, cytokines. Although Alzheimer observed
gliosis in both grey and white matter of his patient's brain using Nissl staining,
the attention to inammatory changes in AD was not paid until the late 1980s
(Grin et al., 1989), and it is only recently that signs of inammatory processes
in AD started to be addressed and recognised as a feature of the disease.Chapter 1. Introduction 9
 Synaptic damage and neuronal loss - these are the ultimate and most consistent
hallmarks of the disease that correlate with clinical symptoms and cognitive de-
cline, and are viewed as the consequence of all the pathological changes listed
above. Synaptic loss, manifested by alterations in the levels of pre- and post-
synaptic proteins and synaptic vesicles, strongly correlates with the level of cogni-
tive decline (Terry et al., 1991; Lassmann et al., 1992). Decreased synaptic density
also correlates with the increased signs of inammation in AD (Lue et al., 1996).
Most of the features found in AD brain are also often observed in aged brain of
individuals who did not show any signs of dementia (CFAS, 2001). However, in an AD
brain, these features are found in combination and in higher densities.
The pressing need for accurate and early diagnosis of AD stimulates the fast evolv-
ing research into biomarkers. The recently revised diagnostic criteria for dementia due
to AD, proposed by the National Institute of Ageing (NIA), include the use of sev-
eral approved biomarkers \to enhance certainty of AD pathophysiological process" as
an optional tool and for research and clinical trial purposes (McKhann et al., 2011).
These biomarkers are: positive Pittsburgh compound B (PiB) [11C] Positron Emis-
sion Tomography (PET) amyloid imaging accompanied by low A42 levels measured
in cerebrospinal uid (CSF), elevated CSF total and phosphorylated tau, decreased
18uorodeoxyglucose (FDG) uptake on PET in temporoparietal cortex, and marked
atrophy on structural magnetic resonance imaging (MRI) in medial, temporal, and pari-
etal lobes (McKhann et al., 2011). Combining clinico-neuropsychological diagnostic tests
and markers of the progressing pathology provides more accurate and early diagnosis,
which helps patients and their relatives plan future arrangements for care, as well as
providing an opportunity for taking part in clinical trials of treatments developed by
pharmaceutical companies.
1.4 Late onset AD - Risk Factors
The most common form of AD is sporadic AD with an onset at more than 65 years
of age (Alzheimer's Association, http://www.alz.org/alzheimers_disease_what_is_
alzheimers.asp). This form is also often referred to as late-onset AD.10 Chapter 1. Introduction
Age is considered to be the major risk factor (Jorm et al., 1987; Katz et al., 2011) for
developing AD. Production of A degrading enzymes, such as metalloprotease neprilysin,
and the density of insulin receptors decrease with age (Frolich et al., 1998; Farris et al.,
2007; Hellstrom-Lindahl et al., 2008; Hersh and Rodgers, 2008; Xiao et al., 2009). The
age-related reduction in expression of low-density lipoprotein receptor-related protein
1 (LRP-1) responsible for transport of A through blood-brain barrier also has been
reported (Shibata et al., 2000). Blood vessels become less elastic, which aects the
perivascular drainage pathway - one of the routes of elimination of A from the brain
(Weller et al., 1998; Preston et al., 2003; Weller et al., 2008). It is also suggested that
the aged organism produces more and deals less eectively with reactive oxygen species
due to impaired mitochondrial activity, contributing to the progression towards AD
(Swerdlow and Khan, 2004). Age-associated lower oestrogen levels in women (Paganini-
Hill and Henderson, 1994), lower testosterone and higher luteinising hormone levels in
men (Butchart et al., 2012) have been suggested to have an eect on AD risk. Immune
system changes with age are also proposed to contribute to the risk of developing AD
(Licastro et al., 2005; von Bernhardi et al., 2010).
Apolipoprotein E (ApoE) genotype is an important risk factor for sporadic AD with
allele "4 associated with higher levels of deposition of A and, therefore, increasing the
risk, while allele "2 being a protective factor (Strittmatter et al., 1993; Saunders et al.,
1993; Poirier et al., 1993; Chartier-Harlin et al., 1994; Brousseau et al., 1994; Polvikoski
et al., 1995; Coon et al., 2007; Harold et al., 2009; Corder et al., 1993). ApoE "4 is also
associated with higher level of inammation in AD brains (Egensperger et al., 1998). In
addition, recent genome-wide association studies (GWAS) identied several other genes
with common variants of smaller eect involved in lipid transport and degradation (CLU,
IDE), vesicle formation and intracellular tracking (PICALM and BIN1), and innate
and adaptive immunity (CLU, CR1, CD33, CD2AP, ABCA7, and MS4A) that may
also contribute to disease initiation and progression (Harold et al., 2009, Lambert et al.,
2009, Carrasquillo et al., 2010, Jones et al., 2010, Seshadri et al., 2010, Zou et al., 2010,
Belbin et al., 2011, Carrasquillo et al., 2011, Carrasquillo et al., 2011a, Hollingworth et
al., 2011, Hu et al., 2011, Kauwe et al., 2011, Naj et al., 2011, Schjeide et al., 2011).
Neuronal stress caused by head injuries has also been linked to the elevated levels of
A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In addition to the above factors it should be noted that AD often occurs with other
pathologies, such as cerebral infarcts, Lewy bodies, and Parkinson's disease (Gearing
et al., 1995; Holmes et al., 1999). Family history of AD particularly in a rst-degree
relative (Silverman et al., 1994), presence of cardiovascular disease (Honig et al., 2003;
Ott et al., 1999), smoking (Rusanen et al., 2011), and high-fat diet (Maesako et al.,
2011; Dasari et al., 2011; Gustaw-Rothenberg, 2009; Julien et al., 2010) have all been
suggested as possible risk factors for the development of AD.
1.5 Early onset AD
Less than 5% of all AD cases develop the disease before the age of 65, (Alzheimer's Asso-
ciation, http://www.alz.org/alzheimers_disease_what_is_alzheimers.asp). This
rare type is called the early-onset AD. It has a genetic basis. A small number of families
worldwide carry gene mutations associated with early onset AD. In this case, it is termed
the familial type AD (although late-onset AD can also have familial basis). Mutations
in APP, presenilin-1 (PS1) and presenilin-2 (PS2) genes on chromosomes 21, 14 and 1
respectively have been established to cause this type of AD (Levy et al., 1990; Goate
et al., 1991; Schellenberg et al., 1992; Sherrington et al., 1995; Levy-Lahad et al., 1995;
Rogaev et al., 1995; Li et al., 1995). Rare genetic disorders that involve duplication of
APP locus on chromosome 21 (Rovelet-Lecrux et al., 2006) also cause AD with CAA.
The early onset AD is also a feature of Down's syndrome (DS) - a genetic disorder due
to trisomy of chromosome 21 (Lemere et al., 1996).
APP mutation at codon 693 (glutamine for glutamic acid) is linked to the corre-
sponding residue 22 of A (Levy et al., 1990). This mutation was found in patients with
hereditary cerebral haemorrhage with amyloidosis (Dutch type), HCHWA-D, which is
believed to be a pathological variant of AD. This condition is characterised by deposi-
tion of amyloid mainly in cerebral vessels, as well as diuse parenchymal A lesions. In
vitro studies showed that this mutation makes A more brillogenic, although the exact
mechanism of this eect is unclear (Wisniewski et al., 1991).
APP double mutation at codons 670/671 leads to higher levels of total soluble A
(sA) peptide production (Mullan et al., 1992). SA peptide species include mainly
A1-40, but also A1-28 and A1-42. Levels of sA are elevated in AD brain preceding12 Chapter 1. Introduction
neuritic plaque formation. The eect of this mutation is assumed to be due to more
favourable interaction between -secretase and the mutated APP.
APP point mutation at codon 717 on chromosome 21 (substitution of valine for
isoleucine) produce higher proportion of longer and more hydrophobic A peptide that
extends to residue 42 (Suzuki et al., 1994; Goate et al., 1991).
With respect to presenilin gene mutations, over 100 PS1 and PS2 mutations have
been linked to familial AD (Alzheimer Research Forum http://www.alzforum.org/
res/com/mut/pre/default.asp). Presenilin protein is one of the constituents of the
enzyme - secretase. Together with - and -secretases, - secretase is involved in
processing and cleavage of APP. The products of - and - secretases include, among
other species, A, although it has been suggested that -secretase may also be implicated
in the toxicity of A aggregates (Mills and Reiner, 1999; Nunan and Small, 2000). PS
mutations are suggested to aect secretase structure and function in multiple ways that
implicate interactions of these proteases with APP and A (Weidemann et al., 2000;
Walker et al., 2005; Bentahir et al., 2006).
Age is still a risk factor for development of AD even in familial cases. Genetic stud-
ies into familial AD provided important information about the pathological processes
involved in the AD and allowed construction of numerous animal models that improved
scientic knowledge about genetic and molecular mechanisms of the disease.
1.6 Models of AD
The knowledge about pathogenesis of AD for a long time has been limited to post-mortem
observations due to the lack of a suitable model. Although studying brains of persons
who died at dierent age has enabled detailed staging of pathological changes associated
with AD (Braak and Braak, 1998), these observations do not provide clear answers
whether and which pathological features are causes, contributors or consequences of the
disease. The mechanism of the disease process is also dicult to establish from autopsy
ndings. Although some animal species show signs of AD-like brain and behaviour
with age, these are not suciently close to human pathology and therefore are dicult
to apply to humans. The information gained from genetic studies of familial AD and
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as well as to the design of animal models, which improved scientic knowledge about
the disease and lead to the development and testing of dierent treatment approaches.
Driven by the genetic studies, a number of AD animal models have been designed.
Initial attempts were made to induce expression of human APP gene in mice (Dodart
et al., 2002). The gene expression was successful, but failed to produce plaques at levels
comparable to those observed in AD brains.
The rst successful transgenic model, PDAPP (V717F), was reported in 1995 (Games
et al., 1995). This model was constructed to express a mutant version of human APP717
and showed robust AD-like pathology with plaques, dystrophic neurites, glial cells and
cytoskeletal changes. The dystrophic neurites were shown to contain phosphorylated
neurolaments. However, no NFTs were formed. Reduced overall synaptophysin im-
munoreactivity was observed, but this was not supported by neuronal loss in the AD
aected areas.
The next model was successful at reproducing early neuropathological features of AD
(Hsiao et al., 1996). Tg2576 was constructed to express human APP695 gene harbour-
ing the 'Swedish' double mutation (APPsw) driven by hamster prion protein promoter.
These mice over-express human APP, develop amyloid AD-like deposits associated with
astrocytic and microglial activity and dystrophic neurites containing hyperphosphory-
lated tau by 9-10 months of age. However, NFTs and neuronal loss or alterations in
synaptophysin immunoreactivity are not manifested in this model.
The subsequent APP-based models (APP23, TgCRND8) managed to accelerate the
development of amyloid deposits at higher levels and even demonstrated some neuronal
loss, but still lacked other important pathological features, such as NFTs (Lewis et al.,
2001; Oddo et al., 2003; Gotz et al., 2001). These models and double cross-over experi-
ments with PS1/2 transgenic mice (Tg2576-PSM146L) and ApoE knock-out mice were
useful in providing evidence for the role played by the mutations in PS1/PS2 and ApoE
genes.
Co-expression of human mutant APP and tau (TAPP and APPSW-tauVLW) pro-
duced a model that showed AD-like pathology with NFTs (Lewis et al., 2001; Ribe
et al., 2005). According to this model A or amyloid can induce formation of NFTs
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tau pathology also seems to enhance A deposition. Interestingly, it has been shown
that in APPSW-tauVLW model cell death precedes both of these pathologies and does
not correlate with amyloid burden (Ribe et al., 2005).
Double transgenic mice with PS1 and tau transgenes underlined the crucial role of
APP mutations for developing the AD-like pathology (Oddo et al., 2003).
Multiple transgene introduction by microinjecting human APPSwe and human tauP301L
into embryos of mice with PS1 mutation (PS1M14V KI) produced the 3Tg-AD (Oddo
et al., 2003a, Oddo et al., 2003b). These mice develop extracellular age- and region-
dependent A deposits and intraneuronal A reactivity prior to tangle formation colo-
calised to the same neurons, suggesting that A has the primary role in the pathogenesis
of the disease. It also demonstrated that synapse loss correlates better with cognitive
decits than either plaques or tangles. More importantly, this model showed correlation
between intracellular A and synaptic degeneration, which is detected prior to A or
tangle deposits. Further experimental work with this model proved this by showing that
in these animals episodic memory is aected rst and is correlated with intraneuronal
A accumulation. Cognitive impairments are rescued by clearance of intraneuronal A
and relapse after re-emergence of the A pathology (Billings et al., 2005).
Accelerated development of high levels of amyloid plaques and moderate neuronal
loss have been achieved in another multiple transgene model, the 5xFAD mice, that
incorporated ve of the APP and PS1 mutations found in familial AD cases (APP
K670N/M671L, I716V, and V717I, and PS1 M146L and L286V) (Oakley et al., 2006).
These mice, however, do not display tau pathology characteristic for AD.
Models that display all features of the disease, A and tau deposits as well as sub-
stantial neuronal loss and behavioral decits, have also been generated by Colton and
Wilcock and colleagues (Colton et al., 2006; Wilcock et al., 2008). These models in-
corporate human APP Swedish mutation (Tg2576) or APPSwDI mutation (which has
low levels of APP but high levels of brain A resulting in CAA-like pathology) on the
homozygous mouse nitric oxide synthase 2 (NOS2) knock-out background. These mod-
els utilise the concept of chronic neuroinammation, and the critical role of nitric oxide
(NO) at appropriate concentrations in neuronal protection. Following age-dependent
human A deposition, hyperphosphorylated mouse tau is observed in neuronal soma
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that also displays associated learning and memory decits. These models more fully
demonstrate the progression of the disease and provide conrmation for the role of neu-
roinammation in the pathogenesis of AD. Similar pathology and memory impairments
have also been reported in a mouse model that was originally developed to study the
role of neurotrophin nerve growth factor (NGF). These mice express neutralising anti-
body to NGF and show A aggregates, AT8-positive mouse tau deposition, neuronal
loss and behavioural decits at 15-17 months of age (Capsoni et al., 2000). This model
also suggests that protection of neurons is impaired in the context of the AD pathology.
All models are valuable and improve our understanding of the disease mechanism.
They provide a base for generating and testing hypotheses related to AD causes and
pathology. These models are also extensively used for testing potential new treatments
aimed at preventing or reducing A plaques in brain. They also allowed development
of various therapies against AD. It should be noted, however, that results from animal
studies, as well as from in-vitro studies, must be interpreted with caution as animals (or
cell lines) are not exposed to the mutations or pathological conditions of the disease for
as long a period of time as humans, and the eects of these conditions may not show
themselves in full (Janus and Westaway, 2001).
1.7 Current hypotheses
The two major hypotheses suggesting explanations for the AD pathology that generated
many research studies and treatment strategies are the amyloid cascade hypothesis and
the tau hypothesis. Recently, the inammation hypothesis has emerged and is becoming
accepted and taken into account as part of the AD pathogenesis.
1.7.1 Amyloid cascade hypothesis
The discovery of the A peptide as the main component of senile plaques in the 1980s and
observations from patients with early onset AD lead to generation of the amyloid cascade
hypothesis that remains one of the most prevalent explanations for neurodegeneration in
AD (Hardy and Selkoe, 2002). The hypothesis views accumulation of A as the initial
event in the complex cascade of cellular and molecular changes leading to dementia.16 Chapter 1. Introduction
Evidence supporting the hypothesis:
 Genetic cases, although rare, all have mutations of the genes responsible either for
over-production (APP genes) or alternative processing (PS genes) of APP. The
link between extra copy of the chromosome 21 containing the APP gene and the
early onset AD in DS also supports this hypothesis.
 Numerous in-vitro studies showed that A species are neurotoxic in cultured cells.
More recent of these studies, however, lead to an uncertainty as to whether brillar
or soluble A species are neurotoxic (Dahlgren et al., 2002; Walsh et al., 2002;
White et al., 2005).
 Recent studies, although initially unsuccessful, managed to show that A species
can induce tangle formation in cultured cells and in animal models (Gotz et al.,
2001; Oddo et al., 2003a).
Lack of evidence for mutations in tau genes alone leading to AD is also often used
as indirect evidence for the amyloid hypothesis.
Evidence questioning the amyloid hypothesis:
 Although some studies found that levels of both A40 and A42 correlated with
the cognitive decline in post-mortem analysis of the brain tissue from patients
with mild to moderate dementia rating (Naslund et al., 2000), longitudinal clini-
copathological studies show that amyloid burden alone does not correlate with the
duration of illness in patients with AD (Lowe et al., 2008).
 As described in the previous section (1.6), in mouse models of AD, genetic A
induction alone failed to induce tangle formation or signicant neuronal loss.
Opinions on the ultimate cause of neurodegeneration in AD are now moving away
from suggestions that amyloid aggregates block the synapses, towards accepting that
soluble and/or oligomeric A species are more neurotoxic than insoluble plaques (Walsh
et al., 2002).
Despite its pitfalls, the amyloid hypothesis generated extensive valuable research
work, which lead to the development of disease-modulating treatments (see Section 1.9)
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1.7.2 Tau hypothesis
Like A, tau is an essential pathological feature of an AD brain. Research into tau
function, therefore, is important for understanding the disease processes. However, just
like the amyloid hypothesis, the tau hypothesis is limited by isolation of one patholog-
ical feature from the rest of the complex disease processes, rather than accepting their
synergistic eect on the whole organism.
Evidence supporting the tau hypothesis:
 The numbers of NFTs correlate with dementia progression (Nagy et al., 1995).
 Tangle formation and accumulation is particularly observed in the areas critical
for memory - the cognitive ability that is usually impaired early in the onset of
the disease (Braak and Braak, 1998).
 Observation of 'ghost neurons' - extracellular NFTs in the shape of neurons sug-
gests that it is tau that causes the neuronal death by eventually occupying most
of the cell body and causing cell lysis.
Evidence questioning the hypothesis:
 Tau mutations alone do not lead to AD, but cause frontotemporal dementia with
parkinsonism and no amyloid deposition. This suggests that tau accumulation does
not cause amyloid deposition, and tau tangles in AD are more likely to appear after
amyloid (Lewis et al., 2001).
 Lack of animal models that show tau accumulation leading to AD-like pathology.
 Transgenic mice expressing human tau (JNPL3 (P301L)) show formation of NFTs,
which increase after intracerebral injection of A (Gotz et al., 2001). Double
transgenic mice with A and tau mutations produce stronger AD-like pathology
with tangles in areas not seen in animals with only tau mutations (Lewis et al.,
2001).
As shown above, both hypotheses have their limitations, mainly due to the fact that
they are largely based on the genetic cases of the disease and animal and in vitro models.18 Chapter 1. Introduction
Familial AD is very rare and does not account for the main population of AD suerers.
With respect to animal models, it was already emphasised that most of the models
does not fully reect the disease processes and the results from these experiments are
suggestive rather than factual.
1.7.3 Inammation hypothesis
In addition to A and tau aggregates, the presence of immune-related antigens around
amyloid plaques in the brain of AD patients has been reported since the 1980s (Rozemuller
et al., 1986; Rogers et al., 1988; Grin et al., 1989). These initial observations brought
about changes to the previously assumed view of the brain as an immunologically iso-
lated organ. In the 1990s, additional ndings of activated complement factors, cytokines
and wide range of receptors in the brain of AD patients further lead to the concept of
neuroinammation (inammation in the CNS). Neuroinammation hypothesis suggests
that immunological processes in the brain are likely to be involved in the pathology of
degenerative diseases of the CNS. Table 1.1 lists signs of an altered immune response
reported in AD patients.
The role of aggregated proteins in the pathology of the disease had to be reconsidered
to account for these observations. The inammation hypothesis emerged relatively re-
cently, when it became clear that observations of altered immune processes could not be
ignored. Neuroinammation is still mainly considered to arise downstream the amyloid
formation, and suggests that A within the CNS brings about activation of immune cells
of the brain, microglia, initiating a pro-inammatory cascade that results in the release
of potentially neurotoxic substances, including cytokines, chemokines, reactive oxygen
and nitrogen species, and various proteolytic enzymes, leading to degenerative changes
in neurons (Kalaria, 1999; Akiyama et al., 2000; Eikelenboom et al., 2006; Grin, 2006).
It has also been suggested that activation of microglia may also lead to phosphorylation
of tau and formation of NFTs (Shepherd et al., 2000; Arnaud et al., 2006; Gorlovoy
et al., 2009). A dierent view has been proposed recently, which suggests that A is
an antimicrobial peptide, produced in the course of the innate immune response to a
persistent sub-acute or transient infection or a non-infectious insult, in this way placing
inammation upstream of A accumulation (Soscia et al., 2010). Either way, the in-
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Table 1.1: Signs of altered immune response in AD patients and relevant references
Signs of altered immune response References
Presence of HLA-DR (human leukocyte antigen)
or LFA-1 (leucocyte function-associated anti-
gen) positive reactive microglia around senile
plaques
Rozemuller et al. (1986);
Rogers et al. (1988); Haga
et al. (1989); Perlmutter et al.
(1992); Overmyer et al. (1999)
Increased hippocampal gene expression of major
histocompatibility complex II (MHCII) in AD
compared to high-pathology controls
Parachikova et al. (2007)
Elevated brain levels of interleukin-1 (IL-1)
and S-100 protein
Grin et al. (1989)
Presence of activated elements of classical com-
plement pathway (C1q, C3d, C4d) within dys-
trophic neurites NFTs and/or A plaques
Ishii and Haga (1984); Eike-
lenboom et al. (1989); McGeer
et al. (1989)
Upregulated mRNA levels of complement ele-
ments C1q and C9 in AD brain
Yasojima et al. (1999)
Strong IL-6 immunoreactivity around plaques
and large cortical neurons
Strauss et al. (1992)
Low levels of tumor necrosis factor  (TNF) in
brain areas with AD pathology
Lanzrein et al. (1998)
Increased levels of TNF in sera of severe stage
AD patients
Bonotis et al. (2007)
Increased levels of intracellular neuronal IL10,
interferon  (IFN) and IL12 in AD patients
compared to age-matched controls
Fiala et al. (2005)
Correlations between Mini Mental State
Examination (MMSE) scores and in vivo
imaging marker of activated microglia
[11C](R)PK11195-PET in AD patients
Edison et al. (2008)
pathogenesis of AD and gave rise to extensive research into the cells involved in their
regulation - microglia, astrocytes and T lymphocytes, and their eect on the neuronal
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The inammation hypothesis is also supported by epidemiological retrospective ob-
servations that patients with rheumatoid disease who are on long-term anti-inammatory
therapy have a lower prevalence of AD (Breitner et al., 1994; Rich et al., 1995; Beard
et al., 1998; Landi et al., 2003; Szekely et al., 2004). Other largely observational studies
have also supported the concept that anti-inammatory approaches may be protective
against the development of AD (in t' Veld et al., 2001; Zandi et al., 2002). Furthermore,
transgenic animal studies and human trials have demonstrated that treatment with nitric
oxide-releasing non-steroidal anti-inammatory drugs (NSAIDs) can reduce and/or pre-
vent the AD pathology (reviewed by McGeer and McGeer, 2007). It has also been shown
that a certain drug with anti-inammatory properties (CNI-1493) suppresses amyloid
pathology and improves memory performance in transgenic mice (Bacher et al., 2008).
Although these eects did not reach signicant levels in large human cohorts (Stew-
art et al., 1997), interest in the inammatory processes of AD pathology has persisted
(McGeer and McGeer, 1998; Eikelenboom and Veerhuis, 1999). One particularly intrigu-
ing aspect of these studies was that (at least in animal models) the observed benecial
action of anti-inammatory drugs was not necessarily attributed to down-regulation of
inammatory processes. Instead, activation of microglia via a route that enhances their
phagocytic activity against A was suggested (Jantzen et al., 2002).
The inammation hypothesis also provided another approach to research into spo-
radic AD and associated risk factors for investigation - polymorphism of genes related to
induction and regulation of inammatory processes. Initial studies suggested a role for
specic cytokine polymorphisms - for example, in the genes encoding IL-1 and TNF
(Nicoll et al., 2000; Culpan et al., 2003) - with evidence that IL-1 polymorphism may
be associated with diering degrees of microglial activation in AD (Hayes et al., 2004).
However, a meta-analysis of genetic inuences in AD has not supported the initial nd-
ings of cytokine gene variation as a risk factor for AD, but has instead emphasised the
over-riding importance of the ApoE gene polymorphism as the major genetic risk fac-
tor (Bertram et al., 2007). Although many mechanisms for the role of ApoE in AD
pathogenesis have been suggested (Horsburgh et al., 2000), the key mechanism remains
unclear. Of particular interest to the inammation hypothesis is the nding that ApoE
4 carrier with AD have more marked microglial activation (Egensperger et al., 1998).
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support to inammation hypothesis has been provided by GWAS (section 1.4) identify-
ing individual genetic variations in innate and adaptive immunity that may contribute
to the initiation and progression of AD (Harold et al., 2009, Lambert et al., 2009,
Carrasquillo et al., 2010, Jones et al., 2010, Seshadri et al., 2010, Belbin et al., 2011,
Carrasquillo et al., 2011, Carrasquillo et al., 2011a, Hollingworth et al., 2011, Hu et al.,
2011, Naj et al., 2011, Schjeide et al., 2011). The identied immune-related genes are:
CLU that encodes brain apolipoprotein clusterin (CLU or ApoJ); PICALM and BIN1,
both associated with clathrin-mediated endocytosis and intracellular tracking of large
molecules (e.g lipids); CR1 responsible for complement receptor 1 (CR1), CD33, which
encodes CD33 receptor, also known as sialic acid binding immunoglobulin G-like lectin
(Siglec), involved in regulation of adaptive immune responses, CD2AP encoding CD2-
associated protein , ABCA7 - ATP-binding cassette, subfamilyA, member7, and MS4A -
membrane-spanning 4-domains, subfamilyA, all expressed by microglia. Although these
genes have much lower population attributable risk (based on relative risk) than ApoE
(2.5-3.2 % compared to 13.6% for ApoE) (Hollingworth et al., 2011), they were consis-
tently replicated in individual genetic studies (Harold et al., 2009, Lambert et al., 2009,
Carrasquillo et al., 2010, Seshadri et al., 2010, Carrasquillo et al., 2011, Carrasquillo
et al., 2011a, Hollingworth et al., 2011, Naj et al., 2011, Schjeide et al., 2011), and in
combined meta-analyses of several studies (Seshadri et al., 2010, Belbin et al., 2011, Hu
et al., 2011). Therefore, it is considered that it is a cumulative eect of several risk
factors related to immune processes that pre-determines the development of late-onset
AD.
1.8 Microglia and inammation in AD
Microglia comprise up to 15% of all cells within the CNS, where they are also the
main representatives of the immune system (Vinters and Kleinschmidt-Demasters, 2008).
First observations of microglia go back to the 1800s starting with drawings of Virchow,
descriptions by Nissl, Robertson, Frommann, Cajal and Alzheimer, naming them as rod
cells, grid cells, clearance cells, and mesoglia (Rock et al., 2004; Kettenmann et al., 2011).
However, Pio del Rio-Hortega is considered to be the \father of microglial biology" as
he was the rst to propose the \modern conception of microglia", that is still relevant
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1.8.1 Microglia - origin and function
The origin of microglia has been a subject of debate up until recently, when it has -
nally been accepted that these cells are of myeloid lineage, derived from the yolk sac
(mesoderm), and therefore share their origin with other tissue macrophages, rather than
cells from their immediate vicinity - neurons, astrocytes and oligodendrocytes (derived
from neuroectoderm) (Alliot et al., 1999; Lichanska et al., 1999; Herbomel et al., 2001;
Ginhoux et al., 2010). In an adult brain microglial cells have a ramied morphology
identied by numerous branched processes and small soma (Ransoho and Perry, 2009).
They are evenly dispersed throughout the CNS, occupying a dened territory, non-
overlapping with neighbouring microglial cells (Kettenmann et al., 2011). Despite often
being described as \resting" with overall down-regulated phenotype, in vivo imaging
studies demonstrated dynamic behaviour of microglia, constantly monitoring their local
environment by palpating their processes and forming contacts with other cells in their
vicinity, while keeping their soma relatively static (Davalos et al., 2005; Nimmerjahn
et al., 2005). Microglia are considered to be long-lived cells, rarely being replaced possi-
bly by bone-marrow-derived cells or local cell division at a very low level (Lawson et al.,
1992; Ajami et al., 2007; Mildner et al., 2007).
In a developing brain, microglia may be involved in the removal of cells undergoing
apoptosis as part of normal brain development (Perry et al., 1985; Hume et al., 1983;
Streit, 2001), synaptic pruning (Fourgeaud and Boulanger, 2007; Stevens et al., 2007),
and in CNS vascularisation (Streit, 2001).Within the adult CNS, microglial role is similar
to other tissue macrophages being the rst line of defense against injury or a pathogen.
Their function in this capacity is to maintain the integrity of the tissue, to recognise and
migrate to the site of injury or pathogen invasion and to mediate an immune response
including resolution of inammation (Wake et al., 2009; Tremblay et al., 2010). In a
healthy organism, microglia display an overall down-regulated and anti-inammatory
prole determined and characterised by cytokines (e.g. TGF and prostaglandin E2)
and receptors CD200R, TREM2 and Siglecs (Ransoho and Perry, 2009). The shielding
of microglia from the serum proteins by the blood brain barrier also determines their
down-regulatory state. Despite this, microglia are highly sensitive to changes in their
environment (Kreutzberg, 1996). Upon activation, microglia change their morphology
into amoeboid macrophage-like shape with larger soma and shortened processes. LikeChapter 1. Introduction 23
macrophages in the periphery, their adopted phenotype upon activation depends on the
nature of the stimulus, the receptors engaged, and their prior state (Gordon, 2003).
Microglia are highly plastic cells, and while displaying similar morphology, may exist
in numerous functionally distinct phenotypes. Based on peripheral macrophage studies,
three major types of microglial activation stages have been proposed (reviewed in Colton
and Wilcock, 2010):
1. Classical activation - often described as pro-inammatory or M1, this phenotype
is IFN-mediated and represents an initial response to injury/pathogen;
2. Alternative activation - described as anti-inammatory or M2, this phenotype is
IL4/IL13-mediated, adopted during resolution of inammation and extracellular
matrix re-construction associated with wound healing;
3. Acquired deactivation (or regulatory prole) - mediated by IL-10, also described as
down-regulatory and immuno-suppressive, adopted during apoptotic cell clearance.
However, microglia are able to switch between phenotypes as well as exist in many
intermediate states (Mosser and Edwards, 2008; Ransoho and Perry, 2009).
It should be mentioned, that in addition to microglia, perivascular macrophages
and macrophages in circumventricular organs, choroid plexus and meninges also form
important population of immune cells within the CNS. These macrophages have distinct
phenotype characterised by expression of mannose receptor (CD163) and higher levels of
MHCII, and have a similar role to peripheral macrophages (Galea et al., 2005; Ransoho
and Perry, 2009; Perry et al., 2010).
1.8.2 Microglia in AD
The research into microglia has been particularly active in the last 20 years owing to
their recognition as important players in many neurodegenerative diseases, including AD
(Rock et al., 2004). Several studies demonstrated that microglia react to the amyloid
and are able to phagocytose A at least in culture (Rogers et al., 2002; D'Andrea et al.,
2004). In AD cases, microglia often surround neuritic plaques but their phagocytic
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receptors) are additionally activated (Fiala et al., 2007). While being unable to clear
the A plaques, microglia have been implicated in generation of prolonged low-grade
inammation around them (Grin et al., 1989; Rogers et al., 1988; Rozemuller et al.,
1989; Overmyer et al., 1999; Ard et al., 1996; Paresce et al., 1997; McGeer et al., 1987,
1988; Mattiace et al., 1990). In transgenic mice it has been shown that microglia have
a very dynamic behaviour around plaques with time and location-dependent changes in
size, volume, and the amount of plaque-binding dye within their lysosomes (Bolmont
et al., 2008). Despite this, the study conrms microglial inability to completely clear
the existing dense plaques. It is also still not clear what functional phenotype microglia
adopt in the AD brain. The proling of genes involved in immune response in the
human AD brain and mouse models of AD suggests heterogeneous phenotype with
evidence for the presence of both classical and alternative activation, characteristic for
chronic inammation (Colton et al., 2006; Wilcock et al., 2011). The A deposition
over the course of many years and the slow progressive neurodegeneration are the likely
candidates for chronic microglial activation in AD. As the disease progresses and with
ageing, the microglial sensitivity to these and any additional stimuli (e.g. systemic
challenges) may further change and determine the inammatory state within the AD
brain (Perry et al., 2010). The lack of conclusive evidence for the benecial eect of
NSAID against AD (Stewart et al., 1997), and the observations of A clearance through
microglial activation reported in NSAID-treated transgenic mice (Jantzen et al., 2002)
as mentioned earlier, further emphasised the lack of understanding of the full complexity
of microglial role in AD.
1.8.3 Overview of current research into inammation in AD
Research into the role of inammation in the AD is driven by questions similar to those
posed for A and abnormal tau accumulation:
1. Can neuroinammation be the cause of AD?
2. Are the inammatory processes in AD contributing to the disease pathology?
3. Is inammation in AD the consequence of the disease, initiated and driven by the
neurodegeneration?
4. Does inammation act as a harmless bystander in the disease course?Chapter 1. Introduction 25
5. Can the immune processes of the brain be harnessed to ght against the disease
pathology?
Inammation as the sole cause of AD is usually considered as unlikely on the basis
that peripheral systemic disorders rarely start with inammation - there is an initial
challenge that is required to stimulate an immune (or inammatory) response (Rogers
and Shen, 2000). However, it should be noted that being a response to an insult rather
than an insult itself, inammation plays an important role in the reaction of an organism
to this insult, with potentially damaging and sometimes fatal consequences (e.g. in
allergy). Autoimmune diseases can aect the CNS (e.g. paraneoplastic syndromes,
multiple sclerosis) but there is little evidence to suggest that AD falls into this category.
With respect to whether inammatory processes in AD contribute to the disease
pathology (question 2), a lot of evidence has accumulated suggesting that inammation
can contribute to the AD process and exacerbate the course of the disease. It is still
unclear exactly how inammation acts on the diseased brain, as most of the observations
about mechanism of its action are based on animal models. However, the supportive
evidence for inammation being the contributor to the disease is as follows:
 The AD patients, who also have a short-term peripheral infection, show signs of
sudden decline in cognitive state, and rarely return to the previous level even after
the recovery from the infection (Perry et al., 2007; Holmes et al., 2009).
 Community-based studies suggest that plasma levels of inammatory proteins,
including cytokines, are increased before clinical onset of dementia, including AD
(Engelhart et al., 2004).
 Observed signs of inammation in the brain of AD patients are comparable to
those seen in peripheral inammatory reactions and are likely to have a strong
cytotoxic eect on neurons (Akiyama et al., 2000; Rogers and Shen, 2000).
 Signs of inammation are particularly localised in the brain areas aected by AD
pathology and co-localise with plaques and tau deposits (Rozemuller et al., 1986;
Rogers et al., 1988; Eikelenboom et al., 1989; Haga et al., 1989; McGeer et al.,
1989; Perlmutter et al., 1992; Strauss et al., 1992; Lanzrein et al., 1998; Overmyer
et al., 1999).26 Chapter 1. Introduction
 High pathology controls (individuals who have A and tau aggregates at levels
similar to AD patients, but do not develop dementia) show lower signs of inam-
mation (Lue et al., 1996).
 MMSE scores of AD patients correlate with the level of cortical microglial activa-
tion as observed from in vivo imaging studies (Edison et al., 2008).
From these observations, inammation could contribute to the course of the disease
in two ways. Firstly, as an initial innate immune response to the changes in the AD
brain. In the periphery, the innate immune system generates a non-specic response
to an invading pathogen or a cell stress stimulus as a general rst-line defense mecha-
nism. Inammation is part of this response, involving signalling via cytokines and via
activation of the complement system to recruit the immune cells to the site of stress. In
the periphery, this response is also often referred to as an acute, strong, but short-lived
immune reaction. In the context of AD, association of microglia with the plaques and
NFTs has been observed suggesting involvement of the innate immunity in the reaction
to the AD-related stimuli. Observations of acute-phase inammatory proteins along-
side cytokines and chemokines associated with plaques and tangles in AD have been
reported, suggestive of multiple ways of interaction between these inammatory medi-
ators (Akiyama et al., 2000). The presence of elements of the complement system and
membrane attack complex C5b-9, in particular, has been reported to correlate highly
with the level of synaptic loss (Lue et al., 1996). This engagement of the complement
system has not been observed in the brains of high pathology controls, contributing to
the evidence of the involvement of acute mediators in the AD. C5b-9 complex is known
to be very potent at killing or damaging neurons through signalling for production of
various cytokines and other complement elements (Rogers and Shen, 2000). However,
most studies refer to the inammation in AD as weak and non-specic. This is ex-
plained on the basis of the multiple mechanisms that regulate inammatory reactions
within the brain and minimise them (Galea et al., 2007). Nevertheless, long exposure
to ongoing inammation, even at low levels, can bring about gradual neurodegenera-
tion that might be more dicult to stop or reverse than acute inammatory episodes
observed in peripheral disorders (Rogers and Shen, 2000).
Secondly, the low-level ongoing inammation in AD contributing to the course of
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inammation. In the periphery, an innate immune response is followed by a switch
to an adaptive response with generation of antibodies and overall down-regulation of
acute pro-inammatory signalling promoting tissue repair (Gordon, 2003; Mosser and
Edwards, 2008). In the brain in the context of AD, a heterogeneous response of mi-
croglia is manifested by co-existence of the initial classical activation response aiming to
eliminate the invading stimulus (be it A or tau) and the alternative activation/acquired
deactivation response aiming to minimise the damage and promoting resolution of the
inammation (Colton et al., 2006). Chronic inammation results from this combina-
tional response allowing the pathological features to \escape" the appropriate immune
reaction and promoting neuronal damage. Impaired activation of microglial Toll-like
receptors in AD brain has also been suggested (Aravalli et al., 2007; Fiala et al., 2007;
Richard et al., 2008). The result is that the phagocytic activity of microglia as well as
their neuroprotective function are impaired (Morgan et al., 2005).
The type of inammation in the AD brain is not well dened and is often blamed
on 'dysfunctional' or 'malactivated' microglia (Streit, 2004). The exact prole of these
microglia has not yet been well characterised (Kalaria, 1999), but the description is often
based on observation of a single marker or a dystrophic and apoptotic appearance of the
cells (Tooyama et al., 1990; Yang et al., 1998; Streit, 2004).
Some studies also report presence of auto-antibodies against A in older people
(Hyman et al., 2001), and possible involvement of T and B cells in the AD processes
(Xu and Gaskin, 1997; Monsonego et al., 2003). However, conclusive positive evidence
for direct involvement of antibody-mediated response in AD has not yet been presented
(Rogers and Shen, 2000).
One could also suggest that inammation, observed in the brain of AD patients is
merely a consequence of the disease (question 3), pointing to an inability of microglia
to clear ever-growing neuronal debris due to extensive neurodegeneration and synaptic
loss. Impaired recruitment of monocytes from the periphery to the site of the disease
in AD brain has been suggested in this respect and demonstrated using animal models
(Simard et al., 2006; El Khoury et al., 2007; Town et al., 2008).
The phagocytic prole of microglia that is often referred to in AD brain is gener-
ally non-aggressive, aiming at clearing the damage/debris with minimal further damage
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brain have a neutral or even benecial role (question 4). However, another perspective
comes from the studies using a model of neurodegeneration - the ME7 mouse model of
prion disease (Boche et al., 2006). These studies suggest that microglia in the context
of a neurodegenerative disease, although generally in an anti-inammatory state, are
\primed" to switch quickly into an aggressive prole should the opportunity arise. Such
an opportunity maybe a peripheral infection, as has been demonstrated in this model
(Combrinck et al., 2002).
Mixed and often contradictory ndings with respect to inammation in AD indicate
the complexity and multi-functional role of the immune system. It became apparent
that inammation in the CNS, as in the periphery, is a mixture of both destructive
and rebuilding processes. The balance between these processes determines the overall
integrity of the tissue or the whole organism (Rogers et al., 2002). Therefore, inam-
mation should not be viewed as wholly detrimental or benecial in AD. Understanding
of the whole spectrum of the immune processes involved is necessary to nd an optimal
solution for the prevention or treatment of the disease.
The possibility of harnessing immune processes (question 5) to direct the system
towards clearance of the disease features has become an actively researched topic of AD.
Much AD research is now aimed at modulation of the immune system to direct it away
from microglial activation that is pro-inammatory (or malactivated) towards a more
controlled productive and phagocytic antibody-mediated immune response (Morgan,
2005).
In summary, the pathological changes associated with AD as described above should
not be considered in isolation. It is more likely that their cumulative action results in
disruption of normal work of the CNS through damage to neurotransmitter systems,
leading to neuronal death.
1.9 Current treatment strategies
Animal models have allowed the development and testing of various treatment strategies,
some of which have progressed to human clinical trials (Stewart et al., 1997; McGeer
and McGeer, 1998; Jick et al., 2000; Lim et al., 2000; Wolozin et al., 2000; Dodart et al.,
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Musial et al., 2007). Most of the treatment approaches, particularly preventative and
disease modifying ones, are based on amyloid cascade hypothesis and, therefore, assume
A as a primary cause of AD. However, none of the strategies tried so far have been able
to revert or stop the pathology of the disease in humans and provide benets without
unwanted side-eects.
1.9.1 Symptomatic interventions
The wide-spread neuronal damage in AD is suggested to lead to depleted levels of neuro-
transmitter acetylcholine (ACh) and over-stimulation of N-methyl-D-aspartate (NMDA)
receptors via glutamate excitotoxicity disrupting transmission of neuronal signals. In
an attempt to increase levels of ACh and to relieve some of the symptoms of AD, in-
hibitors of one of the enzymes that break down ACh, acetylcholinesterase (AChE), are
used clinically (e.g. donepezil, galantamine, and rivastigmine). The mechanism of action
of AChE inhibitors involves enhancement of cholinergic transmission, which regulates
learning and memory processes. However, the ecacy of this treatment approach is
limited, often observed only in a subgroup of patients, and is typically accompanied by
unpleasant side-eects (Kaduszkiewicz et al., 2005). A partial NMDA receptor antago-
nist, memantine, designed to reduce the glutamate-mediated excitotoxicity is also used
for the management of some symptoms in moderate to severe AD (Tampi and van Dyck,
2007; Fox et al., 2012). Combinational therapy of AChE inhibitors and memantine has
also been suggested, but the benets of this approach are debatable (Farrimond et al.,
2012).
1.9.2 Preventative approaches
Two approaches have been suggested as preventative: the use of statins and anti-
inammatory drugs.
As mentioned in Section 1.7.3, retrospective studies of the patients who were on
long-term NSAIDs showed that these patients had lower prevalence of AD. These obser-
vations have generated interest in anti-inammatory strategies for AD. The approach
was tried in APP-PS1 and APPSW transgenic mice using nitric oxide-releasing NSAIDs
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drugs reduces and/or prevents the AD pathology in the animals. The involvement of mi-
croglia was suggested, but the results were contradictory reporting decreased microglial
activation in APPSW model (Lim et al., 2000), but surprisingly raised levels of activated
microglia in the APP-PS1 model (Jantzen et al., 2002). An eect of NSAIDs decreas-
ing secretion of A was observed in cultured cells (Weggen et al., 2001). However, the
mechanism of action of the NSAIDs is not understood. Epidemiological studies show
various degrees (up to 50%) of benecial eect of the use of NSAID on the onset of the
disease and dementia, with increased duration of drug use having a positive eect by
reducing the relative risk of AD (in t' Veld et al., 2001; Stewart et al., 1997; Zandi et al.,
2002). However, the results from randomised controlled clinical trials did not show any
benecial eect (reviewd by McGeer and McGeer, 2007). Conventional NSAIDs can also
cause undesirable side-eects (e.g. gastrointestinal ulceration) (Stewart et al., 1997).
The role of statins in reducing the risk of AD and other forms of dementia through
cholesterol-reducing activity has also been investigated as possible candidate for AD
prevention. Statins inhibit levels of plasma cholesterol, and cholesterol is believed to
aect the biology of A. Again, epidemiological studies suggested decreased risk of AD
in those patients who were prescribed statins to lower the lipid levels (Jick et al., 2000;
Wolozin et al., 2000). However, no positive eect on MMSE score or onset of dementia
was observed in the individuals who used statins in addition to NSAIDs in a randomised
controlled clinical trial (Sparks et al., 2008).
1.9.3 Disease modifying approaches
Several disease modifying approaches have been studied in vitro and in animal models,
or used in relation to other diseases, and some have reached clinical trials but not have
been fully approved due to low eectiveness or undesirable side-eects (Lyketsos et al.,
2007; Hardy and Selkoe, 2002). These approaches include:
 Inhibition of - and - secretases (Tarenurbil - R-urbiprofen) (Imbimbo and
Giardina, 2011).
 Prevention of A deposition through chelation with Cu2+ and/or Zn2+ ions (Bareggi
and Cornelli, 2012) and use of anti-aggregants (GAG-mimetics, e.g. Tramiprosate)
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 Enhancement of neuroprotection by using anti-oxidants to boost the tolerance of
neurons against degeneration and synaptic loss (Frank and Gupta, 2005).
 Immunotherapy against A (Schenk et al., 1999) and tau (Sigurdsson, 2009).
Out of these, immunotherapy against A has attracted most attention and research
interest.
1.10 Immunisation against A
Driven by the amyloid hypothesis and by observations of microglia surrounding the A
plaques, but being unable to clear them in animal models of AD and in human post-
mortem observations, the immunisation approach has emerged. The idea of modifying
the immune system and directing it towards eective clearance of plaques generated a
lot of interest. Development of active and passive immunisation strategies became an
actively researched topic in AD eld.
1.10.1 Animal studies
In animal models immunotherapy has been reported to prevent the formation of and
to clear the existing A deposits, and to remove the dystrophic neurites (Schenk et al.,
1999; Bard et al., 2000; Janus et al., 2000; Morgan et al., 2000; DeMattos et al., 2001;
Sigurdsson et al., 2001; Bacskai et al., 2002; Dodart et al., 2002; Das et al., 2003; Wilcock
et al., 2003, 2004; Brendza et al., 2005; Asuni et al., 2006).
The rst reported immunisation study used PDAPP transgenic mice and synthetic
human A42 peptide as the antigen (Schenk et al., 1999). The animals developed a high
antibody response (titre 1:10,000). Complete prevention of amyloid and neuritic pathol-
ogy was achieved in mice immunised at 6 weeks of age, and extensive plaque clearance
was achieved in older mice immunised at 11 months of age. Immunised older animals
also showed A-containing cells with an activated microglia phenotype, suggestive of Fc
receptor mediated clearance of A42. Signicant reduction in neuritic pathology as well
as reactive astrocytosis were also observed in the older immunised group when compared
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This work was followed by similar studies in Tg2576 and TgCRND8 APP transgenic
mice. Active immunisation in these models showed various levels of plaque clearance
(up to 50%), signicant behavioural improvements in older animals, and prevention of
cognitive decit in a younger group (Janus et al., 2000; Morgan et al., 2000).
Administration of antibodies against A (m266, 3D6, 10D5, PabA1-42) directly
into the brain or via the periphery (passive immunisation) in PDAPP transgenic mice
also showed ndings similar to active immunisation with regard to reduction of AD-
like pathology through clearance of A plaques and improved memory and learning
performance (Bard et al., 2000; DeMattos et al., 2001; Bacskai et al., 2002; Dodart et al.,
2002). In one study, however, memory decits were reversed even without alterations in
A burden (Dodart et al., 2002).
These studies posed questions about possible mechanisms of plaque clearance. Amyloid-
antibody complex interaction with microglial Fc receptors was suggested as one possible
mechanism (Bard et al., 2000). A non-Fc-mediated mechanism of direct plaque destruc-
tion with F(ab')2 antibody fragments that lack Fc component was also proposed (Bacskai
et al., 2002). However, the role of Fc receptor-mediated phagocytosis in plaque clear-
ance after immunotherapy was questioned when A clearance was observed in actively
immunised phagocytosis-decient (FCR-/-) APP mice at levels similar to Fc receptor
non-decient APP mice (Das et al., 2003). Equally, the ability of F(ab')2 fragments
to activate microglia and remove amyloid brils was questioned when another study
showed that these fragments fail to activate microglia and are less eective than IgG
antibodies at clearing plaques (Wilcock et al., 2004). A two-step mechanism of plaque
removal using anti-A antibodies was proposed: an initial rapid decrease in A deposi-
tion 24 hours after antibody administration, followed by microglia-dependent removal 3
days after the antibody injection (Wilcock et al., 2003). A \sink" mechanism was also
suggested, in which monoclonal antibody to A may attract A across the blood-brain
barrier from the brain into the periphery (DeMattos et al., 2001).
Although these studies showed, that immunisation with A was successful in ani-
mals, the models used, however, did not reect the full pathology of the AD, that is they
lacked NFTs or substantial neurodegeneration despite A deposition. It was not clear
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show improvement of cognition in humans. Safety issues were also highlighted with re-
spect to the acceptable and eective levels of antibodies that can be used in the animals
vs humans, the preference of the active over passive immunisation approach, and the
exact mechanism of action of the vaccine (Sigurdsson et al., 2002). The antibody levels
in animals had to be quite high to reach the desired eect of A removal. The concern
was whether suciently high levels of anti-A antibody can be safely produced in hu-
mans. The details of mechanism of action initiated by the immunotherapy was also not
established.
Despite these concerns and unanswered questions, the immunisation approach pro-
gressed to human clinical trials.
1.10.2 The rst human clinical trial
The rst clinical trial testing the active immunisation approach against A42 was set
up by Elan Pharmaceuticals.
Initially, a multicentre randomised multiple-dose double-blind human trial (phase I)
was designed to assess the antigenicity, safety and tolerability of the developed treatment,
and was performed between April 2000 and June 2002. Eighty mild to moderate stage
AD patients 85 years old or less were recruited in the south of the United Kingdom. Of
the recruited patients, 64 received multiple doses of 50 or 225 g of A42 peptide in
combination with the QS21 adjuvant (AN1792), and 16 patients received adjuvant alone
(placebo). Four injections were administered at weeks 0, 4, 12, and 24, with permission
to administer additional injections at weeks 36, 48, 60 and 72. Patients were assessed
every 2 to 3 weeks. At the end of the study, it was reported that the treatment was well
tolerated. Approximately 25 to 50% of the patients who received the active treatment
developed positive immune response to AN1792 (Bayer et al., 2005).
In June 2001, a further study was initiated with larger patient sample (phase IIa);
375 patients were recruited in Europe and the USA, of which 300 were to receive multiple
doses of 225 g of AN1792. This trial was halted after several months as 18 patients
developed aseptic meningoencephalitis (Orgogozo et al., 2003).
The clinical report from the phase IIa study showed that most of the patients who
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varied levels of IgG and measurable IgM levels in serum, although these levels had
no obvious correlation with the incidence or severity of meningoencephalitis (Orgogozo
et al., 2003). The event was predominantly singular, but four patients had moderate
or severe relapses. Most of the diagnosed cases presented with progressively increased
confusion, headache, or lethargy. A high white blood cell count was detected in the
cerebrospinal uid (15-130 cell/l) with no signs of viral or bacterial infection. Twelve
patients recovered to baseline status, and six patients continued to decline cognitively
after the event.
Whilst a report on the 1-year clinical follow-up of a subset of 30 immunised AD
patients from the phase IIa study suggested evidence of a reduced cognitive decline
in patients who generated antibodies against -amyloid (Hock et al., 2003), a 1-year
follow-up of all patients showed no signicant ndings on clinical outcomes (Gilman
et al., 2005). Furthermore, long-term (5 year) clinical and neuropathological follow-up
of patients from the phase I trial showed that despite an antibody response, no overall
positive eect on cognition was observed - the decline was similar to control patients
(Holmes et al., 2008). In the whole cohort, there was no evidence of improved survival
or of an improvement in the time to severe dementia.
Neuropathological reports on patients from the phase I and IIa studies all reported
similar ndings (Nicoll et al., 2003; Ferrer et al., 2004; Masliah et al., 2005; Nicoll
et al., 2006; Bombois et al., 2007; Holmes et al., 2008; Boche et al., 2010). A signi-
cant reduction in A pathology was evident, as well as resolution of some tau features
(dystrophic neurites). The remaining A plaques showed dense core morphology and
patchy distribution in the aected brain areas. No eect on NFTs was found. Most cases
also reported signs of A particles within microglia, suggesting immunisation-induced
A phagocytosis. Increased A40 and A42 burden in the grey matter blood vessels
(CAA) of the immunised AD cases has been reported suggesting the involvement of the
perivascular drainage route (Weller et al., 1998; Preston et al., 2003; Carare et al., 2008;
Weller et al., 2008) in the immunisation-induced A clearance (Boche et al., 2008).
A comparison between neuropathological and clinical data in eight of the immunised
patients from the phase I study showed that the degree of plaque removal correlated with
the mean antibody response attained during the treatment study period (Holmes et al.,
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those with virtually complete plaque removal, with the exception of one patient, who
died very shortly after their rst immunisation dose (due to a cause unrelated to the
immunisation treatment). The conclusion was that although immunisation with A
resulted in clearance of amyloid plaques in patients with AD, this clearance did not
prevent progressive neurodegeneration.
1.10.3 Research focus following the Elan AN1792 clinical trial
The Elan AN1792 immunisation clinical trial provided important lessons for the devel-
opment of subsequent immunisation approaches against AD:
 The specicity of treatment in terms of clearance of A, was predicted by the
animal models and conrmed by the clinical trials.
 The cognitive improvement was not as apparent in humans as in animals, suggest-
ing that early interventions could be more eective (Holmes et al., 2008). Other
AD features, such as tau, also need to be addressed when developing future treat-
ment, as their role on the cognition may be more relevant than that of A.
 The inammatory side eect was linked to autoimmunity response and also not
predicted by the model studies. It has been suggested that absence of the menin-
goencephalitis eect in immunised human APP transgenic mice was due to struc-
tural dierences between human and mouse form of A (Broytman and Malter,
2004). No studies have yet been done in non-transgenic mice immunised with
mouse A .
 The observed acute T cell response in some immunised AD patients reects the in-
dividual dierences with respect to predisposition towards specic T cell responses,
which are hard to predict and are not fully understood (Broytman and Malter,
2004).
 The clinical trials also demonstrated limitations of predictions based on existing
animal models and the necessity for the construction of models that reect the
complexity of the AD pathology.
Following the halting of the Elan active immunisation AN1792 phase IIa trial, sub-
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immune response to AD pathology that avoids strong pro-inammatory reaction. A
necessity for a model that would reect the full pathology of the disease led to the gen-
eration of the triple transgenic mouse model (3xTg-AD), which shows A deposition
as well as tangle formation, synaptic degeneration and behavioural impairments (Oddo
et al., 2003; Billings et al., 2005) (section 1.6). Immunisation studies using this model
showed that intrahippocampal administration of A antibodies clears or prevents plaque
formation as well as clears early phosphorylated tau (Oddo et al., 2004). The same group
further investigated the eect of active and passive A immunisation and demonstrated
the importance of clearing both soluble A and soluble tau for the improvement of
cognitive performance (Oddo et al., 2006).
Active immunisation of 12-month old APPSw/NOS-/- and APPSwDI/NOS-/- mouse
models that display amyloid deposition, mouse tau hyperphosphorylation and neuronal
loss demonstrated reduction in both amyloid and tau deposits with partial protection of
neurons and reversal of memory decits (Wilcock et al., 2009). However, these eects
were accompanied by microhaemorrhages in APPSw/NOS-/- model that showed more
dramatic removal of A and tau than the APPSwDI/NOS-/- mice. This undesirable
eect was linked to a shift in the immune response following the immunotherapy towards
classical pro-inammatory prole leading to increased activation of matrix metallopro-
teinases involved in extracellular matrix and protein degradation (Wilcock et al., 2011a,
Wilcock et al., 2011b). Incidence of microhaemorrhages has been reported in other
passive and active immunisation studies in animal models (Pfeifer et al., 2002; Wilcock
et al., 2004; Racke et al., 2005; Wilcock et al., 2007), as well as following the human
AN1792 active immunisation clinical trial (Boche et al., 2008).
The use of non-toxic, non-brillogenic forms of A together with an adjuvant that
promotes humoral, rather than cell-mediated, response was proposed and tested in active
immunisation of Tg2576 mice aimed at eective removal of AD pathology without ad-
verse inammatory eects and microhaemorrhages (Asuni et al., 2006). This study also
conrmed that immunisation is more eective at early stages of the disease. The same
group tested active immunisation with dierent A species in young lemur primates in
order to evaluate the antibody response and choose the most ecient peptide and adju-
vant for further studies in old lemurs (Trouche et al., 2009). Tau-specic immunisation
in various models of tauopathies is also underway (Sigurdsson, 2008).Chapter 1. Introduction 37
Despite the mixed results of the initial A immunisation human clinical trial, the
information obtained has been inuencing the development of subsequent trials. Several
clinical trials involving active and passive immunisation in AD have since been initiated
(Wisniewski and Konietzko, 2008; Menendez-Gonzalez et al., 2011). These include early
phase active immunisation studies aimed at the carboxyl terminus of A (amino acids
1 to 6, Novartis), passive immunisation using antibodies against the amino terminus
(amino acids 33 to 40, Pzer) and the use of intravenous immunoglobulin (Baxter Bio-
science). Later phase passive immunisation studies include the use of antibodies to the
mid-region of A (amino acids 13-28, Lilly) and to the amino terminus (Bapineuzumab,
amino acids 1 to 5, Elan). Although the initial ndings of the earlier study of Bap-
ineuzumab suggested a benecial eect for subjects not carrying the ApoE 4 allele
(Salloway et al., 2009), the nal results of the large phase III clinical trial of the drug
were disappointing showing no overall clinical improvements in AD patients (Alzheimer's
Research Forum News, 8 August 2012, www.alzforum.org).
1.11 Scope for this project
Research into the inammation in AD so far has demonstrated the complexity of the
mechanisms involved, which interact with each other in multiple ways. This web of
interactions makes it dicult to isolate any particular inammatory process, element or
cell, and pinpoint its individual role in the progress of the disease. Immunisation as one
of the AD treatment approaches has led to an increased interest in the immune processes
associated with this disease and highlighted their role in AD pathogenesis. The ability
to modulate the immune system by active immunisation to generate anti-A antibodies
and stimulate clearance of amyloid plaques underlined the benecial eect that immune
system can have on the pathology of the disease. The inammatory response side-
eect developed by some immunised patients pointed to the complexity of the immune
processes acting in the brain and their potential for harmful eects. Microglia are the
main representatives of the immune system in the CNS and involved in both of these
eects. Yet the mechanism of their action in the AD pathogenesis and in the context
of the A immunisation is still not clear. A detailed analysis of microglia in an AD
brain and their relation to the AD pathology has not been previously done. Equally, the
immunisation studies and clinical trials have not looked in detail into the eect of the38 Chapter 1. Introduction
treatment on microglia despite the recognition that these cells have the capacity to both
protect and damage the neurons, and that some patients may develop an inammatory
side eect to the treatment. The follow-up study of the AN1792 clinical trial presented
a unique opportunity to address these issues and investigate the role of microglia in the
AD pathology and following the A42 immunisation.Chapter 2
Project Hypothesis, Aims and
Experimental Approach
2.1 Hypothesis and Aims
The following hypothesis was formulated in order to address the role of microglia in AD
pathology and following A42 immunisation.
Active A42 immunisation in Alzheimer's disease aects the microglial
level of activation and prole associated with the reduction in A
The hypothesis encompasses the following aims:
1. To assess the level of microglial activation in AD and following the A42 immuni-
sation treatment;
2. To characterise microglia and establish their prole in AD and following the A42
immunisation with respect to receptors involved in antigen recognition and uptake,
presence of cytokines, antibodies (IgG) and elements of complement system;
3. To investigate relationships between microglial receptors and A and tau patho-
logical features of AD in non-immunised and immunised AD brain .
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2.2 Experimental Approach
Two studies were designed to address aims 1 and 2 respectively, with aim 3 being
addressed in both studies. Formalin-xed paran-embedded post-mortem brain tissue
from the participants of the Elan A42 active immunisation clinical trial (AN1792) and
non-immunised Alzheimer's disease controls was used.
Study 1
Tissue from 9 immunised AD cases and 8 non-immunised AD cases (Southampton Neu-
ropathology Department Archives) was available for this study. The experimental ap-
proach included immunohistochemical assessment of two microglial activation markers
(aim 1). The A42 load was also assessed to investigate the relationship between mi-
croglia and the extent of A pathology (aim 3). The distribution of the microglial
activation markers with respect to each other and A was investigated using uores-
cent immunohistochemistry. In addition, perivascular macrophage population was also
assessed in immunised and non-immunised AD brains.
Study 2
11 immunised AD cases were available for this study. A dierent set of 28 non-immunised
control AD cases closely matched to the immunised AD cases for age, gender, dura-
tion of dementia, and ApoE genotype was obtained from South West Dementia Brain
Bank (Bristol). Immunohistochemical analysis of microglial receptors involved in direct
and antibody-dependent antigen recognition and uptake, the level of immunoglobulin G
(IgG) and elements of complement system was performed (aim 2). Assessment of A42
and phospho-tau load was also performed to investigate the relationships between mi-
croglial receptors and A and tau pathology (aim 3). The extraction of genetic material
for assessment of cytokine gene expression using quantitative real-time polymerase chain
reaction (q-RTPCR) was also attempted (aim 2).Chapter 3
Methods
3.1 Outline of follow-up study
This project formed part of the long-term follow-up study of patients, who entered the
rst placebo controlled, double-blind clinical safety trial for active immunisation with
A42 synthetic peptide (AN1792, Elan Pharmaceuticals Inc) (Bayer et al., 2005; Holmes
et al., 2008). All participants had to meet NINCDS-ADRDA criteria for probable AD
with mild to moderate dementia (MMSE range 14-26) (Folstein et al., 1975; Bayer et al.,
2005; Perneczky et al., 2006). 80 patients were enrolled, of whom 64 were randomly
assigned to receive either 50 g or 225 g AN1792 with an adjuvant (QS-21), and 16
individuals were randomly assigned to receive adjuvant alone. The total study treatment
period (including extension phase) was 84 weeks (Bayer et al., 2005). Study enrollment,
based at four sites in the UK (Southampton, Bath, Swindon and Cardi), began in
April 2000 and the last study entrant nished the treatment in June 2002.
3.1.1 Clinical follow-up
Ethical approval for the follow-up study was received in June 2003 (LRC 075/03/w).
Following this, all 80 subjects (or their carers) enrolled in the original study were iden-
tied by the original study centre investigators. The contacts were re-established with
the survived subjects, who were approached for consent for further clinical follow-up and
post-mortem neuropathological examination. 22 patients from the trial were enrolled.
Patients were assessed at yearly intervals, whenever possible coincident with the month
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of their initial baseline assessment in the original treatment study, until death (Holmes
et al., 2008).
3.1.2 Neuropathological follow-up
Immunised Alzheimer's disease cases
Post-mortem neuropathological examination of 16 consented patients was performed in
Southampton General Hospital Neuropathology Department. The details of each im-
munised patient including gender, age, Braak stage, duration of dementia, received dose
of treatment, mean antibody response (as measured by Elan over the immunisation pe-
riod), and survival time from rst immunisation dose are shown in Table 3.1. The brains
were xed in formalin for 2-3 weeks, then sliced in the coronal plane, examined macro-
scopically and sampled for histology. Large tissue samples from one hemisphere were
processed and embedded in paran wax. Five-micrometer-thick sections from these
samples were stained with standard tinctorial stains haematoxylin and eosin, luxol fast
blue / cresyl violet, modied Bielschowsky silver impregnation and immunostaining for
A, tau, -synuclein and TAR-DNA binding protein 43 to conrm the diagnosis of AD
or establish an alternative cause for the dementia. Twelve of the immunised patients
have been conrmed as having AD, and 4 were assigned a dierent diagnosis: progres-
sive supranuclear palsy (PSP), dementia with Lewy bodies (DLB), vascular dementia
(VaD), and frontotemporal dementia (FTD). Eleven out of the 12 AD patients received
A42 plus adjuvant, while one received adjuvant alone (placebo). Three out of the 4
non-AD patients received A42 plus adjuvant, while one case (diagnosed as FTD) re-
ceived placebo. Only 11 AD cases that received the treatment (designated as iAD) were
included in statistical analyses. Cases 1-10 (9 iAD and one PSP) were available at the
time of Study 1. Two more iAD cases (No. 11 and 16), one placebo AD case (No. 15)
and three non-AD cases (No. 12-14) became available at the time of Study 2. Therefore,
9 iAD cases were used for Study 1, and 11 iAD cases were used for Study 2.
Smaller samples were taken from another hemisphere from 24 brain areas. Tis-
sue from four of these areas - temporal, frontal, parietal and the pons - was processed
separately and used in the current project. These areas, except for the pons, are rec-
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aected by the A deposits and responsible for the cognitive function impaired in AD
patients, such as memory formation and association. The pons was chosen as internal
control as this area is not aected by the AD pathology. The samples from the four
areas were processed using Hypercentre (Shandon) tissue processor. Briey, the samples
of tissue were taken through three steps of dehydration in graded alcohol (50%, 70%,
90%), four steps of dehydration in absolute alcohol, a step of mixed medium (equal parts
of absolute alcohol and chloroform) at 37C, two steps of incubation with chloroform at
37C, and two steps of processing with paran wax at 60C. Each step lasted 6 hours.
After processing, the tissue blocks were embedded into paran wax and allowed to set.
Non-immunised (control) Alzheimer's disease cases
As only one placebo case was present within the total number of patients that were
available for neuropathological follow-up during this study, alternative non-immunised
AD control groups were used for histological comparisons. A group of 8 non-immunised
AD cases was obtained from the Neuropathology archives Southampton General Hospital
and used in Study 1. These cases all had a history of progressive dementia and satised
Consensus Criteria for AD (Hyman and Trojanowski, 1997). The clinical characteristics
of control cases used for Study 1 are listed in Table 3.2. For Study 2, a cAD cohort of 28
cases was obtained from the South West Dementia Brain Bank (SWDBB, Bristol) (REC
reference: 08/H0106/28). This cohort was matched as closely as possible to the iAD
cases for age, gender, duration of dementia, and ApoE genotype. All control AD cases
had a clinical diagnosis of dementia made during life by an experienced clinician; all had
had a MMSE score of <17 prior to death and satised post-mortem neuropathological
Consensus Criteria for AD. The clinical characteristics of control cases group used for
Study 2 are listed in Table 3.3.
3.2 Immunohistochemistry
Four-m thick sections were cut from the paran blocks using a microtome (Leica
RM2135). Sections were oated onto glass slides coated with aminopropyltriethoxysi-
lane (APES) and dried at 38C overnight prior to immunostaining. All immunohisto-
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Table 3.1: Clinical characteristics of immunised subjects including case number, gen-
der, age (years), Braak stage (and/or alternative non-AD diagnosis: PSP = progressive
supranuclear palsy, DLB = dementia with Lewy bodies, VaD = vascular dementia,
and FTD = frontotemporal dementia), dementia duration (years), ApoE genotype,
AN1792 dose (g), mean antibody response (ELISA units), and survival time from the
1st immunisation dose (months)
No. Gender Age Braak Dementia ApoE Dose Response Survival
1 F 74 VI 6 3.4 50 1:119 20
2 M 83 V 11 3.3 50 1:100 4
3 M 63 VI 6 3.3 225 1:100 41
4 F 71 VI 10 4.4 225 1:4072 44
5 M 79 PSP 6 2.3 50 1:100 51
6 M 81 VI 7 n/a 50 1:1707 57
7 M 82 VI 6 3.4 50 1:4374 60
8 M 63 VI 10 3.4 50 1:6470 64
9 M 81 VI 11 4.4 225 1:491 63
10 F 88 VI 11 3.3 50 1:137 86
11 M 88 VI 12 3.4 50 1:142 94
12 M 86 III DLB 9 4.4 225 1:5454 89
13 F 90 III VaD 11 3.3 225 0 90
14 M 64 FTD 9 4.4 placebo 0 96
15 F 93 VI 12 3.4 placebo 1:6 104
16 F 89 VI 15 3.4 225 1:142 111
Table 3.2: Clinical characteristics of control (non-immunised) AD subjects used for
Study 1 including case number, gender, age (years), Braak stage and dementia duration
(years); N/A means that the exact number of years was not available
No. Gender Age Braak Dementia
1 F 72 VI 7
2 M 73 VI N/A
3 F 72 VI 1
4 F 84 VI 5
5 F 65 VI N/A
6 F 88 VI 5
7 M 79 V 8
8 F 76 V/VI 7 or 8Chapter 3. Methods 45
Table 3.3: Clinical characteristics of control (non-immunised) AD subjects used for
Study 2 including case number, gender, age (years), Braak stage, dementia duration
(years) and ApoE genotype; N/A means that the information was not available
No. Gender Age Braak Dementia ApoE
1 M 88 VI 8 3.4
2 F 74 VI 7 3.4
3 M 85 VI N/A 3.4
4 F 84 V 10 3.4
5 F 78 N/A 3 4.4
6 M 83 VI N/A 3.3
7 F 81 N/A N/A 3.4
8 M 80 V 6 3.4
9 M 71 V 7 3.4
10 M 63 VI 5 3.3
11 M 64 VI N/A 3.4
12 F 80 N/A 9 4.4
13 M 74 V N/A 3.4
14 F 85 N/A N/A 3.4
15 F 75 VI 6 3.4
16 F 68 N/A 8 3.4
17 F 78 VI 17 4.4
18 M 68 VI 10 3.3
19 F 71 VI 15 4.4
20 M 81 VI 3 N/A
21 F 82 N/A 5 3.4
22 M 83 V 5 3.3
23 M 74 V 10 2.3
24 F 83 V 9 3.4
25 F 82 V 10 2.4
26 F 84 VI 15 2.3
27 F 80 V 9 4.4
28 M 80 IV 3 3.4
according to the University of Southampton Health and Safety regulations.
3.2.1 Primary antibodies
All primary antibodies were anti-human.
Microglial markers - Study 1
Two markers commonly used for identication of activated microglia were chosen for
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brain - Table 3.4:
 CD68 - labels lysosomal and endosomal trans-membrane glycoprotein of macrophages
and microglia, indicating phagocytic activity (Rabinowitz and Gordon, 1991, 1989).
 HLA-DR, DP, DQ - human leukocyte antigen class II, the human analogue of
MHC class II antigen-presenting protein complex, used as a marker of activated
microglia and, at least in peripheral macrophages, is known to be associated with
antigen presentation (McGeer et al., 1987; Styren et al., 1990). HLA-DR is ex-
pressed on the cell membrane of and in vesicles within antigen-presenting cells,
transporting antigens for presentation between the cell surface and the Golgi. In
the periphery, macrophages play the role of antigen-presenting and phagocytosing
cells. In the CNS antigen-presentation is one of the microglial functions, and since
immunisation acts via stimulation of the immune system, HLA-DR was chosen as
one of the markers of microglial activation.
In addition, CD163 was chosen as a marker for assessment of the perivascular
macrophage level as well as an indicator of possible macrophage inltration into the
parenchyma in the immunised and control AD subjects. CD163 is the cell surface gly-
coprotein expressed by macrophages in most tissues, but not by microglia. In the brain,
this marker is normally restricted only to perivascular macrophages (Galea et al., 2005).
These cells are positioned at the interface of the brain and the periphery and may play
an important role in clearance of A through the vascular system. CD163 is also a
membrane-bound scavenger receptor of monocyte-origin cells.
Microglial markers - Study 2
Study 2 was set up to investigate the prole of microglia in AD and after immunisa-
tion. Markers chosen for this purpose included those indicative of microglial direct and
antibody-dependent antigen recognition, engagement of classical complement system,
presence of immunoglobulin class G (IgG), and microglial pro- or anti-inammatory
state. The details of markers that were successfully optimised on the brain tissue and
used for the immunostaining of iAD and cAD cases in Study 2 are listed in Table 3.5
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Table 3.4: Primary antibodies used as microglial/macrophage markers for immuno-
histochemistry in Study 1
Name Clone
(Company)
Species
raised in
Dilution Staining
CD68 PG-M1
(Dako)
Mouse 1:50 Microglial lysosomes, marker of
phagocytosis
HLA-DP,
DQ, DR
CR3/43
(Dako)
Mouse 1:200 Microglial cell surface protein (hu-
man homologue of MHC II), anti-
gen presenting complex in periph-
eral macrophages, general marker of
activated microglia in CNS
CD163 EDHu-1
(Serotec)
Mouse 1:1000 Perivascular macrophages
or macrophage-like cells in
parenchyma in areas of broken
blood-brain barrier
 Iba-1 is an ionised calcium-binding adapter molecule 1, which has been reported
as an eective marker of both resting and activated microglia (Ahmed et al., 2007;
Imai and Kohsaka, 2002; Streit et al., 2009). Therefore, this marker was chosen
to assess the overall level of microglia present in AD and after immunisation.
Immunohistochemistry for this marker was performed by a medical student Viraj
Bharambe as part of his science project.
 Macrophage scavenger receptor A (MSR-A) is a lipoprotein receptor involved in
direct ligand recognition, including that of A. In animal studies, its homologue,
scavenger receptor A (SR-A), is expressed by microglia associated with plaques,
and is involved in production of reactive oxygen species and neurotoxic substances
by microglia stimulated with brillar A (El Khoury et al., 1996; Husemann et al.,
2002). This marker was chosen to assess the level of antibody-independent clear-
ance of A in AD and after immunisation.
 Fc receptor I (Fc RI or CD64) and Fc receptor II (Fc RII or CD32) are cell
surface receptors involved in mounting of an immune response and phagocytosis
(Ravetch and Bolland, 2001; Nimmerjahn and Ravetch, 2006). These are expressed
by all tissue macrophages, including microglia. As mentioned in Chapter 1, results
from immunisation studies in animal models of AD suggested that anti-A anti-
body and antibody-A complexes interact with microglia through Fc receptors as
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(Bard et al., 2000; Schenk et al., 1999). Therefore, these markers were chosen to
investigate whether the antibody-dependent mechanism is involved in A clear-
ance in AD and after immunisation. Fc RI has high anity for human IgG, while
Fc RII is a low anity receptor for the Fc region of complexed human IgG and
is involved in phagocytosis of immune complexes.
 Human IgG is the most abundant immunoglobulin involved in protection of an or-
ganism from pathogens. It acts via activation of complement system, opsonisation
of pathogens for phagocytosis, and neutralisation of toxins. Active immunisation
relies on induction of the humoral immune response, i.e. production of antibodies.
Opsonisation of A by antibodies has been suggested (Bard et al., 2000; Britschgi
et al., 2009; Kellner et al., 2009; Seabrook et al., 2004; Trouche et al., 2009),
and increased uptake of IgG-coated amyloid brils has been demonstrated in vitro
(Brazil et al., 2000). As anti-A antibodies have been found to persist in the
serum of immunised AD patients for many years following the treatment (Holmes
et al., 2008), the level of IgG in immunised and non-immunised AD brain was also
investigated. In the current study all brain IgG was assessed.
 C1q is an early element of the classic complement pathway. The classic complement
system plays an important role in mounting of an immune response and indicate
antibody-mediated immune response. C1q is a protein secreted by all cells of
monocyte-macrophage lineage. It engages antibodies, including IgG, initiating
a cascade reactions leading to down-stream products (C3 to C5 proteins) with
nal formation of the C5b-9 cell membrane attack complex. Presence of elements
of the classic complement system linked to microglial activation has been long
reported in the brain of AD patients (McGeer et al., 1989; McGeer and McGeer,
1998). Therefore, C1q was chosen to assess the presence of complement in AD and
following immunisation.
The details of markers that failed to produce convincing evidence of specic im-
munostaining on the brain tissue following optimisation are listed in Table B.1 Appendix
B. Some of these markers (e.g. CD11b, CD14, CD16, CD36, and CD40) showed positive
immunostaining on tonsil tissue (used for protocol optimisation), and, therefore, the ab-
sence of positive immunostaining in AD tissue may indicate disease-specic changes inChapter 3. Methods 49
Table 3.5: Primary antibodies used for immunohistochemistry in Study 2
Name Clone
(Company)
Species
raised in
Dilution Staining
Iba-1 polyclonal
(Wako)
Rabbit 1:500 Ionised calcium-binding adapter
molecule 1 - calcium channel
protein, marker of resting and
activated microglia/macrophages,
up-regulated during activation.
MSR-A polyclonal
(R&D)
Goat 0.5g/ml Macrophage scavenger receptor A -
cell surface lipoprotein receptor in-
volved in direct ligand recognition,
including that of A.
CD64 polyclonal
(R&D)
Goat 5g/ml FcRI - cell surface receptor, high
anity receptor for human IgG,
main role in mounting an immune
response.
CD32 polyclonal
(R&D)
Goat 2g/ml FcRII - cell surface receptor, low
anity receptor for human IgG,
phagocytosis of immune complexes.
Anti-
human
IgG
polyclonal
(Dako)
Rabbit 1:2000 Human immunoglobulin class G.
C1q polyclonal
(Dako)
Rabbit 1:3000 Early component in the classic acti-
vation of complement system
microglial prole. Further investigations using control non-AD brain tissue may provide
supporting evidence for this suggestion.
Markers of AD pathology
As one of the aims of this projected included investigating the relationship between
microglial receptors and pathological features of AD, A42 load and phospho-tau load
were assessed in the iAD and cAD groups.
Isoform-specic monoclonal antibody for A42 (clone 21F12) was provided by Elan
Pharmaceuticals, Inc. (South San Francisco, CA). The iAD cases and both of the cAD
groups were assessed for A42 load in Studies 1 and 2.
The immunohistochemistry for phosphorylated tau protein was performed using
mouse anti-human phospho-tau antibody (clone AT8, Autogenbioclear, UK). The im-
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student Jane Donald as part of her science project. The immunostaining for the ad-
ditional iAD cases iAD11 and iAD16, the placebo AD case 15, and the non-AD cases
12-14, was completed for Study 2 by the author.
3.2.2 DAB immunostaining for light microscopy analysis
All antibodies were titrated and techniques optimised for the best performance prior
to main application. To minimise any variability due to the technique, the slides from
one brain area of control (non-immunised) and immunised cases were immunostained
together in one batch. Therefore, one batch contained a maximum of 46 slides (including
a negative and a positive control). One set of reagents prepared on the day of the
experiment was used for all slides. The slides were mixed so that immunised and control
cases were evenly distributed throughout the batch.
Slides with the tissue slices were taken through two baths of Clearene (Surgipath)
for 10 min each to remove paran, and then the tissue was rehydrated through graded
alcohol solutions and water. Slides were rinsed in TBS (TRIS buered saline pH7.6)
after each subsequent step of the protocol. The endogenous peroxidase was blocked
by incubation with 3% hydrogen peroxide in methanol for 10 minutes. An appropri-
ate antigen retrieval method was used for each antibody: heat-induced pretreatment
of the tissue in a microwave oven (800 Watt, medium power setting) in either 10 mM
citrate buer pH6.0 (for A42, CD68, HLA-DR, Iba-1, and MSR-A) or 1 mM ethylene-
diaminetetraacetic acid (EDTA) buer pH8.0 (for CD163, CD32, CD64) for 25 minutes;
and enzymatic pretreatment of the tissue in 0.5% solution of protease in TBS (for C1q)
or 0.05% solution of protease in TBS (for IgG) for 20 minutes at room temperature. No
antigen retrieval pretreatment was necessary for the phospho-tau (AT8) staining. Ad-
ditional treatment of sections with 98% formic acid for 3 minutes at room temperature
prior to microwave pretreatment was used for A42 staining. The microwaved slides
were cooled in running water and brought back to room temperature in TBS, while
slides pre-treated at room temperature were rinsed with TBS. Non-specic sites were
blocked by incubation in the blocking medium (80% Dulbecco's modied Eagles medium
/ 20% fetal calf serum / 1% bovine serum albumin) for 20 minutes at room temperature.
Incubation time in the primary antibody was 90 minutes at room temperature for all an-
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antibodies were diluted in TBS or in a commercial antibody diluent (Dako, S0809) for
CD32, CD64 and MSR-A to the required concentration (Table 3.4 and 3.5). Secondary
antibodies included rabbit anti-mouse diluted 1:800, swine anti-rabbit diluted 1:400, and
rabbit anti-sheep for goat anti-human primary antibodies, diluted 1:400 (all from Dako).
Incubation time in secondary antibody was 30 minutes at room temperature. Specic
binding was amplied with VECTASTAIN Elite ABC Kit (Standard) (Vector Labora-
tories) for 30 minutes at room temperature. The staining was visualised using DAB
Substrate Kit, 3,3-diaminobenzidine, (Vector Laboratories) to produce brown staining.
The incubation time was adjusted for each antibody to ensure optimal specic visual-
isation with minimum background. The slides were counter-stained to expose the cell
nuclei using Mayer's haematoxylin solution for 20-60 seconds. Slides were dehydrated in
a sequence of baths with graded alcohol (from 70% to 100%) and Clearene. Cover-slips
were mounted using Pertex mounting medium (HistoLab). Slides were allowed to dry
overnight prior to the microscopy analysis.
3.2.3 Triple uorescent immunostaining for confocal microscopy anal-
ysis
In order to assess distribution of the microglial markers CD68 and HLA-DR relative
to each other and A plaques, general immunohistochemistry protocol described above
(Section 3.2.2) was altered and optimised for triple immunostaining of A42, CD68
and HLA-DR visualised using uorescent secondary antibodies and confocal microscopy
(Section 3.3.2).
Slides were deparanised and re-hydrated as per protocol described in section 3.2.2.
Sections were treated with 98% formic acid for 3 minutes at room temperature, rinsed in
TBS and microwave-heated (800 Watt, medium power setting) in 10 mM citrate buer
pH6.0. Following cooling in tap water and in TBS at room temperature, slides were
incubated in the blocking medium (80% Dulbecco's modied Eagles medium/20% fetal
calf serum/1% bovine serum albumin) for 30 minutes at room temperature. The 21F12
antibody at concentration 1:2000 was applied for 90 minutes at room temperature,
followed by incubation in a mixture of HLA-DR and CD68 antibodies (both at 1:50
dilution) for further 90 minutes at room temperature. Sections were then rinsed in TBS
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Table 3.6: Secondary antibodies for uorescent immunohistochemistry (Invitrogen)
Name IgG
speci-
city
Labels
primary
Fluorescent emission
maximum at
AF647 IgG2a 21F12 647 nm
AF594 IgG3 CD68 594 nm
AF488 IgG1 HLA-
DR
488 nm
labeled with uorescent dyes (Invitrogen). Each secondary antibody recognised one of
the three primary antibodies applied in previous steps and had a distinct uorescent
tag, with its own absorption/emission peak when excited by a light source. The details
of the uorescent secondary antibodies are listed in Table 3.6. The incubation time was
60 minutes at room temperature in the dark.
Sections were then incubated in Sudan Black dye (1% dye powder in 70% alcohol)
in the dark at room temperature for 5 min to reduce the lipofuscin-like autouorescence
(Schnell et al., 1999). SYTOX Blue Nucleic Acid Stain (Invitrogen, 1:10000) was used to
counter-stain cell nuclei (10 minutes in the dark at room temperature). Cover slips were
then mounted onto the sections using Mowiol anti-fade medium (Polysciences, Inc.).
Sections were stored at 2-8C in the dark until confocal microscopy analysis.
3.3 Staining analysis and quantication
The immunostaining was quantied using either light microscopy (for DAB immunos-
taining) or Leica confocal microscopy image capturing platform for uorescent immunos-
taining.
3.3.1 Light microscopy
The microglial markers used in this project labelled microglial cell bodies as well as
processes. Two approaches were considered for the quantication of the immunostain-
ing: the counting of the immunopositive cells and the measuring of the antigen loadChapter 3. Methods 53
(percentage immunopositive area of total area examined). The quantication approach
based on the number of cells usually relies on the presence of the cell nucleus within the
immunopositive area. The use of this approach as a sole method of quantication would
leave out large proportion of immunostaining that was observed in microglial processes.
Therefore, the DAB immunostaining of all markers used in this project was quantied as
antigen load using ImageJ software (W. Rasband, NIH, USA). This type of quantication
was chosen as a more reliable and reproducible method that was based on a development
of a consistent image analysis protocol applied to all images within the same batch of
immunostained cases. However, in addition to the antigen load analysis, Iba-1-positive
cells, MSR-A-positive clusters, and AT8-positive neurobrillary tangles and clusters of
dystrophic neurites were quantied. The rational for the additional quantication of
Iba-1 and MSR-A markers was based on the proposed specicity of Iba-1 to label all
microglia (resting and activated) (Streit et al., 2009), and the unique clustering pattern
of the MSR-A immunostaining, not observed with any of the other microglial markers,
possibly indicating a distinct functional characteristic of MSR-A-positive microglia. For
the AT8 immunostaining, the counting of neurobrillary tangles and dystrophic neurite
clusters allowed exploring relationships between microglia and the dierent features of
the phospho-tau pathology. The count analysis of phospho-tau immunostaining was
performed in 20 elds in each of the three brain areas (temporal, frontal and parietal)
dened by an ocular morphometric grid inserted into one of the eyepieces of the Nikon
Eclipse E600 microscope at magnication x10 (performed by medical student Jane Don-
ald for all cAD and 9 iAD cases). Iba-1-positive cells and MSR-A-positive clusters were
counted in similar way in 30 elds in each of the three brain areas at magnication x20.
The counting of Iba-1-positive cells was performed by medical student Viraj Bharambe.
The antigen load analysis involved a series of steps outlined below.
3.3.1.1 Image capture
The quantication of the protein load involved capturing images from each slide using
Nikon Eclipse E600 microscope, and either a digital camera Nikon Coolpix950 (CP950)
for A42, AT8, CD68, HLA-DR, CD163, CD64, CD32, Iba-1, IgG, and C1q, or a digital
camera Nikon Coolpix4500 (CP4500) for MSR-A set at full zoom. The same camera
model and camera settings were used for all sections in a given antibody batch. The54 Chapter 3. Methods
CP4500 is a more recent camera model that was introduced at the later stage of the
project (Study 2).
Twenty images of grey matter immunostained for A42 (Studies 1 and 2), Iba-1,
CD32, CD64, IgG, and C1q (Study 2), and of each grey and white matter immunos-
tained for CD68, HLA-DR, and CD163 (Study 1) were captured at magnication x10
using CP950 camera. For the analyses of immunostaining of CD68 and phospho-tau
(AT8) in Study 2, 30 images of cortical grey matter were captured at magnication
x20 using CP950 camera. Higher magnication was chosen for these markers to obtain
an optimum detection of immunostaining of ner features during image analysis (e.g.
phospho-tau-positive dystrophic neurites and intracellular lysosomal structures labeled
by CD68). For the immunostaining of MSR-A, 40 images of cortical grey matter were
captured at magnication x10 using camera CP4500. As mentioned above, CP4500 is
a more recent camera model that was introduced at the end of Study 2. This camera
allows capturing images at higher resolution providing higher quality images and clarity
of the immunostained features. Examples of images taken with CP950 camera at mag-
nications x10 and x20 and with CP4500 at magnication x10 are shown in Figures 3.1,
3.2 and 3.3.
Images of grey matter were taken in a zig-zag sequence to ensure that all layers
of neurons were included in quantication. Larger number of images per brain region
was captured when using CP950 at magnication x20 (30 images) or CP4500 at mag-
nications x10 (40 images) compared to CP950 set at magnication x10 (20 images)
to partially compensate for the discrepancies between the area covered by each camera
when set at full zoom. CP950 camera resolution allowed capturing images of the size
1600 by 1200 pixels, which corresponded to 0.9 mm2 of tissue per image taken at mag-
nication x10, and 0.2 mm2 of tissue per image taken at magnication x20. CP4500
camera resolution allowed capturing images of the size 2272 by 1704 pixels correspond-
ing to 0.4 mm2 of tissue per image taken at magnication x10. In this way, the total of
54 mm2 area was analysed using CP950 set at magnication x10, 20 mm2 area - using
CP950 set at magnication x20, and 48 mm2 area - using CP4500 set at magnication
x10 (Table 3.7).Chapter 3. Methods 55
Figure 3.1: Example of a picture taken for quantication from a cAD case immunos-
tained for HLA-DR using camera CP950 set at full zoom at magnication x10. Scale
bar = 100m.
Figure 3.2: Example of a picture taken for quantication from a cAD case immunos-
tained for CD68 using camera CP950 set at full zoom at magnication x20. Scale bar
= 100m.56 Chapter 3. Methods
Figure 3.3: Example of a picture taken for quantication from a cAD case immunos-
tained for MSR-A using camera CP4500 set at full zoom at magnication x10. Scale
bar = 100m.Chapter 3. Methods 57
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3.3.1.2 Image analysis
Images were analysed using software ImageJ. The software is a public domain, Java-
based image processing program developed at the National Institutes of Health (US)
(Rasband, 2005). It allows usage of in-built Java plug-in(s) as well as development of
user-written macros for image analysis. Therefore, for the purpose of the project, macros
specic for each antibody analysis were designed using in-built functions of the software
as well as user-dened functions to extract the necessary information from each image.
Two quantication methods were used during the course of the project.
Method 1
Images from Study 1 (A42, CD68, HLA-DR, and CD163) were processed using this
method. The following steps were applied to each image:
1. Background correction using the Subtract Background function, which removed
the smooth continuous light background using the \rolling ball" algorithm (Stern-
berg, 1983). A local background value was determined for every pixel by averaging
over a 50 pixel radius ball around it, and then subtracted from the original pixel
(Figures 3.4 and 3.5).
Figure 3.4: An original image of DAB-stained HLA-DR, 16001200 pixelsChapter 3. Methods 59
Figure 3.5: Image as in 3.4 with subtracted background.
2. Enhancement of the contrast with saturation of 0.5% of all pixels (Figure 3.6).
This procedure applied a histogram stretching technique that scanned the im-
age, identied the lowest and the highest pixel values present, reset these pixels
as maximum (white) and minimum (black) and re-scaled the rest of the pixels
accordingly.
Figure 3.6: Image as in 3.5 with enhanced contrast.
3. Re-colour of the image. Original images were taken in the RGB format with all
colours present in the image composed of various levels of red, green and blue. Prior
to re-colouring, all three colours were given an automatic equal scaling factor of
1, i.e. all colours were present in full intensity. In this step, the scaling factors for60 Chapter 3. Methods
red and green colours were set to 0, to make everything that contained these two
colours appear black. The images did not contain any red or green staining alone,
so this method was suitable, because brown staining of the DAB is composed of
green and red. The blue scaling factor remained at 1, so everything that was not
green or red (or brown in this type of images) appeared blue (Figure 3.7).
Figure 3.7: Image as in 3.6 re-coloured making brown (DAB) staining appear black.
4. Conversion of the image into an 8-bit format. This step converted images into a
grey scale format (Figure 3.8).
Figure 3.8: Image as in 3.7 converted into an 8-bit grey format.
5. Adjustment of the threshold (Figures 3.9 and 3.10). This step allowed setting of the
threshold value in the black and white version of the image to leave only the specicChapter 3. Methods 61
staining as black. The software allowed setting maximum and minimum threshold
values. The chosen values were based on the visual assessment of images with
the most intense and the least intense staining, and comparison to an unprocessed
image to see whether most of the specic staining was included, performed by
the user. All sections for each antibody analysis were stained together in batch
runs to minimise any variability in the staining intensity between the slides due
to the procedure. Any dierence in slide staining was, therefore, due to individual
case variability or treatment (immunised/non-immunised) only. The threshold was
dened by a single user (the author) based on several images from each case over
the course of several sessions performed on dierent days. One set of threshold
values was selected and applied to the images of all cases stained by the same
antibody. This approach, together with the experience of the user, was used to
minimise the intra-rater variability. The minimum threshold was set at 0 for all
of the markers. For A42 staining the maximum threshold was set at 65. For the
microglial CD68, HLA-DR, and CD163 staining both thresholds were set at 0.
Figure 3.9: HLA-DR-stained example image: unprocessed as in 3.4 (left) and pro-
cessed as in 3.8 with threshold set at 0/0 (right).
6. Measurement of the stained (black) area was performed using the Measure function
for A42 staining or the Analyse Particles function for HLA-DR, CD68 and CD163
staining in Study 1 built into the ImageJ software. The Measure function calculates
and displays the proportion (in %) of the black area in relation to the total area of
that image. The Analyse Particles function counts and measures objects present
on a thresholded image. It works by scanning the image until it nds the edge62 Chapter 3. Methods
Figure 3.10: A42-stained example image: unprocessed (left) and processed with
threshold set at 0/65 (right).
of an object. It then outlines the object using the wand tool, measures it using
the Measure command, lls it to make it invisible, then resumes scanning until
it reaches the end of the image. This function allows user to select the particle
size limit and circularity. The limit was set at 10m2. The objects with the area
size smaller than the limit were not included in the count. This option was used
to ensure that any remaining background noise was not counted. The circularity
was set to zero to allow objects of all shapes to be included into the count. The
combined area occupied by all objects on the image was recorded as a percentage
(%) of the total area of the analysed image.
For the CD68 staining in Study 1 the obvious staining in blood vessels was cut out
from images manually using Freehand Selection and Cut functions of the ImageJ
software. The aim was to assess only the parenchymal population of microglial
cells. However, the results were similar in terms of dierences between cAD and
iAD groups whether the perivascular cells were excluded or not, and all subsequent
analyses included all visible staining to save time.
A macro was designed that incorporated all the above steps (1-6) to allow automatic
image processing and data collection into a text le for individual cases. A sample of
the programming code is included below:
run("Subtract Background...", "rolling=50 white");Chapter 3. Methods 63
run("Enhance Contrast", "saturated=0.5");
run("RGB Recolor", "red=0 red=0 green=0 green=0 blue=1 blue=0");
run("8-bit");
setAutoThreshold();
//run("Threshold...");
setThreshold(0, 0);
run("Convert to Mask");
run("Analyze Particles...", "size=10-Infinity circularity=0.00-1.00
show=Nothing summarize");
The resulted values from individual cases were compiled into a spreadsheet and
plotted as a scatter plot for quality control purposes to visually identify any outliers
with particularly high or low values, which were then checked manually to conrm that
the analysis was performed correctly.
Method 2
Images from Study 2 (A42, AT8, CD68, CD64, CD32, MSR-A, IgG, and C1q) were pro-
cessed using Method 2, which represented a modied and improved version of Method 1.
Modications to Method 1 were introduced based on the advice provided by the ImageJ
Information and Documentation portal (ImageJ Wiki, http://imagejdocu.tudor.lu/) and
Hypermedia Image Processing Reference (HIPR) portal (http://homepages.inf.ed.ac.uk).
The ImageJ portal is regularly updated by registered users and developers of the ImageJ
software. The HIPR was developed by the Department of Articial Intelligence, Univer-
sity of Edinburgh, in 2004. Their portal was designed to provide detailed information
on image processing with examples of images and outputs. ImageJ portal often refers
to HIPR portal for explanations and examples of ImageJ functions.
Step 1 in Method 1 involved correction of each image for the background. In light
microscopy, it is dicult to obtain an even \at" illumination across the whole image
as a result of the microscope condenser not being able to provide a homogeneous light
across the view eld. There are usually a bright eld (often in a centre of an image)
and dark elds (often in the corners of an image) as shown in Figure 3.11. Correction
for the background illumination is an important stage in image processing, particularly64 Chapter 3. Methods
if thresholding is applied during the image analysis. As mentioned in Method 1, the
Subtract Background function in ImageJ was used for this purpose. However, advice
provided by the ImageJ portal on \How to correct background illumination in brighteld
microscopy" (Landini, 2010) describes this type of correction as retrospective (or a pos-
teriori) image correction method that relies on assumptions about image characteristics
that may not be applicable to all images analysed and compared in one experiment.
Figure 3.11: Examples of images taken for quantication demonstrating uneven il-
lumination within the same image and between images of dierent immunostaining:
CD64 (top left), A42 (top right), Iba-1 (bottom left), and CD32 (bottom right).
Indeed, the \rolling ball" algorithm used by the Subtract Background function gen-
erates a background based only on the currently analysed image, which is then removed
from the original image using pixel subtraction method. The generated background im-
age is individual to each image within the batch and therefore, the background that is
removed is not consistent for all images. Figure 3.12 demonstrates two example images
taken from the same AD case and their respective background images generated using
the Subtract Background function when an option \Create background (don't subtract)"
is selected. As seen from the gure, the generated background of an image that contains
numerous plaques has more dark areas than the generated background of an image that
contains only a few plaques.
The recommended method for the background illumination correction is the acquisi-
tion (or a priori) correction (Landini, 2010). This method involves capturing a Darkeld
image by blocking the lightpath between the microscope lamp and the camera while theChapter 3. Methods 65
Figure 3.12: Examples of A42 images taken for quantication from a cAD case (top)
and their respective background images (bottom) generated using the Subtract Back-
ground function of ImageJ. Original features (plaques) can be visible on the background
images demonstrating that background generation using this method depends on the
characteristics of individual image and therefore cannot be assumed as a consistent
method for background correction of multiple images.
microscope is switched on, and a Brighteld image with the lightpath open but no spec-
imen present, at the time of taking the Specimen image, keeping all the microscope
and camera settings constant. It is recommended that the Darkeld and the Brighteld
images are taken regularly throughout the Specimen image capturing session. These
can then be stacked to produce an average Darkeld and an average Brighteld images.
In this way, a consistent background image can be applied to all images to correct the
uneven illumination. This method was identied when all the images from Study 2 were
already taken, without darkeld and brighteld images. As shown in Figure 3.11, images
from dierent immunostaining batches showed dierent uneven illumination. Therefore,
it was not feasible to replicate the exact microscope and camera settings in order to take
the Brighteld and the Darkeld images for each case.
A compromising method was developed taking into account the image correction
method recommended by Landini. The Subtract Background function of ImageJ with
the \Create background (don't subtract)" option selected was used to generate back-
ground images of individual original images within each case as shown in Figure 3.13.
The individual background images (20, 30 or 40 per case, depending on the magni-
cation used) were saved and then stacked using the Images to Stack function (Figure
3.14), and an image reecting average intensity across the stack was produced using66 Chapter 3. Methods
the Z Project Average Intensity function of ImageJ (Figure 3.15) as recommended by
the Landini method. As images for each slide (cAD or iAD case) were captured in one
microscopy session, the resulted average background image was comparable to a Bright-
eld image captured with no specimen (slide) (Figure 3.16) and reected the uneven
illumination at the time of the original image capture. The average background image
was generated and used for each case, providing a consistent way of image processing.
The Darkeld image was assumed to be constant with all pixel values being zero.
Figure 3.13: Generation of background images of individual images prior to quan-
tication. Each image was opened and the Subtract Background function of ImageJ
with \Create background (don't subtract)" option selected was used (top) to produce
a corresponding background image (bottom).
Another issue with the Subtract Background function of ImageJ used for background
correction in Method 1 is the choice of image arithmetics. The highly variable individual
background image generated by the program was subtracted from the original image
using the following equation:
Corrected Image = Specimen   Background + 255 (3.1)Chapter 3. Methods 67
Figure 3.14: All generated background images from each case were opened (top) and,
using the Images to Stack function of ImageJ, a stack was produced (bottom).
Figure 3.15: The Z project function of ImageJ with \Average Intensity" as Projection
Type option selected was applied to the stack of generated background images (top) to
produce an average background image for each case (bottom).68 Chapter 3. Methods
Figure 3.16: An example of 1 of 20 images taken from a cAD case immunostained for
Iba-1 (top), an average intensity background image generated from 20 images (middle),
and a brighteld image taken with microscope settings as at the time of the capture
of the 20 images from this case (bottom). The generated average background image
reects the uneven illumination of the original image and is comparable to the original
brighteld image.Chapter 3. Methods 69
A constant oset value of 255 (the maximum pixel intensity in an 8-bit image) was
used in order to avoid negative values.
Pixel subtraction can partially improve an unevenly illuminated image but at a cost
of altering the contrast. For example, two objects of interest that are of the same size
and intensity but dier in their position on an image, one being in the centre (bright
part) of the image, while the other - in a (darker) corner of the image, will have dierent
intensity values following the image subtraction procedure, as calculated in Table 3.8.
The method recommended by Landini relies on Brighteld and Darkeld images in
addition to the Specimen image, and utilises pixel division in the correction equation as
follows:
Corrected Image = (Specimen Darkfield)(Brightfield Darkfield)255 (3.2)
A constant oset value of 255 is used in this equation to produce an image that can
be visualised (i.e. the intensity value of each pixel is a whole number, rather than a
fraction of 1).
Pixel division is more appropriate for image analysis as the light that passes through
the object of interest (e.g. A plaque) represents a proportion of the total light from
the microscope light source. Therefore, contrast discrepancies between the bright part
and the dark parts of an image are corrected by pixel division. Using the same example
of two identical but unevenly illuminated objects, Table 3.8 demonstrates how pixel
division can correct the illumination resulting in identical pixel values (127.5) of the
two objects following the procedure. Compare this to pixel subtraction that produces
higher pixel value (155) for an object in a dark part of an image than for an identical
object in the bright part of the image (127.5). The eect of the discrepancies due to
pixel subtraction would be reected in a size (area) dierences between two originally
identical objects following image thresholding, and, therefore, inaccurate nal data.70 Chapter 3. Methods
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Step 2 in Method 1 involved the Enhance Contrast function of ImageJ. Although
this step visually improved the contrast of colours, allowing weak staining to be included
in the quantication, the procedure itself is not recommended for image analysis as it
articially alters the contrast and is highly inconsistent. The lowest and the highest pixel
intensity values are likely to dier between images. Therefore, histogram stretching and
re-scaling of pixel values according to the lowest and the highest values are inconsistent
between images. In addition, the same number (0.5%) of pixels was allowed to become
saturated in each image. In this way, the same number of pixels would always be satu-
rated in each image, irrespective of how many pixels \qualify" for saturation according
to the histogram. For example, assuming that 5 pixels are allowed to become saturated
in each image, two images are considered. Image A has 10 pixels that have intensity
value 1 (nearly black), while Image B has only 2 pixels with intensity value 1. 5 of the 10
nearly black pixels from Image A would become black (of value 0) upon application of
the Enhance Contrast function, while the remaining 5, although would have value lower
than 1 after re-scaling, would not be completely black, as the \quota" for saturation
(maximum 5 pixels) has been fullled. However, in the original Image A all 10 pixels
were of the same intensity. In Image B, 2 pixels that were of value 1 would become
saturated (black, or of value 0), but as there are still 3 pixels left in the \quota", the
scanning of the image would continue until the next pixel, e.g. of value 2, is found, and
allowed to become black (of value 0). The process would continue until 5 pixels became
saturated. In this way, pixels that were of dierent values in the original image, become
the same after the enhancement of the contrast. It is then becomes obvious, that two
pixels of the same intensity in two dierent images become dierent upon enhancement
of the contrast depending on the number of pixels of similar intensity values present on
these images. Although not always obvious to the naked eye, this inconsistency may
lead to articially higher quantication of staining load for images with only few objects
of interest (plaques or positive microglial staining), and underestimated staining load in
the images with large number of objects. The Enhance Contrast function was, therefore,
omitted from Method 2.
Step 3 in Method 1 involved re-colouring of the image in a way that converted all
the pixels that were red or green (not blue) into black. Although this procedure allows
only specic staining to be visualised in an 8-bit format, the process of recolouring of
compressed images (in jpeg format) may lead to artifacts. Instead, splitting of channels72 Chapter 3. Methods
of the original image is recommended, and was used in Method 2.
Based on the revision of Method 1, Method 2 was developed and consisted of 5 steps
listed below illustrated by the analysis screen shots of a CD64-immunostained image
from a single cAD case (Figure 3.17):
Figure 3.17: Example of an original image for analysis using Method 2 - cAD case
temporal lobe immunostained for CD64.
1. The Average Background image generated for each case as outlined above was
opened, and the red, green and blue channels were split using the Split Channels
function of the Image menu, producing three 8-bit (grey scale) images as shown in
Figure 3.18.
Figure 3.18: Method 2 Step 1 - Example of an original Average Background image
(produced from 20 images of CD64-immunostained temporal lobe of a cAD case, in-
cluding the image in Figure 3.17) and its corresponding individual colour (red, green
and blue) channel 8-bit images produced using the Split Channels function of the Image
menu.Chapter 3. Methods 73
2. A Specimen image was opened and the channels split in the same way as the Av-
erage Background image (Figure 3.19). The blue channel images of the Specimen
and the Average Background images depicted all non-blue (i.e. green and red)
pixels as black.
Figure 3.19: Method 2 Step 2 - Example of an original Specimen image (as in Figure
3.17) and its corresponding individual colour (red, green and blue) channel 8-bit images
produced using the Split Channels function of the Image menu.
3. The blue channel image of the Specimen was corrected for uneven illumination
using a modied version of the Landini's equation (3.2) and the Calculator Plus
plug-in (Figure 3.20). The modied equation was as follows:
Corrected Image = (Specimen Blue)  (Background Blue)  255 (3.3)
4. A threshold was applied to each Specimen image using the Adjust Threshold func-
tion of the Image menu (Figure 3.21). The minimum threshold value was 0 for
all images. The maximum threshold values were determined by visually assess-
ing a number of images from each iAD and cAD cases by the user as described
in 5 to minimise the intra-rater variability. The chosen values were constant for
all images within each batch consisting of cAD and iAD slides of one brain area
immunostained with a specic antibody as listed in Table 3.9.
5. The total positive immunostaining was quantied using Measure function of the
Analyze menu, calculating the immmunopositive proportion (in %) of each image
(Figure 3.22).74 Chapter 3. Methods
Figure 3.20: Method 2 Step 3 - Correction for uneven illumination using blue channel
images of a Specimen and its corresponding Average Background images using division
option of the Calculator Plus plugin (top) produced an evenly illuminated 8-bit (gray
scale) version of the original image.
A macro was designed to incorporate the above steps for automatic image analysis
and to record the data into one spreadsheet (Microsoft Excel) le. A sample of the java
script is included below:
open(avg_bg_image);
run("RGB Split");
open(Specimen);
run("RGB Split");
cpString = "i1=[" + Specimen_blue + "] i2=[" + avg_bg_image_blue + "]
operation=[Divide: i2 = (i1/i2) x k1 + k2] k1=255 k2=0 create";
run("Calculator Plus", cpString);
setAutoThreshold();
setThreshold(0, 180);
run("Convert to Mask");Chapter 3. Methods 75
Figure 3.21: Method 2 Step 4 - A threshold value (195 in this case) applied to the
corrected image (Figure 3.20) displaying only antibody-specic staining.
Table 3.9: Maximum threshold values used for antibody-specic immunostaining
quantication in Study 2 using Method 2.
Antibody Threshold
value
Brain area
A42 190 temporal, frontal, parietal
Phospho-tau (AT8) 145 temporal, frontal, parietal
FcRI (CD64) 195 temporal, frontal, parietal
FcRII (CD32) 180 temporal, parietal
185 frontal
MSR-A 160 temporal, frontal, parietal
Iba-1 190 temporal
180 frontal, parietal
CD68 170 temporal
180 frontal, parietal
IgG 195 temporal, frontal, parietal
C1q 180 temporal, frontal, parietal76 Chapter 3. Methods
Figure 3.22: Method 2 Step 5 - The antibody-specic immunostaining was calculated
using the Measure function of ImageJ.
run("Measure");
3.3.2 Confocal microscopy
The triple uorescent immunostaining and confocal image analysis were chosen to pro-
vide descriptive information about microglial activity, in addition to the information
on overall immunostaining load obtained from the DAB immunostaining and light mi-
croscopy image analysis. Therefore, a suitable approach to taking images and quanti-
fying the colocalised staining of CD68 and HLA-DR was necessary. Two approaches
were considered for the image capture and quantication. Both relied on assigning each
marker, CD68 and HLA-DR, to red (R) and green (G) colour respectively. Pixel that
was coloured yellow was assumed to contain overlapping R and G coloured proteins,
indicating overlap of the two markers. The details of the two approaches are discussed
below.
1. Quantication of a proportion of the area within each eld that had both, G and
R, colours vs one, G or R, colour.
This approach provides information on total colocalised material (i.e. protein)
without being able to distinguish whether the two markers belong to the same cell.
The aim was to establish whether the two types of microglial activities were located
in the same eld, regardless of whether they belonged to the same cell or not.
Therefore, this approach was sucient to extract the necessary information. The
magnication variable had to be considered in this approach, as it aects the degree
of colocalisation. CD68 (lysosomal marker) is located in the cytoplasm of the
cells, whereas HLA-DR (antigen-presenting complex) is located on the cell surfaceChapter 3. Methods 77
as well as in the cytoplasm (in vesicles). After testing several magnications,
magnication 20 was chosen as it provided a suciently low spatial resolution
for overlaying the surface and cytoplasm of cells and a suitable colour resolution
in the areas of overlap.
2. Quantication of the total number of \patches" of pixels (assumed to be cells) that
contain both green and red colours.
This approach can provide the information on the number of cells that have both
proteins expressed. To use it, a \smoothing" eect would need to be applied to
the images to pick out patches of coloured pixels. A major assumption in this ap-
proach is that a stained patch is assumed to represent a cell. Magnication choice
presents an issue with this assumption. To avoid overlap of two dierent cells, the
magnication would have to be higher than 20. This, in turn, presents a ques-
tion of the number of images that would need to be taken to cover a representative
area in a realistic time-scale. Another problem with this method is the choice of
criteria for a \cell". Microglial processes as well as cell bodies can contain both
G and R proteins, but be distant from each other. Therefore, this approach can-
not distinguish whether colocalisation event is within one cell or between two (or
more) cells. This would introduce a major error to the counts. Equally, counting
only G and R near nucleus leaves out large proportion of staining that is found in
microglial processes.
As seen from above, both approaches have limitations, but approach 1 was chosen
as more suitable for the question addressed in this experiment. It allows extracting
information on colocalisation of the two proteins in systematic, reproducible, biologically
meaningful and more accurate way as it quanties the area of colocalised proteins that
are clearly stained and visible, rather than an abstract and user-specic denition of a
cell. It also requires fairly low magnication, meaning a more representative area could
be covered by the analysis.
3.3.2.1 Confocal image capture
Leica TCS SP5 confocal microscopy and scanning system was used for image capture.
The system has ve confocal channels that can be used simultaneously. A range of78 Chapter 3. Methods
colours is available that can be assigned to specic staining. Red colour was chosen for
CD68 staining, and green for HLA-DR, so that the overlap of the two markers produced
yellow colour to simplify the visualisation of the colocalised staining.
The absorption and uorescence emission maxima for the Sytox Blue stain are 444
nm and 480 nm respectively. The emission maxima for all other markers used are
specied in Table 3.6.
Figure 3.23: Screen-shot of LAS-AF program demonstrating settings used for se-
quential scanning - Scan 1, with active channel 1 (PMT1, Sytox Blue, cell nuclei) and
channel 3 (PMT3, Alexa 594, CD68).
Parietal area of the brain from seven immunised and nine control AD cases was
assessed. Ten confocal images were obtained from each slide using a Leica TCS SP5
laser scanning confocal microscope tted on a Leica DMI6000 inverted microscope stand.
Specimens were imaged using Leica LAS-AF software (v1.8) with an oil immersion 20
HC Plan Apochromat objective, 400 Hz scan rate, pixel resolution of 512512 and
pinhole set to 1 Airy unit. Four channels were monitored in 2 pairs by sequential
imaging to avoid cross talk between the uorochromes. Each area was rst scanned
under the conditions of Scan 1 (PMT 1 and PMT 3), and then Scan 2 (PMT 2 and
PMT 4) (Figures 3.23 and 3.24). Each scanned eld was saved in a format that allowedChapter 3. Methods 79
to view and analyse images of each channel separately (i.e. one colour at a time - Figure
3.25) and a combined image with all (or selected) channels overlaid (Figure 3.26).
Figure 3.24: Screen-shot of LAS-AF program demonstrating settings used for sequen-
tial scanning - Scan 2, with active channel 2 (PMT2, Alexa 488, HLA-DR) and channel
4 (PMT3, Alexa 647, A42).80 Chapter 3. Methods
Figure 3.25: Screen-shot of LAS-AF program demonstrating individual channel im-
ages of a eld scanned by four channels at 20 magnication: nuclear staining - blue
(top left), CD68 - red (top right), HLA-DR - green (bottom left), and A42 - cyan
(bottom right).Chapter 3. Methods 81
Figure 3.26: Screen-shot of LAS-AF program demonstrating an image of a eld
scanned by four channels at 20 magnication as in Figure 3.25. All channels are
overlaid to produce a multi-coloured image.82 Chapter 3. Methods
The details of each lter are listed in Table 3.10
Table 3.10: Details of confocal lters used in SP5 system
PMT
No.*
Laser
line
(nm)
Detection
range
(nm)
Assigned
colour
For anti-
body
Staining
PMT 1 458 463-506 Blue SYTOX
Blue
Cell nuclei
PMT 2 488 506-550 Green HLA-
DR
Microglial antigen-
presenting complex
PMT 3 594 602-636 Red CD68 Microglial lysosomes
PMT 4 633 648-721 Cyan 21F12 A42
* Note: PMT = photomultiplier tube. The PMT measures the 8-bit (256 level grey
scale) intensity of the uorescence emitted from the positions that the laser excites as
it raster scans across the specimen, and the software builds this up into a 2D image of
the sample.
Z slices were taken at 1 m intervals through the sections with photomultiplier gains
and osets adjusted to optimal settings for each specimen.
As mentioned above, only parietal area of the brain from seven immunised and nine
control AD cases was assessed for colocalisation due to time constraints and technical
issues (replacement of the magnication 20 lens).
3.3.2.2 Confocal image analysis
Data analysis was performed on the 3D maximum projection of the Z series of the red
(CD68) and green (HLA-DR) pair of images for each specimen using ImageJ macro -
JACoP (Just Another Colocalisation Plugin) (Bolte and Cordelieres, 2006).
This macro (or plug-in) is a compilation of general colocalisation indicators and more
recently published methods allowing quantication of the colocalisation level in a pair
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on two images according to the selected methods. For the current analysis the Pear-
son's coecient, the Overlap coecient, the k1 and k2 coecients, and the Manders'
coecients M1 and M2 were used (Manders et al., 1993).
The Pearson's coecient is a linear equation describing the relationship between
the intensities in two images calculated by linear regression. The slope of this linear
approximation provides the rate of association of two uorochromes. In contrast, the
Pearson's coecient provides an estimate of the goodness of this approximation. Its
value can range from 1 to -1, with 1 standing for a complete positive correlation and -1
for a negative correlation, with zero standing for no correlation (Bolte and Cordelieres,
2006).
The Overlap coecient, the k1, and the k2 coecients were introduced by Manders
and colleagues (Manders et al., 1993). The three coecients rely on the Pearson's
coecient. The Overlap coecient is calculated as the Pearson's coecient with the
mean intensity value of both channels being taken out of the expression. The k1 and k2
coecients are dened as two components of the Overlap coecient, the former being
related to the total intensity of the rst channel (e.g. red), the later being related to the
total intensity of the second channel (e.g. green).
Although the above coecients were obtained from the image analysis, only the
Manders' coecients M1 and M2 were used for the nal comparison of images and the
data analysis. These Manders' overlap coecients are based on the Pearson's correlation
coecient with average intensity values being taken out of the mathematical expression
(Manders et al., 1993). The coecients vary from 0 to 1. For a red-green pair M1=1
and M2=0.2 indicate that 100% of red pixels colocalise with green pixels, and 20% of
green pixels colocalise with red pixels (Zinchuk et al., 2007). M1 is dened as the ratio
of the \summed intensities of pixels from the red image for which the intensity in the
green channel is above zero" to the the \total intensity in the red channel" and M2 is
dened conversely for the green channel (Manders et al., 1993). Therefore, M1 and M2
are suitable indicators of the proportion of the coincident red and green signals, which
may even apply if the intensities in both channels are very dierent from one another.
These coecients were used with set thresholds, which were dened as 51 for the red
channel and 60 for the green channel on the basis of visual assessment by the user. These
threshold settings were used in the analysis of all images.84 Chapter 3. Methods
The JACoP plugin was automated to allow analysis of images in batches.
Each pair of images (red and green) were taken through the following steps:
1. Open two images - green (HLA-DR) and red (CD68) (Figure 3.27)
Figure 3.27: Examples of red and green images of the same eld scanned at magni-
cation 10: CD68 - red (left), HLA-DR - green (right).
2. Running the JACoP macro:
 Choose parameters to be shown: Pearson's coecient, M1, M2, Overlap co-
ecient, k1, and k2 (Figure 3.28).
 Set threshold of 51 for the red (A) and 60 for the green (B) images - Figure
3.29.
 Run the macro - a summary of results is produced (Figure 3.30).
The Manders' coecients using set thresholds (termed as tM1 and tM2), were
compared between the immunised group and the non-immunised group of AD cases.Chapter 3. Methods 85
Figure 3.28: Screen-shot of ImageJ running JACoP macro. CD68-Red image (back-
ground right) and HLA-DR-Green image (background left) are assigned to images A
and B respectively (foreground middle). The required \Correlation-based colocaliza-
tion" parameters are ticked: Pearson's Coecient, Overlap coecient, k1 & k2, and
M1 & M2 coecients (foreground middle).86 Chapter 3. Methods
Figure 3.29: Screen-shot of ImageJ running JACoP macro. Threshold parameters
are set at 51 for Image A (Threshold A - CD68-Red image (background right)) and at
60 for Image B (Threshold B - HLA-DR-Green image (background left)). Note that
setting a threshold function converts both images into red/black format.Chapter 3. Methods 87
Figure 3.30: Screen-shot of ImageJ running JACoP macro. A log le is generated for
each pair of images analysed listing the calculated results of all the required coecients.
3.4 Data analysis
Data were analysed using statistical software SPSS (SPSS Inc., Chicago IL).
Results were expressed as: protein load (% of area stained of area examined) obtained
from the light microscopy analysis, the sum numbers of Iba-1-positive microglial cells
or MSR-A-positive microglial clusters per 90 elds obtained from manual counting, and
thresholded Manders' coecients (tM1 and tM2) obtained from the confocal microscopy
colocalisation analysis.
For the light microscopy analysis, data obtained for the three brain areas aected
by the AD pathology (temporal, frontal and parietal) were combined for each case.
Only cases that had tissue from all of the three areas were taken into the nal data
analysis to ensure that data were representative of each case, and each case had similar
amount of data. Therefore, eight control cases were used in Study 1. Not all of these
cases and not all of the immunised cases in Study 1 had available tissue from the pons.
Therefore, when analysing protein level in the pons, the number of cases was reduced
to six controls (No. 5, 7, 10, 11, 12, 13) and seven immunised. Non-AD participants of88 Chapter 3. Methods
the AN1792 clinical trial (PSP (No. 5), DLB (No. 12), VaD (No. 13), and FTD (No.
14)) were omitted from the data analysis. Only immunised AD subjects were compared
to non-immunised AD controls.
Data obtained for each case (immunised or control) were assessed for normal dis-
tribution using one-sample Kolmogorov-Smirno test and by constructing Q-Q plots.
Kolmogorov-Smirno is a goodness-of-t test, which assesses whether a given distri-
bution is not signicantly dierent from the hypothesised distribution (normal, in this
case). Two-tailed signicance of less than 0.05 meant the data was not normally dis-
tributed. Q-Q plots were also constructed for each case to visually conrm the distribu-
tion of the data.
Assessment of the protein load generated 60 or 90 data points for each case, de-
pending on the number of elds analysed (20 or 30 per each of the three brain areas).
Equally, 90 data points were generated for the manual counts. The confocal image anal-
ysis produced 10 data points for each case as 10 elds were analysed in one brain area
only (parietal lobe). Some of the cases fullled the normal distribution criteria, whereas
others did not. Therefore, normal distribution could not be assumed for all cases, and
median (rather than mean) values were used for constructing and comparing two data
sets - immunised (assigned Group 1 in SPSS) and non-immunised (Group 0). The dis-
tribution of the individual median values in the immunised and the non-immunised data
sets were also assessed for normal distribution. Consistent normal distribution was not
observed between the data sets. Therefore, two-tailed Mann-Whitney non-parametric
statistical test was used to compare the two AD groups and to test for signicant dif-
ferences. For the manual counts, the sum numbers for all three brain areas rather than
median values were used due to the skewness of the data. Non-parametric correlations
were constructed when analysing microglial data in relation to the A42 load using
Spearman's approximation and Correlation Coecient R. P values less than 0.05 were
taken to indicate signicant dierence between the two groups. Median values for protein
load or sum values for manual counts are quoted in the Results (Chapter 4).Chapter 3. Methods 89
3.5 Extraction of genetic material and quantitative real-
time polymerase chain reaction analysis (qRT-PCR)
In order to assess the expression of cytokines in AD brain and following A42 immunisa-
tion, total RNA extraction followed by qRT-PCR was attempted using the formalin-xed
paran-embedded (FFPE) tissue from the temporal lobe of immunised and control AD
cases. RNeasy FFPE kit (Qiagen, USA) was used for isolation and purication of total
RNA and included the following steps:
1. 5 m-thick sections were either cut from the temporal lobe blocks embedded into
paran or scraped from glass slides into 1.5ml vials lled with xylene, and sub-
jected to mixing using Vortex mixer in order to deparanise the tissue.
2. The vials were centrifuged at 4400 rpm for 2 minutes at room temperature, and
the supernatant discarded.
3. 100% ethanol was added to the vials to remove any residues of xylene. The contents
were mixed using Vortex mixer and centrifuged at 4400 rpm for 2 minutes at room
temperature. The supernatant was then removed and discarded. This step was
performed twice.
4. The vials were left open at room temperature to allow evaporation of the remaining
ethanol (approximately 30 minutes).
5. 150 l of lysis buer PKD designed to partially reverse formaldehyde modication
of nucleic acids, and 10 l of proteinase K for digestion of the material were added
to each vial followed by incubation at 55C for 15 minutes and at 80C for further
15 minutes.
6. The binding conditions were adjusted with RBC buer (320 l per vial).
7. The lysates were then passed through QIAshredder homogeniser column via cen-
trifugation for 2 minutes at 10000 rpm. This step was introduced for some samples
in an attempt to improve the purity of the extracted RNA by ltering out insoluble
debris.
8. The samples were then passed through the gDNA Eliminator spin column via
centrifugation for 30 seconds at 10000 rpm to remove genomic DNA.90 Chapter 3. Methods
9. Collected sample was mixed with 720 l of 100% ethanol and passed through
RNeasy Mini Elute spin column via centrifugation for 15 seconds at 10000 rpm.
10. The ltered precipitate was washed with RPE buer and passed through the
RNeasy MinElute spin column three times.
11. The RNA was then eluted from the sample using RNase-free water (20 l per
sample) and centrifugation for 1 minute at 10000 rpm.
12. DNAse digestion step was also tested on some samples in an attempt to improve
the quality of the extracted material.
The RNA extraction from 8 control and 9 immunised AD cases was attempted using
this method. The total RNA content was measured using NanoDrop spectrophotometer
(Thermo Scientic, USA). Absorbance at 230, 260 and 280 nm was measured.
Reverse transcription of extracted RNA into complementary DNA (cDNA) was per-
formed using Precision Reverse Transcription Kit (PrimerDesign Ltd., UK). Oligo-dT
and random nonamer primers were used in the annealing step, while the MMLV reverse
transcriptase provided by the kit was used for the cDNA synthesis step. The cDNA con-
tent and purity in samples were measured using NanoDrop spectrophotometer. Negative
control (without reverse transcriptase) was also included.
To establish the optimal normalising genes, geNorm Housekeeping Gene Selection
Kit with PerfectProbe (PrimerDesign) was used. The kit contained the following hu-
man genes: beta actin (ACTB) mRNA, phospholipase A2 (YWHAZ) mRNA, ubiquitin
(UBC) mRNA, topoisomerase I (TOP1) mRNA, splicing factor 3a subunit 1 (SF3A1)
mRNA, succinate dehydrogenase complex (SDHA) mRNA, glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) mRNA, eukaryotic translation initiation factor 4A isoform 2
(EIF4A2) mRNA, cytochrome c-1 (CYC1) mRNA, beta-2-microglobulin (B2M) mRNA,
ATP synthase (ATPB5) mRNA, and 18S rRNA. PrimerDesign 2xqPCR Mastermix con-
taining thermo-stable TAQ polymerase in an appropriate buer was used for the PCR.
The PCR was performed using high-resolution melt (HRM) analysis on a Rotor-Gene
6000 real-time thermocycler (Corbett Life Science Ltd., Australia). The analysis was
set up for 50 cycles.
As no consistent results were obtained for any of the above housekeeping genes (see
Chapter 4), the analysis did not progress to specic cytokine genes analysis.Chapter 4
Results
The results from the two studies addressing the eect of active A42 immunisation on
the activation level and prole of microglia are presented in this chapter.
4.1 Study 1: Activation level of microglia
Study 1 was designed to assess the impact of the A42 immunisation on the level of
microglial activation. The cAD cohort consisted of 8 cases obtained from the Archives
of the Neuropathology Department, Southampton General Hospital. The iAD group
consisted of 9 cases from the AN1792 clinical trial. The assessment of A42, CD68,
HLA-DR, and CD163 was carried out in the two AD groups. The data on A42,
CD68, and HLA-DR obtained from this study were published in the Neuropathology
and Applied Neurobiology (Zotova et al., 2011) (Appendix A).
The results are presented as a median antigen load in the brain areas aected by
the AD pathology: temporal, parietal, and frontal for A42, CD68 and HLA-DR; and
temporal and parietal for CD163. For CD68, HLA-DR and CD163 the level of protein
load in these brain areas was assessed in the grey and the white matter separately due to
structural and functional dierences of these two regions (mainly neuronal cell bodies in
the grey matter and neuronal axons in the white matter). The protein load in the area
not aected by the AD pathology - the pons - is also reported for CD68 and HLA-DR.
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4.1.1 A42
The quantication of A42 immunostaining showed a signicantly lower level in the im-
munised AD group (2.1%) compared to the non-immunised AD group (4.3%, P=0.036,
Figure 4.1) consistent with previously published observations (Nicoll et al., 2003; Holmes
et al., 2008).
Larger distribution of the data points within the iAD compared to the cAD group
was apparent from the plots in Figure 4.1, particularly in the upper level of the data
set, reecting an individual variability and patchiness of the A clearance. This is
demonstrated in Figure 4.2 depicting representative A42 immunostaining from 8 out
of the 9 iAD cases compared to a cAD case. The A42 immunostaining distribution
varied from being similar to the non-immunised case (iAD case 4) to almost complete
removal of the plaques (iAD cases 1, 7 and 8), with various level of plaque removal in
between (iAD cases 2, 3, 6 and 9). Figure 4.3 depicts A42 immunostaining at a higher
magnication demonstrating well circumscribed and discrete plaques in a cAD case,
plaques with more disrupted structure and \moth-eaten" appearance in an iAD case
with relatively high plaque burden, and abundant intensely stained small A granules,
interpreted as A within microglia, and a few small spherical structures of residual
plaque cores in an iAD with very low A burden.
Figure 4.1: Scatter plot with median values (left) and box and whiskers plot (right)
of A42 levels in control (cAD) and immunised (iAD) AD cases in temporal, frontal
and parietal lobes combined.  - the level of A42 in iAD (2.1%) was 50% lower than
in cAD (4.3%) - two-tailed Mann-Whitney's P=0.036.Chapter 4. Results 93
Figure 4.2: An illustration of representative A42 immunostaining in the temporal
cortex of 8 immunised AD cases (iAD1-4 and iAD6-9) and a non-immunised AD control
(in the middle), adapted from Holmes et al. (2008). All pictures were taken using Nikon
Eclipse E600 microscope at magnication x10 and a digital camera Nikon Coolpix 950.
Figure 4.3: A panel of examples of A42 immunostaining in a non-immunised AD
case (left) with presence of well-circumscribed plaques, an immunised AD case with
high A42 load (middle) characterised by a \moth-eaten" appearance of plaques and
small clusters of intensely stained granules reecting A in microglia (arrows), and
in an iAD case with low A load (right) with residual plaque cores (*) and stained
granules in microglia (arrows). Scale bar = 50 m.94 Chapter 4. Results
4.1.2 CD68
Immunostaining for CD68 revealed a pattern of small round granular structures within
the cytoplasm, consistent with expected appearance of lysosomes within phagocytic mi-
croglia (Figure 4.4). The results for the CD68 immunostaining are presented separately
for the grey matter, the white matter, and the pons, followed by a correlation analysis
between the areas and between CD68 and A42 immunostaining.
Figure 4.4: An illustration of CD68 immunostaining in AD. Scale bar = 20m
CD68 level in the grey matter
Representative images of the CD68 immunostaining in the grey matter from one of the
immunised and one of the control AD cases are shown in Figure 4.5.
Observational dierences were noticed between the cAD and iAD groups with re-
spect to the CD68 immunostaining. The CD68 immunoreactivity was evenly distributed
throughout the cortex with little or no clustering around plaques in cAD cases. How-
ever, as with the A42 load, the iAD cases displayed a high degree of variability in CD68
immunoreactivity compared with the cAD group. Thus, in iAD cases with a high A42
load, CD68 immunoreactivity appeared in clusters associated with plaques; whereas in
iAD cases with a very low A42 load, there was very little CD68 immunoreactivity and
no clustering (Figure 4.6).
Quantitative analysis of the CD68 immunostaining in the cortical grey matter showed
that the protein load was higher in the immunised group of AD cases than in the controls
(0.04% and 0.02% respectively, P=0.046, Figure 4.7). Similar to the A42 data, the boxChapter 4. Results 95
Figure 4.5: Example pictures of CD68 immunostaining in the grey matter of an iAD
case (left) and a cAD case (right) taken at magnication 10 (top) and 20 (bottom).
Figure 4.6: A panel of examples of CD68 immunostaining. In a cAD case (left), the
CD68 immunoreactivity was mostly scattered throughout the analysed area with little
or no clustering around plaques. In an iAD case with high A42 load (middle) the CD68
immunoreactivity was mainly in clusters associated with A plaques (arrows), whereas
in an iAD case with low A42 load (right) there was very little CD68 immunoreactivity
and no clustering. Scale bar = 50 m.
plot in Figure 4.7 also revealed larger dispersion of the data points within the immunised
group compared to the control AD group.
CD68 level in the white matter
The analysis of the CD68 immunostaining in the white matter showed that although
CD68 protein load was higher in the immunised AD cases than in the controls (0.06% and
0.03% respectively), the dierence was not signicant (P = 0.093, Figure 4.8). Similar96 Chapter 4. Results
Figure 4.7: Scatter plot with median values (left) and box and whiskers plot (right)
of CD68 levels in the grey matter (GM) of control (cAD) and immunised (iAD) AD
cases.  The level of CD68 in iAD (0.04%) was higher than in cAD (0.02%, P=0.046).
to the grey matter, the data dispersion within the immunised AD group was higher
relative to the control group, particularly in the upper limit (reected in the box plot
of Figure 4.8). Representative examples of CD68 immunostaining in the white matter
from one immunised and one control AD cases are shown in Figure 4.9.
Figure 4.8: Scatter plot with median values (left) and box and whiskers plot (right)
of CD68 levels in the white matter (WM) of control (cAD) and immunised (iAD) AD
cases. Although the level of CD68 in iAD (0.06%) was higher than in cAD (0.03%),
the dierence was not signicant (P=0.093).
CD68 level in the pons
Assessment of the CD68 protein load in the pons showed no signicant dierences be-
tween the immunised and the control AD group (0.04% and %0.05 respectively, P=0.836,
Figure 4.10). Larger data dispersion was observed in the immunised than in the control
data set (box plot Figure 4.10). It should be noted that only six control and seven
immunised cases were compared as tissue from this brain area for the remaining cases
was not available.Chapter 4. Results 97
Figure 4.9: Example pictures of CD68 immunostaining in the white matter of an iAD
case (left) and a cAD case (right) taken at magnication 10 (top) and 20 (bottom).
Figure 4.10: Scatter plot with median values (left) and box and whiskers plot (right)
of CD68 levels in the pons of control (cAD) and immunised (iAD) AD cases. There
was no signicant dierence between the two groups (P=0.836).
CD68 data - correlations
Relationships between the phagocytic function of microglia in the grey and the white
matter, as well as between the phagocytic activity of microglia and the A42 level in
the control and immunised AD cases were explored.
CD68 correlation between grey and white matter
A signicant correlation () between the CD68 load in the grey and the white matter98 Chapter 4. Results
was observed in the cAD group (Spearman's =0.786, P=0.021, Figure 4.11). No such
correlation was noted in the iAD group.
Figure 4.11: Correlation plot of the CD68 load (in %) in the white matter (WM) and
in the grey matter (GM) of control (cAD) and immunised (iAD) AD cases. CD68 load
in the cAD group showed a signicant () correlation between the grey and the white
matter (Spearman's =0.8, P = 0.021). No correlation was observed in the iAD group
(Spearman's =0.4, P=0.244)
Correlations between CD68 level and A42 load
To explore the eect of the immunotherapy on the level of the microglial phagocytic
activity in relation to the A42, correlations between the two protein loads were con-
structed.
A signicant correlation () was observed between the A42 and the CD68 protein
load in the grey matter of the immunised AD cases (Spearman's =0.8, P=0.005), but
not in the control AD group (Spearman's =0.3, P=0.531, Figure 4.12).
No correlations were observed between the A42 load in the cortex (grey matter)
and the CD68 load in the white matter (where there are no A plaques) neither in
control nor in immunised AD cases (Figure 4.13).
A signicant correlation was also observed in the immunised, but not in the control,
AD group between the A42 protein load in the cortex of the areas with AD pathology
and the CD68 protein load in the pons, where no A plaques or other feature of the AD
pathology are present (Spearman's =0.8, P=0.023, Figure 4.14).Chapter 4. Results 99
Figure 4.12: Correlation plot of the CD68 load and A42 load in the cortical grey
matter in control (cAD) and immunised (iAD) AD cases. A signicant correlation ()
was observed in the immunised group (Spearman's =0.8, P=0.005), but not in the
control AD group (Spearman's =0.3, P=0.531).
Figure 4.13: Correlation plot of the CD68 load in the white matter and A42 load
in the cortex in control (cAD) and immunised (iAD) AD cases. No correlations were
observed in either group (cAD Spearman's =-0.1, P=0.752, iAD Spearman's =0.05,
P=0.912).100 Chapter 4. Results
Figure 4.14: Correlation plot of the CD68 load in the pons and cortical A42 load
in control (cAD) and immunised (iAD) AD cases. A signicant correlation () was
observed in the iAD group (Spearman's =0.8 and P=0.023), but not in the cAD
group (Spearman's =0.4 and P=0.468).Chapter 4. Results 101
The CD68 level in the grey matter of the areas aected by the AD pathology in the
immunised AD cases can also be expressed as a proportion (in %) of protein load in
each immunised case relative to the median value of the CD68 load in the same areas of
the control group (iAD:cADmedian). Similarly, the A42 level in the immunised cases
can be represented as a proportion of the median value of the A42 load in the control
group (iAD:cADmedian), in %. Plotting these values against each other suggests an
allocation of the immunised cases into three groups (Figure 4.15).
The immunised AD cases that have A42 load similar to the median A42 load in
the control cases (65-107%) fall into Group 1 (n=4). This group (cases 3, 4, 6, and 10)
demonstrates the highest level of microglial phagocytic activity (up to four times for
iAD 10) compared to the median level of the CD68 in the non-immunised AD cases.
The immunised AD cases that have the A42 load 20-50% that of the non-immunised
AD group (i.e. show signs of removal of A) fall into Group 2 (n=3). The microglial
phagocytic activity in this group (cases 1, 2, and 9), although lower than in Group 1, is
still up to twice as high as in the non-immunised AD.
The remaining two cases (7 and 8) fall into Group 3. This group shows almost
complete A42 removal - level of A42 in these cases is 1-4% of the median value for
the non-immunised AD group. The level of the microglial phagocytic activity in these
cases is strikingly low when compared to the median value of the CD68 load in the
non-immunised AD cases with up to 50% reduction.
The data in Figure 4.15 is shown for the grey matter only. However, a similar trend
was observed in the white matter, when CD68 protein load was compared to the level of
A42 in the adjacent grey matter. Although this grouping was not tested statistically
due to the low number of cases, this exercise further demonstrated the relationship
between CD68 and A42 in the immunised AD cases.102 Chapter 4. Results
Figure 4.15: Correlation plot of ratios (in %) for each iAD case relative to the median
value of the cAD group for CD68 and A42 load. The colour-coded symbols for each
case and circles outline the groups of iAD cases. Increased CD68 levels was observed
in Groups 1 (green, cases 3, 4, 6, and 10) and 2 (red, cases 1, 2, and 9), where A42
was higher, similar or marginally lower than in the cAD group. Decreased CD68 level
was observed in Group 3 (blue, cases 7 and 8), where the A42 load was the lowest.
Dashed lines indicate the median level of the CD68 load (horizontal line) and the A42
load (vertical line) within the cAD group.Chapter 4. Results 103
4.1.3 HLA-DR
Immunostaining for HLA-DR revealed ramied microglia-like shapes, consistent with the
expected appearance of a cell-surface protein (Figure 4.16). The results for the HLA-DR
immunostaining are presented separately for the grey matter, the white matter, and the
pons, followed by a correlation analysis between the areas and between HLA-DR and
A42 immunostaining.
Figure 4.16: An illustration of HLA-DR immunostaining in AD. Scale bar = 20m
HLA-DR level in the grey matter
Representative images of the HLA-DR immunostaining in the grey matter from one
immunised and one non-immunised AD cases are shown in Figure 4.17.
Although higher level of HLA-DR was observed in the grey matter of iAD group
(0.08%) than in cAD group (0.04 %), this dierence was not signicant (P=0.321, Figure
4.18).
There was higher variability of the values for HLA-DR load within the iAD group
compared to the cAD group. In cAD cases, the HLA-DR showed some clustering of104 Chapter 4. Results
Figure 4.17: Example pictures of HLA-DR immunostaining in the grey matter of
an iAD cases (left) and a cAD case (right) taken at magnication 10 (top) and 20
(bottom).
microglia around plaques. Such clustering was more obvious in iAD cases with A42
load similar to the cAD group, while in iAD cases with a very low A42 load, there was
very little HLA-DR immunoreactivity and no clustering (Figure 4.19).
Figure 4.18: Scatter plot with median values (left) and box and whiskers plot (right)
of HLA-DR levels in the grey matter of control (cAD) and immunised (iAD) AD cases.
The analysis did not reveal a signicant dierence in the protein load between the two
groups (cAD 0.04% vs iAD 0.08%, P=0.321).Chapter 4. Results 105
Figure 4.19: A panel of examples of HLA-DR immunostaining in a cAD case (left)
showing clustering of microglia around plaques, more intense clusters associated with
A plaques in an iAD case with a high A42 load (middle), and little HLA-DR im-
munoreactivity and no clustering are demonstrated in an iAD case with a very low
A42 load (right). Scale bar = 50 m.
HLA-DR level in the white matter
The HLA-DR protein load in the white matter was similar to the grey matter in both,
immunised and the control AD groups, and the data comparison and dispersion followed
a similar pattern. Despite a higher level of HLA-DR in iAD group (0.09%) than in cAD
group (0.04%), the dierence between these two groups was not signicant (P=0.370,
Figure 4.20). As in the grey matter, the large data dispersion, particularly in the
immunised AD group was observed (box plot in Figure 4.20).
Representative images of the HLA-DR immunostaining in the white matter from
one immunised and one non-immunised AD cases are shown in Figure 4.21.
Figure 4.20: Scatter plot with median values (left) and box and whiskers plot (right)
of HLA-DR levels in the white matter of control (cAD) and immunised (iAD) AD cases.
No signicant dierences were revealed between the two groups (cAD 0.04% vs iAD
0.09%, P=0.370).
HLA-DR level in the pons
The comparison of the HLA-DR load in the pons between the two AD groups showed
no signicant dierences (cAD 0.14% and iAD 0.06%, P=0.628, Figure 4.22). Large106 Chapter 4. Results
Figure 4.21: Example pictures of HLA-DR immunostaining in the white matter of
an iAD case (left) and a cAD case (right) taken at magnication 10 (top) and 20
(bottom).
variation of the pons HLA-DR levels within the cAD and iAD groups was observed, and
the number of analysed cases was even smaller than for the analyses of the AD-aected
brain areas.
Figure 4.22: Scatter plot with median values (left) and box and whiskers plot (right)
of HLA-DR levels in the pons of control (cAD) and immunised (iAD) AD cases. No
signicant dierence was observed between the level of HLA-DR in the cAD group
(0.14%) and the iAD group (0.06%, P=0.628).Chapter 4. Results 107
HLA-DR data - correlations
The relationship between antigen presenting activity of microglia in the grey and the
white matter was assessed in the same way as for the phagocytic activity. Correlations
with the A42 load were also investigated.
HLA-DR - grey and white matter correlations
Figure 4.23 shows that the HLA-DR level in the grey matter signicantly correlated
with the HLA-DR level in the white matter in both AD groups. The correlation was
stronger in the immunised AD group ( Spearman's =0.950 P 0.001 in iAD, and 
Spearman's =0.786 P=0.021 in cAD).
Figure 4.23: Correlation plot of the HLA-DR protein load (in %) in the grey matter
(GM) and in the white matter (WM) in control (cAD) and immunised (iAD) AD cases.
A signicant correlations were observed in both groups (cAD Spearman's =0.786
P=0.021, iAD Spearman's =0.950 P 0.001).
Correlations between HLA-DR level and A42 load
No correlations were observed between the the cortical A42 load and the HLA-DR level
in the grey matter, the white matter or the pons in either cAD or iAD group (Figures
4.24, 4.25 and 4.26).108 Chapter 4. Results
Figure 4.24: Correlation plot of the HLA-DR load in the grey matter and cortical
A42 load in control (cAD) and immunised (iAD) AD cases. No correlations were
observed in either group (cAD Spearman's =0.1, P=0.736, iAD Spearman's =-0.2,
P=0.668).
Figure 4.25: Correlation plot of the HLA-DR load in the white matter and cortical
A42 load in control (cAD) and immunised (iAD) AD cases. No correlations were
observed in either group (cAD Spearman's =-0.3, P=0.531, iAD Spearman's =-0.2,
P=0.637).
Figure 4.26: Correlation plot of the HLA-DR load in the pons and cortical A42
load in control (cAD) and immunised (iAD) AD cases. No correlations were observed
in either group (cAD Spearman's =0.4, P=0.468, iAD Spearman's =-0.5, P=0.294).Chapter 4. Results 109
4.1.4 CD163
The results for the CD163 immunostaining in the temporal and parietal lobes (combined)
are presented for the grey matter and the white matter, followed by correlation analyses
between the areas and between CD163 and A42 immunostaining.
CD163 level in the grey and the white matter
CD163 is a scavenger receptor and a marker of perivascular macrophages. The im-
munostaining for CD163 revealed positively-stained macrophage-like round cells in the
meningeal areas, and more elongated shapes of perivascular cells (Figure 4.27). No stain-
ing was observed within the parenchyma. The assessment of the immunostaining level
in the grey and the white matter of temporal and parietal lobes showed no signicant
dierences between the immunised and the control AD groups (Figures 4.28 and 4.29).
Figure 4.27: An illustration of CD163 immunostaining in AD demonstrating
macrophage-like cells in the meninges (left), and perivascular cells (right).
The CD163 load in the white matter blood vessels was much lower than in the grey
matter in both, immunised and control AD groups (Figure 4.30).
The representative immunostaining of the CD163 in the grey and the white matter
is shown in Figure 4.31.
CD163 correlations
The relationship between the level of expression of the CD163 in the grey and the white
matter was assessed as well as between CD163 and A42 in control and immunised AD
cases.110 Chapter 4. Results
Figure 4.28: Scatter plot with median values (left) and box and whiskers plot (right)
of CD163 levels in the grey matter of control (cAD) and immunised (iAD) AD cases.
No dierence in the level of CD163 between the two AD groups was detected (cAD
0.027%, iAD 0.034%, P=0.481).
Figure 4.29: Scatter plot with median values (left) and box and whiskers plot (right)
of CD163 levels in the white matter of control (cAD) and immunised (iAD) AD cases.
The level of CD163 in iAD and cAD was the same (cAD 0.0002% and iAD 0.0002%,
P=0.743).
Figure 4.30: Scatter plots with median levels of CD163 load in the grey matter (GM)
and the white matter (WM) of control (cAD, left) and immunised (iAD, right) AD
cases. In both AD groups, the level of CD163 in the white matter was signicantly
lower than in the grey matter (P0.001).Chapter 4. Results 111
Figure 4.31: Example pictures of CD163 immunostaining in the grey matter (top)
and in the white matter (bottom) of an iAD case (left) and a cAD case (right) taken
at magnication 10.
CD163 - correlations between grey and white matter
Signicant positive correlations were observed between the CD163 protein load in the
grey and the white matter in both immunised (Spearman's =0.783, P=0.013) and
non-immunised (Spearman's =0.881, P=0.004) AD groups (Figure 4.32).
Figure 4.32: Correlation plot of the CD163 protein load in the grey matter (GM) and
in the white matter (WM) of control (cAD) and immunised (iAD) AD cases. Signicant
correlations were observed in both groups (cAD Spearman's =0.881, P=0.004, iAD
Spearman's =0.783, P=0.013).112 Chapter 4. Results
Correlations between CD163 and A42
No correlations between the CD163 protein load and the A42 load was observed in
either control or immunised AD group (Figures 4.33 and 4.34).
Figure 4.33: Correlation plot of the CD163 load and A42 load in the cortical grey
matter in control (cAD) and immunised (iAD) AD cases. No correlations were ob-
served in either group (cAD Spearman's =0.2, P=0.693 and iAD Spearman's =-0.2,
P=0.606).
Figure 4.34: Correlation plot of the CD163 load in the white matter and A42 load
in the cortical grey matter in control (cAD) and immunised (iAD) AD cases. No
correlations were observed in either group (cAD Spearman's =0.2, P=0.610 and iAD
Spearman's =-0.2, P=0.637).
4.1.5 CD68 and HLA-DR colocalisation results
Observational assessment of the colocalisation of the two markers indicative of phago-
cytic and antigen-presenting function of microglia in the grey matter of an area aected
by the AD pathology (parietal lobe) using confocal microscopy showed that both CD68
and HLA-DR were consistently present around the A plaques in the iAD cases, while
only some CD68 and very little HLA-DR was rarely found in A plaque areas in cADChapter 4. Results 113
group. These observations provided evidence for spatial redistribution of the microglial
markers CD68 and HLA-DR in addition to quantication of protein load of the individ-
ual markers using DAB immunostaining and light microscopy.
However, the quantitative approach did not produce any conclusive results. The
proportion of CD68 protein colocalised with HLA-DR protein (Manders' colocalisation
coecient tM1) was similar in the immunised and the control AD groups (iAD 0.02 and
cAD 0.01, P=0.606, Figure 4.35). Similarly, no dierence in the proportion of HLA-DR
protein colocalised with CD68 protein (tM2) was observed between the two AD groups
(cAD 0.02 and iAD 0.03, P=0.606, Figure 4.36). Representative images of the triple
uorescent immunostaining from one immunised and one control AD case are shown in
Figure 4.37.
Both coecients (tM1 and tM2) were very small, indicating very low degree of
overlap between the two markers (when equals to 1, M coecient indicates 100% colo-
calisation). It was also noted that the data dispersion within the immunised group of
AD cases was up to six times larger than in the control AD group for both tM1 and tM2
data sets (reected in box plots of Figures 4.35 and 4.36). This high degree of variation,
as well as low number of data points in terms of case numbers (nine control and seven
immunised AD cases) and the brain area analysed (estimated 6 mm2 of parietal lobe
only), when compared to the light microscopy analysis (estimated 54 mm2 over three
brain areas) are likely to contribute to the observed lack of the signicance between the
two AD groups in this type of analysis.
Figure 4.35: Manders' correlation coecient tM1 reecting colocalisation ratio of
CD68 to HLA-DR in the parietal lobe. No signicant dierence between the con-
trol (cAD, tM1=0.01) and the immunised (iAD, tM1=0.02) groups was observed
(P=0.606). The box plot (right) demonstrates the large data dispersion in the im-
munised compared to the control AD group.114 Chapter 4. Results
Figure 4.36: Manders' correlation coecient tM2 reecting colocalisation ratio of
HLA-DR to CD68 in the parietal lobe of the immunised (iAD, tM2=0.03) and the non-
immunised (cAD, tM2=0.02) groups. No signicant dierence was observed (P=0.606).
The box plot (right) demonstrates the large data dispersion in the immunised compared
to the control AD group.
Figure 4.37: Example images of uorescent triple immunostaining of the grey matter
of an iAD case (left) and a cAD case (right). Cell nuclei are stained blue, CD68 - red,
HLA-DR - green, and A42 - cyan. Images were taken using Leica TCS SP5 laser
scanning confocal microscope and Leica LAS-AF software (v1.8) with an oil immersion
HC Plan Apochromat objectives 40 (top) and 160 (bottom).Chapter 4. Results 115
4.2 Study 2: Microglial functional prole
Study 2 was designed to investigate the eect of the immunisation on microglial receptors
involved in A recognition and uptake. A larger and better matched control AD group
was obtained from South West Dementia Brain Bank (Bristol). Additional six cases
became available from the AN1792 follow-up study at the time of this Study. Three of
these (No. 11, 15, and 16) were conrmed as AD on post-mortem examination, while
the remaining three (No. 12, 13 and 14) were assigned dierent dementia diagnoses.
Two out of three AD cases received the AN1792 treatment, and one (iAD 15) received
placebo. Two out of three non-AD cases received the AN1792 treatment, and one (No.
14 FTD) received placebo. All of the clinical trial participant cases were included in
staining and quantication procedures, but only immunised AD cases were included in
the statistical analyses relative to the cAD group. The results for the placebo AD and
non-AD cases are included in the graphs for demonstrative purposes only. The data
for the A42 load, the phospho-tau load, the microglial markers Iba-1, CD68, MSR-
A, CD32, and CD64, the antibody IgG and the complement C1q are presented in this
section.
4.2.1 A42 load
The immunostaining for A42 revealed plaque features and patterns consistent with ob-
servations in smaller cohort of cAD and iAD cases of Study 1 (4.1.1). The quantication
of the A42 load was consistent with the results of Study 1 - the A42 load in the iAD
group (0.72%) was signicantly lower than in the cAD group (4.06%, P<0.001, Figure
4.38). A higher percentage of reduction was observed in Study 2 (82%) than in the
smaller group of cAD and iAD cases of Study 1 (51%).
The A42 load in the placebo AD case was 1.94 %, lower than any of the non-
immunised AD cases. The non-AD cases all had low levels of A42 load (immunised
PSP 0.4 %, immunised DLB 0.003%, immunised VaD 0.007%, and placebo FTD 0.35%).116 Chapter 4. Results
Figure 4.38: Scatter plot (left) of the A42 load quantication in the cortex of
non-immunised AD (cAD), immunised AD (iAD), placebo AD (pAD), immunised non-
AD (inAD), and placebo non-AD (pnAD) cases, and box and whiskers plot (right)
summarising data for the cAD and iAD groups only. The median protein load of
A42 in iAD (0.72%) was signicantly lower than in cAD (4.06%, P<0.001).
4.2.2 Phospho-tau
The immunostaining for the phospho-tau in the cAD cohort and 9 out of the 16 AN1792
participants, and the counting of neurobrillary tangles and dystrophic neurite clusters
were performed by a medical student Jane Donald (Boche et al., 2010). For the purpose
of Study 2, phospho-tau immunostaining was completed for the remaining 7 cases, and
the immunostaining load was quantied for all the immunised, control and placebo cases
as described in Chapter 3. The immunostaining revealed the phospho-tau pathology
features: neuropil threads, neurobrillary tangles and dystrophic neurite clusters (Figure
4.39). The total phospho-tau load was lower in the iAD group (0.46%) compared to
the cAD group (0.77%, P=0.034, Figures 4.40). The number of dystrophic neurite
clusters was also signicantly lower in the iAD group (16) compared to the cAD group
(54, P=0.020, Figure 4.41). The number of neurobrillary tangles was not signicantly
dierent between the two groups (cAD 260 vs iAD 267, P=0.454, Figure 4.42). Examples
of the phospho-tau (AT8) immunostaining in the cAD and iAD brain reecting the data
are shown in Figure 4.43.
The placebo AD case had phospho-tau load 0.29%, 149 DN clusters, and 254 NFTs
- all within the range of the values for the cAD group. Within the non-AD group the
phospho-tau load was 0.12% for immunised PSP, 0.03% for immunised DLB, 0.04% for
immunised VaD, and 0.05% for placebo FTD. No DN clusters were found in any of the
non-AD cases. No NFTs were observed in immunised VaD and placebo FTD, while one
NFT was scored in immunised DLB. However, 189 NFTs were observed in immunised
PSP case reecting the characteristic pathology of this condition.Chapter 4. Results 117
Figure 4.39: An illustration of the phospho-tau (AT8) immunostaining in AD de-
picting neuropil threads (>), a neurobrillary tangle (arrowhead), and a cluster of
dystrophic neurites around an amyloid plaque (). Scale bar = 20m.
Figure 4.40: Scatter plot (left) of the phospho-tau load quantication in the cortex
of non-immunised AD (cAD), immunised AD (iAD), placebo AD (pAD), immunised
non-AD (inAD), and placebo non-AD (pnAD) cases, and box and whiskers plot (right)
summarising the data for the cAD and iAD groups only. The median phospho-tau
load in iAD (0.46%) was signicantly lower than in cAD (0.77%, P=0.034).
Figure 4.41: Scatter plot (left) of the DN cluster counts in the cortex of non-
immunised AD (cAD), immunised AD (iAD), placebo AD (pAD), immunised non-AD
(inAD), and placebo non-AD (pnAD) cases, and box and whiskers plot (right) sum-
marising the data for the cAD and iAD groups only. The median sum number of DN
clusters in iAD (16) was signicantly lower than in cAD (54, P=0.020).118 Chapter 4. Results
Figure 4.42: Scatter plot (left) of the NFT counts in the cortex of non-immunised
AD (cAD), immunised AD (iAD), placebo AD (pAD), immunised non-AD (inAD), and
placebo non-AD (pnAD) cases, and box and whiskers plot (right) summarising the data
for the cAD and iAD groups only. The median sum number of NFTs in iAD (267) was
not signicantly dierent from cAD (260, P=0.454).
Figure 4.43: Examples of phospho-tau (AT8) immunostaining in the cortex of a cAD
case (left) and an iAD case (right). Scale bar = 100m.
A correlation between the number of NFTs and the phospho-tau load in both
the cAD group (Spearman's =0.8, P<0.001) and the iAD group (Spearman's =0.7,
P<0.010, Figure 4.44) was noticed. No such relationship was observed between DNs
and phospho-tau load, suggesting that NFTs are the main contributors to the tau load
in AD. The DN numbers, however, correlated with the A42 load in the iAD group only
(Spearman's =0.9, P<0.001, Figure 4.45). This observation, together with the reduced
A42 load and DN cluster numbers in the iAD compared to the cAD group, reects the
association of DN pathology with the remaining A plaques in AD brain following the
immunisation.Chapter 4. Results 119
Figure 4.44: Correlation plots of the neurobrillary tangle numbers (NFTs) and
phospho-tau load in cAD (left) and iAD (right) groups. Signicant correlations were
observed in cAD group ( Spearman's =0.8, P<0.001) and iAD group ( Spearman's
=0.7, P=0.010).
Figure 4.45: Correlation plots of the dystrophic neurite clusters (DNs) and A42
load in cAD (left) and iAD (right) groups. A signicant correlation was observed in
iAD group ( Spearman's =0.9, P<0.001) but not cAD group (Spearman's =0.2,
P=0.266).120 Chapter 4. Results
4.2.3 Iba-1
Immunostaining for Iba-1 revealed both ramied and amoeboid microglial structures
(Figure 4.46). A trend towards lower Iba-1 load in iAD (0.04%) compared to cAD
(0.08%) was observed, but the results showed no signicant evidence that the two AD
groups were dierent in this respect (P=0.086, Figure 4.47). No signicant dierence
was observed in the number of Iba-1-positive microglial cells between iAD (103) and
cAD (82) groups (P=0.553, Figure 4.47).
The Iba-1 load in the immunised non-AD cases was 0.02% (PSP), 0.03% (DLB), and
1.15% (VaD), while in placebo cases the load was 0.05% (AD) and 0.07% (FTD). The
total microglial cell counts in the immunised and placebo non-AD cases and the placebo
AD case were within the range of the cAD and iAD groups (Figure 4.47).
Figure 4.46: An illustration of Iba-1 immunostaining in AD. Scale bar = 20m.
A correlation was observed between the Iba-1 load and the number of Iba-1-positive
cells within the cAD group (Spearman's =0.7, P<0.001, Figure 4.49). A similar trend
was noted within the iAD group (Spearman's =0.6, P=0.056).
In relation to the AD pathology, relationships between Iba-1 and A42, and Iba-1
and phospho-tau load were noticed in cAD group only. A42 load inversely related
to Iba-1 load (Spearman's =-0.6, P=0.001) and to the number of Iba-1-positive cells
(Spearman's =-0.4, P=0.026) in the cAD group (Figure 4.50). With respect to the tau
pathology, the Iba-1 load positively correlated with the phospho-tau load (Spearman'sChapter 4. Results 121
Figure 4.47: Scatter plots of the Iba-1 protein load (top left) and sum numbers of
Iba-1-positive cell counts (bottom left) in the cortex of non-immunised AD (cAD),
immunised AD (iAD), placebo AD (pAD), immunised non-AD (inAD), and placebo
non-AD (pnAD) cases, and box and whiskers plots (right) summarising the data for
cAD and iAD groups only. Although the median Iba-1 load in iAD (0.04%) was lower
than in cAD (0.08%), the dierence was not statistically signicant (P=0.086). No
signicant changes in the number of Iba-1-positive cells were observed between iAD
(103) and cAD (82) groups (P=0.553).
Figure 4.48: Example pictures of Iba-1 immunostaining in the cortex of a cAD case
(left) and an iAD case (right). Scale bar = 100m.122 Chapter 4. Results
Figure 4.49: Correlation plots of cortical Iba-1 load and Iba-1-positive cells in cAD
(left) and iAD (right). A signicant correlation was observed within the cAD group (
Spearman's =0.7, P<0.001), and a similar trend, although not signicant, was noted
within the iAD group (Spearman's =0.6, P=0.056).
=0.4, P=0.046) in cAD group (Figure 4.51). A trend towards an inverse correlation be-
tween Iba-1-positive cells and dystrophic neurite clusters (Spearman's =-0.4, P=0.050)
was also noted within the cAD group (Table 4.1). As discussed in Section 3.3.1, the Iba-1
load is more reliable than the number of Iba-1-positive cells, and this needs to be kept in
mind when interpreting these results. No correlations were observed between the Iba-1
data and A42 or phospho-tau data within the iAD group (Table 4.2).
Table 4.1: cAD: Summary (Spearman's  and P values) of the correlation analyses
results for the Iba-1 load or the number of Iba-1-positive cell vs the A42 load, the
phospho-tau load, the number of dystrophic neurite clusters (DNs), and the number
of neurobrillary tangles (NFTs). Signicant correlations are highlighted in bold. The
strength of correlations is indicated by .
Iba-1 load Iba-1+ cells
A42 load  =-0.6 P=0.001  =-0.4 P=0.026
phospho-tau load  =0.4 P=0.046 =0.3 P=0.151
DNs =-0.3 P=0.106 =-0.4 P=0.050
NFTs =0.2 P=0.258 =0.3 P=0.119
Table 4.2: iAD: Summary (Spearman's  and P values) of the correlation analyses
results for the Iba-1 load and the number of Iba-1-positive cell vs the A42 load, the
phospho-tau load, the number of dystrophic neurite clusters (DNs), and the number of
neurobrillary tangles (NFTs).
Iba-1 load Iba-1+ cells
A42 load =0.1 P=0.689 =0.2 P=0.650
phospho-tau load =0.2 P=0.612 <-0.1 P=0.915
DNs =0.2 P=0.484 =0.1 P=0.670
NFTs =0.4 P=0.235 =0.2 P=0.537Chapter 4. Results 123
Figure 4.50: Correlation plots of cortical Iba-1 load (top) or Iba-1-positive cells (bot-
tom) and A42 load in cAD (left) and iAD (right) groups. An inverse correlation was
observed between Iba-1 load and A42 load in the cAD group ( Spearman's =-0.6,
P=0.001), but not in the iAD group (Spearman's =0.1, P=0.689). An inverse corre-
lation was also observed between the number of Iba-1-positive cells and A42 load in
the cAD group ( Spearman's =-0.4, P=0.026), but not in iAD group (Spearman's
=0.2, P=0.650).
Figure 4.51: Correlation plots of cortical Iba-1 load and phospho-tau load in the cAD
(left) and iAD (right) groups. Positive correlation was observed within the cAD group
( Spearman's =0.4, P=0.046), but not iAD group (Spearman's =0.2, P=0.612).124 Chapter 4. Results
4.2.4 CD68
Immunostaining for CD68 revealed dot-like features distributed within the cytoplasm of
microglial cells consistent with the staining of lysosomes within microglia as was shown
in Study 1 (Figure 4.4). However, in contrast to Study 1, the CD68 antigen load was
lower in the iAD group (0.02%) compared to the cAD group (0.05%, P=0.018, Figure
4.52). The likely reasons for this discrepancy are discussed in Chapter 5 (Section 5.2).
The immunostaining levels in the remaining cases were: 0.02% in immunised PSP,
<0.01% in immunised DLB , 0.01% in immunised VaD, <0.01% in placebo FTD, and
0.03% in placebo AD.
Representative immunostaining from a cAD and an iAD case is shown in Figure
4.53.
Figure 4.52: Scatter plots (left) of the CD68 load in the cortex of non-immunised AD
(cAD), immunised AD (iAD), placebo AD (pAD), immunised non-AD (inAD), and
placebo non-AD (pnAD) cases, and box and whiskers plots (right) summarising the
data for cAD and iAD groups only.  The median protein load of CD68 in iAD (0.02%)
was signicantly lower than in cAD (0.05%, P=0.018).
Figure 4.53: Example pictures of CD68 immunostaining in the cortex of a cAD case
(left) and an iAD case (right). Scale bar = 100m.Chapter 4. Results 125
In relation to the AD pathology features, CD68 load correlated with the phospho-
tau load in cAD group only (Spearman's =0.4, P=0.036, Figure 4.54). No correlations
were observed between the CD68 load and the A load in either of the groups - the
correlation analysis data are summarised in Table 4.3.
Figure 4.54: Correlation plots of cortical CD68 load and phospho-tau load in cAD
(left) and iAD (right). A signicant correlation was observed in the cAD group (
Spearman's =0.4, P=0.036), but not iAD group (Spearman's =0.2, P=0.484).
Table 4.3: Summary (Spearman's  and P values) of the correlation analyses results
for the CD68 load vs the A42 load, the phospho-tau load, the number of dystrophic
neurite clusters (DNs), and the number of neurobrillary tangles (NFTs) in cAD and
iAD groups. Signicant correlations are highlighted in bold. The strength of correla-
tions is indicated by the .
cAD iAD
A42 load =-0.3 P=0.091 =0.2 P=0.484
phospho-tau load  =0.4 P=0.036 =0.2 P=0.484
DNs =-0.2 P=0.441 =0.1 P=0.670
NFTs =0.1 P=0.480 =-0.1 P=0.670126 Chapter 4. Results
4.2.5 FcRI (CD64)
The CD64 immunostaining labelled microglial cells, including their processes, consistent
with the expected pattern for a cell surface membrane receptor (Figure 4.55). The total
staining load was signicantly lower in the iAD group (0.36%) compared to the cAD
group (0.82%, P=0.001, Figure 4.56). The representative staining from a cAD and an
iAD case is shown in Figure 4.57.
The immunostaining level of the AD placebo case was 0.27%. Within non-AD group
the CD64 load was 0.54% in immunised PSP, 0.42% in immunised DLB, 0.30% in im-
munised VaD, and 0.48% in placebo FTD.
Figure 4.55: An illustration of CD64 (FcRI) immunostaining in AD. Scale bar =
20m.
Figure 4.56: Scatter plots (left) of the CD64 protein load in the cortex of non-
immunised AD (cAD), immunised AD (iAD), placebo AD (pAD), immunised non-
AD (inAD), and placebo non-AD (pnAD) cases, and box and whiskers plot (right)
summarising the data for cAD and iAD groups only. The median CD64 load in iAD
(0.36%) was signicantly lower than in cAD (0.82%, P=0.001).Chapter 4. Results 127
Figure 4.57: Example pictures of CD64 immunostaining in the cortex of a cAD case
(left) and an iAD case (right). Scale bar = 100m.
Similar to Iba-1, CD64 load correlated with the phospho-tau load in the cAD group
only (Spearman's =0.5, P=0.010, Figure 4.58). No correlations were observed between
CD64 and the A42 load in either of the AD groups. Summary of the correlation analysis
data is presented in Table 4.4.
Figure 4.58: Correlation plots of cortical CD64 load and phospho-tau load in cAD
(left) and iAD (right). A signicant correlation was observed in the cAD group (
Spearman's =0.5, P=0.010), but not iAD group (Spearman's =0.2, P=0.574).
Table 4.4: Summary (Spearman's  and P values) of the correlation analyses results
for the CD64 load vs the A42 load, the phospho-tau load, the number of dystrophic
neurite clusters (DNs), and the number of neurobrillary tangles (NFTs) in cAD and
iAD groups. Signicant correlations are highlighted in bold. The strength of correla-
tions is indicated by the .
cAD iAD
A42 load =-0.1 P=0.477 =0.5 P=0.151
phospho-tau load  =0.5 P=0.010 =0.2 P=0.574
DNs =-0.1 P=0.539 =0.3 P=0.340
NFTs =0.2 P=0.274 =-0.1 P=0.750128 Chapter 4. Results
4.2.6 FcRII (CD32)
Immunostaining for CD32 demonstrated microglial cells, although the cell processes
were less strongly dened than with CD64 antibody (Figure 4.59). The CD32 load was
signicantly lower in the iAD group (0.02%) compared to the cAD group (cAD 0.04%,
P=0.002, Figure 4.60). Representative staining from a cAD and an iAD case is shown
in Figure 4.61.
The CD32 immunostaining level of the AD placebo case was within the range of the
cAD group (0.11%). Within the non-AD group the CD32 load was 0.01% in immunised
PSP, 0.04% in immunised DLB, 0.06% in immunised VaD, and 0.06% in placebo FTD.
Figure 4.59: An illustration of CD32 (FcRII) immunostaining in AD. Scale bar =
20m.
Figure 4.60: Scatter plots (left) of the CD32 load in the cortex of non-immunised
AD (cAD), immunised AD (iAD), placebo AD (pAD), immunised non-AD (inAD),
and placebo non-AD (pnAD) cases, and box and whiskers plot (right) summarising the
data for the cAD and iAD groups only.  The median CD32 load in iAD (0.02%) was
signicantly lower than in cAD (0.04%, P=0.002).Chapter 4. Results 129
Figure 4.61: Example pictures of CD32 immunostaining in the cortex of a cAD case
(left) and an iAD case (right). Scale bar = 100m.
CD32 load correlated with the AD pathology features, A42 load and phospho-tau
load, in a similar fashion to Iba-1, in cAD group only. A strong inverse correlation
was observed between the CD32 load and the A42 load (Spearman's =-0.6, P<0.001,
Figure 4.62). A weaker, but also signicant, positive correlation between the CD32 load
and the phospho-tau load was also noted (Spearman's =0.4, P=0.032, Figure 4.63).
Within the iAD group, no relationship between the CD32 load and either the A42 or
phospho-tau load was observed (Table 4.5).
Figure 4.62: Correlation plots of cortical CD32 load and A42 load in cAD (left)
and iAD (right) groups. An inverse correlation was observed within the cAD group (
Spearman's =-0.6, P<0.001), but not the iAD group (Spearman's =0.3, P=0.326).130 Chapter 4. Results
Figure 4.63: Correlation plots of the cortical CD32 load and total phospho-tau load
in cAD (left) and iAD (right). A signicant correlation was observed within the cAD
group ( Spearman's =0.4, P=0.032), but not the iAD group ((Spearman's =0.5,
P=0.110).
Table 4.5: Summary (Spearman's  and P values) of the correlation analyses results
for the CD32 load vs the A42 load, the phospho-tau load, the number of dystrophic
neurite clusters (DNs), and the number of neurobrillary tangles (NFTs) in the cAD
and iAD groups. Signicant correlations are highlighted in bold. The strength of
correlations is indicated by the .
cAD iAD
A42 load  =-0.6 P<0.001 =0.3 P=0.326
phospho-tau load  =0.4 P=0.032 =0.5 P=0.110
DNs =-0.2 P=0.313 =0.2 P=0.502
NFTs =0.3 P=0.125 =0.1 P=0.689Chapter 4. Results 131
4.2.7 Macrophage scavenger receptor A
Immunostaining for MSR-A demonstrated microglia, including their processes, in a pat-
tern consistent with the expression of this receptor on the cell surface membrane (Figure
4.64). A striking feature, not observed so markedly with other microglial markers, was
clustering of the labelled cells. This feature prompted the manual counting of clusters
in addition to the quantication of the total protein load. An observational dierence
was noted in the cluster structure between cAD and iAD. In cAD most clusters were
large and intensely stained with numerous microglial processes within clusters. In iAD
a fainter staining of fewer processes outlining a core of an amyloid plaque (identied
as a faint blue globular structure in the center of a cluster) was more common (Figure
4.65). Low-power images representative of the MSR-A immunostaining from a cAD and
an iAD case are shown in Figure 4.66.
Figure 4.64: An illustration of MSR-A immunostaining in AD. Scale bar = 20m.
The MSR-A load was signicantly lower in the iAD (0.01%) than in cAD (0.10%,
P<0.001, Figure 4.67). The sum number of MSR-A-positive clusters was also signi-
cantly lower in the iAD group (22) than in the cAD group (70, P<0.001, Figure 4.68).
The MSR-A load and the sum number of clusters in the placebo AD case was within
the lower range of the cAD group (0.05% and 39). The MSR-A load in all non-AD cases
(immunised and placebo) was below 0.001 %. Within the non-AD group, one cluster
was observed in the immunised DLB and the placebo FTD cases, while no clusters were
found in the immunised PSP and VaD cases.132 Chapter 4. Results
Figure 4.65: An illustration of MSR-A-positive clusters of microglia observed in cAD
(top) and iAD (bottom). In cAD the clusters were larger, with more microglial pro-
cesses. In iAD, the clusters were small, with fewer microglial processes, often revealing
a plaque core in the centre. Scale bar = 20m.
Figure 4.66: Example pictures of MSR-A immunostaining in the cortex of a cAD
case (left) and an iAD case (right). Scale bar = 100m.Chapter 4. Results 133
Figure 4.67: Scatter plots (left) of the MSR-A load in the cortex of non-immunised
AD (cAD), immunised AD (iAD), placebo AD (pAD), immunised non-AD (inAD), and
placebo non-AD (pnAD) cases, and box and whiskers plot (right) summarising data
for the cAD and iAD groups only. The median MSR-A load in iAD (0.01%) was
signicantly lower than in cAD (0.10%, P<0.001).
Figure 4.68: Scatter plots (left) of the sum numbers of MSR-A-positive clusters per
90 elds of cortex in non-immunised AD (cAD), immunised AD (iAD), placebo AD
(pAD), immunised non-AD (inAD), and placebo non-AD (pnAD) cases, and box and
whiskers plot (right) summarising the data for the cAD and iAD groups only. The
median sum number of the MSR-A-positive clusters in iAD (22) was signicantly lower
than in cAD (70, P<0.001).
A correlation was observed between the MSR-A load and the number of MSR-A-
positive clusters in cAD group (Spearman's =0.6, P=0.002, Figure 4.69), suggesting
that in AD MSR-A is expressed mainly in microglia that are clustered around plaques.
In iAD, no such correlation was observed, reected by the smaller number and size of
clusters and extremely low MSR-A load in this group.
With respect to the AD pathology features, signicant correlations were observed
between the number of MSR-A-positive clusters and the A42 load (Spearman's =0.7,
P=0.024) as well as the number of dystrophic neurite clusters (Spearman's =0.7,
P=0.020) in iAD group only (Figures 4.70 and 4.71). In cAD, the MSR-A load correlated
with the phospho-tau load (Spearman's =0.4, P=0.045, Figure 4.72). No correlations
were observed for the MSR-A load in iAD group. The correlation analysis results are
summarised in Tables 4.6 and 4.7.134 Chapter 4. Results
Figure 4.69: Correlation plots of the number of MSR-A-positive clusters and MSR-A
load in the cAD (left) and iAD (right) groups. A correlation was observed in the cAD
group ( Spearman's =0.6, P=0.002), but no the iAD group (Spearman's =0.4,
P=0.264).
Figure 4.70: Correlation plots of the sum number of MSR-A-positive clusters and
A42 load in cAD (left) and iAD (right). A signicant correlation was observed in
the iAD group ( Spearman's =0.7, P=0.024), but not the cAD group (Spearman's
=0.1, P=0.660).
Figure 4.71: Correlation plots of the sum number of MSR-A-positive clusters and the
number of dystrophic neurite clusters (DNs) in cAD (left) and iAD (right). A signicant
correlation was observed within the iAD group ( Spearman's =0.7, P=0.020), but
not the cAD group (Spearman's =0.2, P=0.299).Chapter 4. Results 135
Figure 4.72: Correlation plots of the MSR-A load and phospho-tau load in cAD (left)
and iAD (right). A signicant correlation was observed in the cAD group ( Spearman's
=0.4, P=0.045), but not the iAD group (Spearman's =0.4, P=0.201).
Table 4.6: Summary (Spearman's  and P values) of the correlation analyses results
for the MSR-A load vs the A42 load, the phospho-tau load, the number of dystrophic
neurite clusters (DNs), and the number of neurobrillary tangles (NFTs) in cAD and
iAD groups. Signicant correlations are highlighted in bold. The strength of correla-
tions is indicated by the .
cAD iAD
A42 load =-0.2 P=0.087 =0.4 P=0.272
phospho-tau load  =0.4 P=0.045 =0.4 P=0.201
DNs =0.1 P=0.551 =0.4 P=0.247
NFTs =0.1 P=0.727 =0.3 P=0.312
Table 4.7: Summary (Spearman's  and P values) of the correlation analyses results
for the number of MSR-A-positve clusters vs the A42 load, the phospho-tau load, the
number of dystrophic neurite clusters (DNs), and the number of neurobrillary tangles
(NFTs) in cAD and iAD groups. Signicant correlations are highlighted in bold. The
strength of correlations is indicated by the .
cAD iAD
A42 load =0.1 P=0.660  =0.7 P=0.024
phospho-tau load <-0.1 P=0.936 =0.5 P=0.098
DNs =0.2 P=0.229  =0.7 P=0.020
NFTs =-0.2 P=0.302 =0.4 P=0.290136 Chapter 4. Results
4.2.8 All microglial markers
Correlations were noticed between dierent microglial markers, particularly within the
cAD group, suggesting engagement of multiple mechanisms by microglia in the disease
process, and demonstrating the eect of active A immunisation on microglial function.
Within the cAD group, correlations were observed between the Iba-1 load and the
CD68 load (Spearman's =0.5, P=0.004, Figure 4.73), the CD64 (FcRI) load (Spear-
man's =0.5, P=0.007, Figure 4.74), and the CD32 (FcRII) load (Spearman's =0.7,
P<0.001, Figure 4.75). The CD32 load also correlated with the number of Iba-1-positive
cells within the cAD group (Spearman's =0.5, P=0.011, Figure 4.75). Correlation
trends were noted between the Iba-1 load and the MSR-A load in both the cAD group
(Spearman's =0.4, P=0.054) and the iAD group (Spearman's =0.6, P=0.051). A
trend for an inverse correlation was also noted between the number of Iba-1-positive
cells and the CD68 load within the iAD group (Spearman's =-0.6, P=0.051).
Figure 4.73: Correlation plots of the Iba-1 load and CD68 load in cAD (left) and
iAD (right). A signicant correlation was observed in the cAD group ( Spearman's
=0.5, P=0.004), but not the iAD group (Spearman's =-0.1, P=0.770).
Figure 4.74: Correlation plots of the Iba-1 load and CD64 load in cAD (left) and
iAD (right). A signicant correlation was observed in the cAD group ( Spearman's
=0.5, P=0.007), but not the iAD group (Spearman's =0.2, P=0.593).Chapter 4. Results 137
Figure 4.75: Correlation plots of the CD32 load and Iba-1 load (top) or the number
of Iba-1-positive cells (bottom) in cAD (left) and iAD (right). A signicant correlation
was observed between the CD32 and Iba-1 load in the cAD group ( Spearman's =0.7,
P<0.001), but not the iAD group (Spearman's =0.5, P=0.096). The number of Iba-
1-positive cells also correlated with the CD32 load in the cAD group ( Spearman's
=0.5, P=0.011) but not the iAD group (Spearman's <0.1, P=0.979).
In addition to the correlation with Iba-1 in cAD group, the CD68 load correlated
with CD64 (FcRI) load in both the cAD group (Spearman's =0.7, P<0.001), and the
iAD group (Spearman's =0.8, P=0.004, Figure 4.76).
Figure 4.76: Correlation plots of the CD68 load and CD64 (FcRI) load in cAD
(left) and iAD (right). A signicant correlation was observed in the cAD group (
Spearman's =0.7, P<0.001), and the iAD group ( Spearman's =0.8, P=0.004).
Correlations were also observed between the CD68 load and the CD32 (FcRII) load
(Spearman's =0.7, P<0.001, Figure 4.77), as well as the MSR-A load (Spearman's
=0.6, P<0.001, Figure 4.78) in cAD group only. Within the iAD group, a trend for138 Chapter 4. Results
correlation between the CD68 load and MSR-A load was noted (Spearman's =0.6,
P=0.060).
Figure 4.77: Correlation plots of the CD68 load and CD32 (FcRII) load in cAD
(left) and iAD (right). A signicant correlation was observed in the cAD group (
Spearman's =0.7, P<0.001), but not the iAD group (Spearman's =0.4, P=0.180).
Figure 4.78: Correlation plots of the CD68 load and MSR-A load in cAD (left) and
iAD (right). A signicant correlation was observed in the cAD group ( Spearman's
=0.6 P<0.001), and a non-signicant trend was noted in the iAD group (Spearman's
=0.6, P=0.060).
In addition to Iba-1 and CD68, the CD64 (FcRI) load also correlated with the
CD32 (FcRII) load within the cAD group only (Spearman's =0.6, P=0.001, Figure
4.79), and with MSR-A load in both the cAD group (Spearman's =0.6, P=0.003) and
the iAD group (Spearman's =0.7, P=0.016, Figure 4.80).
Non-signicant trends for correlation were observed between the CD32 load and
MSR-A load in both, the cAD group (Spearman's =0.4, P=0.052) and the iAD group
(Spearman's =0.6, P=0.071).
The results of the correlation analyses are summarised in Tables 4.8 and 4.9.Chapter 4. Results 139
Figure 4.79: Correlation plots of the CD64 (FcRI) load and CD32 (FcRII) load in
cAD (left) and iAD (right). A signicant correlation was observed in the cAD group (
Spearman's =0.6 P=0.001), but not the iAD group (Spearman's =0.5, P=0.102).
Figure 4.80: Correlation plots of the CD64 (FcRI) load and MSR-A load in cAD
(left) and iAD (right). Signicant correlations were observed in the cAD group (
Spearman's =0.6 P=0.003), as well as the iAD group ( Spearman's =0.7, P=0.016).140 Chapter 4. Results
Table 4.8: cAD all microglial markers: Summary (Spearman's  and P values) of the
correlation analyses results of Iba-1 (load and positive cells), CD68, CD64 (FcRI),
CD32 (FcRII), and MSR-A (load and positve clusters) in the cAD group. Signicant
correlations are highlighted in bold. The strength of correlations is indicated by the .
Iba-1 Iba-1+
cells
CD68 CD64 CD32 MSR-A MSR-
A+
clusters
Iba-1 
=0.7
P<0.001

=0.5
P=0.004

=0.5
P=0.007

=0.7
P<0.001
=0.4
P=0.054
=0.1
P=0.750
Iba-1+
cells

=0.7
P<0.001
=0.1
P=0.586
=0.2
P=0.444
 =0.5
P=0.011
=-0.1
P=0.725
=-0.1
P=0.524
CD68 
=0.5
P=0.004
=0.1
P=0.586

=0.7
P<0.001

=0.7
P<0.001

=0.6
P<0.001
=0.2
P=0.441
CD64 
=0.5
P=0.007
=0.2
P=0.444

=0.7
P<0.001

=0.6
P=0.001

=0.6
P=0.003
=0.2
P=0.387
CD32 
=0.7
P<0.001
 =0.5
P=0.011

=0.7
P<0.001

=0.6
P=0.001
=0.4
P=0.052
<0.1
P=0.912
MSR-A =0.4
P=0.054
=-0.1
P=0.725

=0.6
P<0.001

=0.6
P=0.003
=0.4
P=0.052

=0.6
P=0.002
MSR-A
clusters
=0.1
P=0.750
=-0.1
P=0.524
=0.2
P=0.441
=0.2
P=0.387
<0.1
P=0.912

=0.6
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Table 4.9: iAD all microglial markers: Summary (Spearman's  and P values) of the
correlation analyses results of Iba-1 (load and positive cells), CD68, CD64 (FcRI),
CD32 (FcRII), and MSR-A (load and positive clusters) in iAD group. Signicant
correlations are highlighted in bold. The strength of correlations is indicated by the .
Iba-1 Iba-1+
cells
CD68 CD64 CD32 MSR-A MSR-
A+
clusters
Iba-1 =0.6
P=0.056
=-0.1
P=0.770
=0.2
P=0.593
=0.5
P=0.096
=0.6
P=0.051
=0.4
P=0.194
Iba-1+
cells
=0.6
P=0.056
=-0.6
P=0.051
=-0.2
P=0.593
<0.1
P=0.979
<-0.1
P=0.915
=0.2
P=0.492
CD68 =-0.1
P=0.770
=-0.6
P=0.051

=0.8
P=0.004
=0.4
P=0.180
=0.6
P=0.060
=0.3
P=0.377
CD64 =0.2
P=0.593
=-0.2
P=0.593

=0.8
P=0.004
=0.5
P=0.102
 =0.7
P=0.016
=0.4
P=0.174
CD32 =0.5
P=0.096
<0.1
P=0.979
=0.4
P=0.180
=0.5
P=0.102
=0.6
P=0.071
=0.5
P=0.141
MSR-A =0.6
P=0.051
<-0.1
P=0.915
=0.6
P=0.060
 =0.7
P=0.016
=0.6
P=0.071
=0.4
P=0.264
MSR-A
clusters
=0.4
P=0.194
=0.2
P=0.492
=0.3
P=0.377
=0.4
P=0.174
=0.5
P=0.141
=0.4
P=0.264142 Chapter 4. Results
4.2.9 IgG
The anti-human IgG was detected on A plaques, on microglia surrounding plaques,
and within neurons (often adjacent to the plaque areas), in both cAD and iAD cases
(Figure 4.81). It should be noted, however, that extensive areas of cortex did not
contain immunodetectable IgG, even where abundant plaques were present. Some IgG-
positive cortical and meningeal blood vessels were also noticed, particularly those with
A immunostaining in their walls (i.e. with cerebral amyloid angiopathy, Figure 4.81).
Figure 4.81: Examples of IgG immunostaining in AD illustrating positively-stained
plaque (#), microglia (*), neurons (arrowhead), and a blood vessel (). Scale bar =
50m.
Quantication of the IgG load showed no signicant dierence between the iAD
group (0.40%) and the cAD goup (0.13%, P=0.533, Figure 4.82).
The placebo AD case had IgG load of 0.68%. The IgG load within the non-AD cases
was 0.001% (immunised PSP), 0.40% (immunised DLB), 0.93% (immunised VaD), and
1.12 (placebo FTD).
In relation to the AD pathology, a signicant correlation was observed between the
IgG load and the phospho-tau load in cAD group only (Spearman's =0.4, P=0.030,Chapter 4. Results 143
Figure 4.82: Scatter plots (left) of the IgG load in the cortex of non-immunised
AD (cAD), immunised AD (iAD), placebo AD (pAD), immunised non-AD (inAD),
and placebo non-AD (pnAD) cases, and box and whiskers plot (right) summarising the
data for the cAD and iAD groups only. The median IgG load in the cAD group (0.13%)
was not signicantly dierent from the iAD group (0.40%, P=0.533).
Figure 4.83). There were no correlations with the A42 load in either of the groups.
The results of the correlation analyses are summarised in Table 4.10.
Figure 4.83: Correlation plots of cortical IgG load and phospho-tau load in cAD
(left) and iAD (right). A signicant correlation was observed within the cAD group (
Spearman's =0.4, P=0.030), but not the iAD group (Spearman's =-0.1, P=0.811).
Table 4.10: Summary (Spearman's  and P values) of the correlation analyses results
for the cortical IgG load and the A42 load, the phospho-tau load, the number of
dystrophic neurite clusters (DNs), and the number of neurobrillary tangles (NFTs) in
cAD and iAD groups. Signicant correlations are highlighted in bold. The strength of
correlations is indicated by the .
cAD iAD
A42 load =-0.2 P=0.370 =-0.2 P=0.537
phospho-tau load  =0.4 P=0.030 =-0.1 P=0.811
DNs <0.1 P=0.965 =-0.3 P=0.450
NFTs =0.2 P=0.404 =-0.2 P=0.650
IgG relationships with microglial markers were also investigated. Within the cAD
group, IgG load correlated with the load of all microglial markers examined: Iba-1144 Chapter 4. Results
(Spearman's =0.4, P=0.036, Figure 4.84), CD68 (Spearman's =0.7, P<0.001, Fig-
ure 4.85), CD64 (Spearman's =0.7, P<0.001, Figure 4.86), CD32 (Spearman's =0.5,
P=0.003, Figure 4.87), and MSR-A (Spearman's =0.6, P=0.001, Figure 4.88). Within
the iAD group, trends towards correlations were noted for the IgG load and the CD64
load (Spearman's =0.6, P=0.077, Figure 4.86), the CD32 load (Spearman's =0.6,
P=0.066, Figure 4.87), and the MSR-A load (Spearman's =0.6, P=0.066, Figure 4.88).
The results of the correlation analyses are summarised in Table 4.11.
Figure 4.84: Correlation plots of cortical IgG load and Iba-1 load in cAD (left) and
iAD (right). A signicant correlation was observed within the cAD group ( Spearman's
=0.4, P=0.036), but not the iAD group (Spearman's =0.4, P=0.285).
Figure 4.85: Correlation plots of cortical IgG load and CD68 load in cAD (left)
and iAD (right). A signicant correlation was observed within the cAD group (
Spearman's =0.7, P<0.001), but not the iAD group (Spearman's =0.5, P=0.117).Chapter 4. Results 145
Figure 4.86: Correlation plots of cortical IgG load and CD64 (FcRI) load in cAD
(left) and iAD (right). A signicant correlation was observed within the cAD group (
Spearman's =0.7, P<0.001), and a similar, although not signicant, trend was noted
in the iAD group (Spearman's =0.6, P=0.077).
Figure 4.87: Correlation plots of cortical IgG load and CD32 (FcRII) load in cAD
(left) and iAD (right). A signicant correlation was observed within the cAD group (
Spearman's =0.5, P=0.003), and a similar, although not signicant, trend was noted
in the iAD group (Spearman's =0.6, P=0.066).
Figure 4.88: Correlation plots of cortical IgG load and MSR-A load in cAD (left)
and iAD (right). A signicant correlation was observed within the cAD group (
Spearman's =0.6, P=0.001), and a similar, although not signicant, trend was noted
in the iAD group (Spearman's =0.6, P=0.066).146 Chapter 4. Results
Table 4.11: Summary (Spearman's  and P values) of the correlation analyses results
for the cortical IgG load and the microglial markers Iba-1 (load and the number of
positive cells), CD64 load, CD32 load, and MSR-A load (load and the number of
positive clusters) in the cAD and iAD groups. Signicant correlations are highlighted
in bold. The strength of correlations is indicated by the .
cAD iAD
Iba-1 load  =0.4 P=0.036 =0.4 P=0.285
Iba-1+ cells =-0.1 P=0.701 =-0.3 P=0.450
CD68  =0.7 P<0.001 =0.5 P=0.117
CD64  =0.7 P<0.001 =0.6 P=0.077
CD32  =0.5 P=0.003 =0.6 P=0.066
MSR-A load  =0.6 P=0.001 =0.6 P=0.066
MSR-A+ clusters =0.2 P=0.459 =-0.1 P=0.709Chapter 4. Results 147
4.2.10 C1q
The antibody to a complement element C1q, similar to IgG, labelled neurons, amyloid
plaques, microglia, as well as other cells (possibly astrocytes), and occasional blood
vessels (Figure 4.89).
Figure 4.89: Examples of C1q immunostaining in AD illustrating positively-stained
plaque (#), microglia (*), neurons (arrowhead), blood vessel (), and other cells (pos-
sibly astrocytes, <). Scale bar = 50m.
Quantication of C1q showed no detectable dierence between the iAD group (0.04%)
and cAD group (0.03%, P=0.553, Figure 4.90).
The C1q load in the AD placebo case was 0.03%. Within the non-AD group the
C1q load was 0.003% in immunised PSP, 0.002% in immunised DLB cases, 0.03% in
immunised VaD, and 0.04% in placebo FTD.
With respect to the AD pathology features, the C1q load inversely correlated with
the A42 load in the iAD group only (Spearman's =-0.6, P=0.047, Figure 4.91). How-
ever, in cAD group C1q load related to phospho-tau load (Spearman's =0.6, P=0.003,
Figure 4.92) and the number of NFTs (Spearman's =0.4, P=0.028, Figure 4.93). No
correlations were found between the C1q load and any of the features of the tau pathol-
ogy within the iAD group, although a trend towards an inverse correlation with the148 Chapter 4. Results
Figure 4.90: Scatter plots (left) of the C1q load in the cortex of non-immunised AD
(cAD), immunised AD (iAD), placebo AD (pAD), immunised non-AD (inAD), and
placebo non-AD (pnAD) cases, and box and whiskers plot (right) summarising the
data for the cAD and iAD groups only. The median C1q load in cAD (0.03%) was not
signicantly dierent from the iAD (0.04%, P=0.553).
number of dystrophic neurite clusters (Spearman's =-0.6, P=0.077) was noted. The
results of the correlation analyses are summarised in Table 4.12.
Figure 4.91: Correlation plots of cortical C1q load and A42 load in cAD (left) and
iAD (right). An inverse correlation was observed in the iAD group ( Spearman's
=-0.6, P=0.047), but not the cAD group (Spearman's =-0.2, P=0.258).
Table 4.12: Summary (Spearman's  and P values) of the correlation analyses re-
sults for the cortical C1q load vs the A42 load, the phospho-tau load, the number of
dystrophic neurite clusters (DNs), and the number of neurobrillary tangles (NFTs) in
cAD and iAD groups. Signicant correlations are highlighted in bold. The strength of
correlations is indicated by the s.
cAD iAD
A42 load =-0.2 P=0.258  =-0.6 P=0.047
phospho-tau load  =0.6 P=0.003 =-0.2 P=0.502
DNs =-0.1 P=0.769 =-0.6 P=0.077
NFTs  =0.4 P=0.028 =0.1 P=0.811
Similar to IgG, within the cAD group signicant correlations were observed between
the C1q load and the load of all microglial antigens examined: Iba-1 (Spearman's =0.5,Chapter 4. Results 149
Figure 4.92: Correlation plots of cortical C1q load and phospho-tau load in cAD
(left) and iAD (right). A signicant correlation was observed within the cAD group (
Spearman's =0.6, P=0.003), but not the iAD group (Spearman's =-0.2, P=0.502).
Figure 4.93: Correlation plots of cortical C1q load and the number of neurobrillary
tangles (NFTs) in cAD (left) and iAD (right). A signicant correlation was observed
within the cAD group ( Spearman's =0.4, P=0.028), but not the iAD group (Spear-
man's =0.1, P=0.811).
P=0.017, Figure 4.94), CD68 (Spearman's =0.5, P=0.012, Figure 4.95), CD64 (FcRI,
Spearman's =0.6, P=0.001, Figure 4.96), CD32 (FcRII, Spearman's =0.7, P<0.001,
Figure 4.97), and MSR-A (Spearman's =0.4, P=0.036, Figure 4.98). No such correla-
tions were observed in iAD group.
Correlations between the C1q load and the IgG load were noticed in both the cAD
group (Spearman's =0.7, P<0.001) and the iAD group (Spearman's =0.6, P=0.035)
- Figure 4.99. The results of the correlations analyses are summarised in Table 4.13.150 Chapter 4. Results
Figure 4.94: Correlation plots of cortical C1q load and Iba-1 load in cAD (left) and
iAD (right). A signicant correlation was observed within the cAD group ( Spearman's
=0.5, P=0.017), but not the iAD group (Spearman's =0.3, P=0.340).
Figure 4.95: Correlation plots of cortical C1q load and CD68 load in cAD (left) and
iAD (right). A signicant correlation was observed within the cAD group ( Spearman's
=0.5, P=0.012), but not the iAD group (Spearman's =0.3, P=0.350).
Figure 4.96: Correlation plots of cortical C1q load and CD64 (FcRI) load in cAD
(left) and iAD (right). A signicant correlation was observed within the cAD group (
Spearman's =0.6, P=0.001), but not in iAD group (Spearman's =0.3, P=0.417).Chapter 4. Results 151
Figure 4.97: Correlation plots of cortical C1q load and CD32 (FcRII) load in cAD
(left) and iAD (right). A signicant correlation was observed within the cAD group (
Spearman's =0.7, P<0.001), but not in iAD group (Spearman's =0.1, P=0.770).
Figure 4.98: Correlation plots of cortical C1q load and MSR-A load in cAD (left) and
iAD (right). A signicant correlation was observed within the cAD group ( Spearman's
=0.4, P=0.036), but not in iAD group (Spearman's =0.3, P=0.417).
Figure 4.99: Correlation plots of cortical C1q load and IgG load in cAD (left) and
iAD (right). Signicant correlations were observed within both group: cAD Spearman's
=0.7, P<0.001 () and iAD Spearman's =0.6, P=0.035 ().152 Chapter 4. Results
Table 4.13: Summary (Spearman's  and P values) of the correlation analyses results
for the cortical C1q load vs the microglial markers Iba-1 (load and the number of
positive cells), CD64 load, CD32 load, and MSR-A (load and the number of positive
clusters) in cAD and iAD groups. Signicant correlations are highlighted in bold. The
strength of correlations is indicated by the .
cAD iAD
Iba-1 load  =0.5 P=0.017 =0.3 P=0.340
Iba-1+ cells =0.3 P=0.165 =-0.1 P=0.750
CD68  =0.5 P=0.012 =0.3 P=0.450
CD64  =0.6 P=0.001 =0.3 P=0.417
CD32  =0.7 P<0.001 =0.1 P=0.770
MSR-A load  =0.4 P=0.036 =0.3 P=0.417
MSR-A+ clusters =0.1 P=0.801 =-0.1 P=0.852
4.3 Extraction of genetic material and quantitative real-
time polymerase chain reaction analysis (qRT-PCR)
The isolation of the total RNA yielded less than 100 ng/l in most samples with low
purity of the extracted RNA - the 260/280 ratio was 1.80 or less. Two samples were
identied that were taken from the most recent (at the time of the experiment) im-
munised cases (iAD6 and iAD9) and, therefore, were less likely to be aected by the
prolonged storage of the tissue in paran blocks. These samples had the highest yields
of the extracted RNA and cDNA (following reverse transcription stage). The cDNA
yields were 1500 ng/l (for iAD6) and 1200 ng/l (for iAD9) with the 260/280 ratios of
1.7-1.8 indicating low purity of cDNA, and the 260/230 ratios of 2.0-2.3 indicating high
purity of nucleic acid, i.e. absence of other contaminants that may absorb in this range.
No dierence was found between the RNA extraction from the tissue cut specically
for the analysis or scraped from a glass slide. Additional DNAse digestion step did not
improve the quality of the extracted RNA.
PCR was performed on the two samples with the highest cDNA yields (iAD6 and
iAD9) for 12 housekeeping genes. No consistent results were obtained for any of the
genes tested. Although low cycle threshold values were obtained for most genes (<25),
melting curve analysis produced either no specic peaks or a peak in both the samples
and a negative control suggesting presence of non-specic double-stranded DNA. The
results were similar for both non-intron-spanning genes (18sRNA, ACTB, SF3A1, B2M,Chapter 4. Results 153
EIF4A2, and YWHA2) and intron-spanning genes (ATPB5, CYC1, GAPDH, SDHA,
TOP1, UBC) indicating that the extracted RNA (as well as any DNA present in the
sample) was highly fragmented. Low specic gene abundance could also explain the poor
results. However, some of the genes (e.g. the 18s ribosomal RNA) are very abundant
in the brain and would be expected to show a clear specic peak. The protocol used,
therefore, was not suitable for obtaining accurate information on cytokine expression
in the cohorts of the control and the immunised AD. Considering the availability of
FFPE tissue only, an extraction method that produced higher RNA content and purity
yields, as well as the use of probe-specic primers for the reverse transcription stage
could possibly improve the results. Successful qRT-PCR analysis of FFPE brain tumor
samples has been reported (Hunter et al., 2005; Kunz et al., 2006). Both studies in-
cluded prolonged proteinase K digestion stage either at higher temperature (60C for
16 hours (Hunter et al., 2005)), or at room temperature (overnight (Kunz et al., 2006)).
However, due to time-constrains and the complementary nature of the information on
cytokine expression that could be provided by a successful RT-PCR analysis in addition
to the immunohistochemical evidence of the microglial receptors in AD brain, no further
optimisation of the protocol was undertaken.Chapter 5
Discussion
The current project aimed to investigate the microglial state in human AD brain and the
relation of microglia to the AD pathology before and after A42 immunisation treatment.
The long-term clinical outcomes of the AN1792 immunised AD patients showed that the
removal of A, even when it was very extensive, was not enough to halt the cognitive
decline (Holmes et al., 2008). Microglial activation promoted by the immunotherapy was
proposed as one of the possible explanations for continued neurodegeneration (Holmes
et al., 2008). Therefore, in the Study 1 two most frequently utilised markers of microglial
activation - CD68 and HLA-DR, and the marker of perivascular macrophages (CD163)
were chosen to assess the activation level of parenchymal and vascular cells of the immune
system in AD and in response to the immunotherapy. A more detailed investigation of
microglial receptors involved in recognition and clearance of antigens (including A)
followed in Study 2 that involved a larger group of control and more immunised AD
cases. The relationship between microglia and A pathology was investigated in both
studies. Persistent tau pathology was suggested as another potential explanation for the
poor outcome of the A immunisation approach (Holmes et al., 2008). Therefore, the
relationship between microglia and phospho-tau pathology was also explored in Study
2.
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5.1 Study 1
5.1.1 The eect of immunisation on A42
The assessment of the A42 level in the cAD and iAD groups was performed in order to
investigate the relationship between microglia and A pathology. The cortical A42 load
in the nine immunised cases was signicantly lower compared to the eight non-immunised
AD cases. A wider range of values for the A42 load was apparent in the iAD group, with
some iAD cases having a load similar to the cAD group and two iAD cases (iAD7 and
iAD8) almost completely clear of A42, reecting the expected pathological response to
the immunisation. These ndings are in accordance with previously published data for
the A load assessed using a pan-A antibody, indicating a variable extent of plaque
clearance as a result of the immunisation (Nicoll et al., 2003, 2006; Holmes et al., 2008).
As for the pan-A level (Holmes et al., 2008), no signicant correlation between the
mean anti-A antibody titres and the cortical level of A42 at the post-mortem stage
was observed in this Study.
5.1.2 The eect of A42 immunisation on CD68 - the phagocytic func-
tion of microglia
The results of the CD68 immunostaining showed that the microglial phagocytic activity
was signicantly (although just) raised in the 9 iAD cases compared to the 8 cAD
controls in the brain areas aected by the AD pathology (the cerebral neocortex). The
area unaected by the AD pathology (the pons) remained unaltered by the immunisation
with respect to this microglial marker, suggesting that the eect of the treatment on
microglia was selective for areas of brain containing the immunotherapy target (A).
Consistent with this interpretation, the phagocytosis in the iAD group appeared more
specic and eective against A42 supported by the signicant correlation between the
CD68 load and the cortical A42 load. The relationship of microglial phagocytosis to
A was also reected by the observed clustering of the CD68 immunostaining around
the plaques in iAD cases. The approach of dividing the immunised cases into three
groups according to the proportional change in the A42 and CD68 load relative to the
control AD group further demonstrated that immunisation targeted the A plaques, at
least in part, through the phagocytic activity of microglia by triggering the target forChapter 5. Discussion 157
phagocytosis towards A. These ndings suggest that immunisation had a stimulating
eect on the phagocytic function of microglia against A.
Phagocytosis is the rst response of innate immunity in a pathogenic context and
is tightly controlled to minimise the damage to the surrounding healthy tissue. This
control is particularly strong in the brain, where microglia are the main representatives
of the innate immunity (Neumann et al., 2009). The lower level of microglial phagocytic
activity in the iAD cases with no plaques (iAD7 and iAD8 - Figure 4.15) suggested a
downregulation of phagocytosis once plaques have been cleared. On the other hand, a
two to threefold increase in the phagocytic level in iAD cases with active plaque removal
relative to cAD group may pose a risk of a strong inammatory reaction. One of the
iAD cases showed signs of meningoencephalitis at the post-mortem examination (Nicoll
et al., 2003), consistent with the identication of this side eect observed in a subset of
patients from the Phase II clinical trial (Orgogozo et al., 2003). However, this case did
not demonstrate any outstanding neuropathological features in the assessment of the
microglial markers compared to the rest of the iAD group.
The assessment of microglial phagocytic activity separately in the grey and the white
matter in this Study revealed a relationship that may play an important role in AD.
In the control AD group, but not in the immunised cases, a correlation was observed
between the CD68 load in the grey and the white matter. The uniform phagocytosis
in AD brain suggests a common target for phagocytosis. Debris of dying or damaged
neurons due to synaptic degeneration would be expected in both, the grey and the white
matter, and could present such a target. Although not all of the axons found in the
white matter necessarily come from the grey matter next to it, at least the beginnings of
the axons are likely to be found close to the neuronal bodies. Therefore the more neu-
rodegeneration and associated phagocytic activity there is in the grey matter, the more
white matter axonal debris and related phagocytosis can be expected. Immunisation
against A42 seemed to break this relationship, suggesting an introduction of another
target for phagocytosis. The observed correlation between the CD68 level in the grey
matter and the A42 load within the iAD group, and the lack of such correlation in the
control AD group indicated the specicity of the signal sent by the immunisation against
A42. The phagocytic activity in the area free from the AD pathology, the pons, did
not dier between the two AD groups. Such observation would suggest a spatial eect
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with AD pathology. However, a correlation between the level of CD68 in the pons and
the level of A42 in the cortex of AD-aected areas was noted within the iAD group.
This eect of immunisation even on microglia distant from the site of the A pathology
and, in fact, being dependent on the extent of the A pathology in the cortex, suggests
non-discriminatory nature of the immunotherapy on all microglia within the brain. In
vivo imaging study in AD patients also reported microglial activation signal in areas not
aected by the brillar amyloid (cerebellum), as well as no direct correlation between
the microglial and the amyloid signals, suggesting that factors other than A may ac-
tivate microglia in AD (Edison et al., 2008). Although immunisation did not aect the
overall level of microglial CD68 in the pons, it seemed to relate it to the extent of the
A pathology in the aected areas.
Lack of correlation between the CD68 load in the white matter and the A42 load in
the adjacent cortex (the grey matter) in either of the AD groups suggests that phagocy-
tosis in the white matter may not be necessarily related to A, and that immunisation
did not have an eect on the white matter. In primates (rhesus monkeys) it has been
shown that microglial activation in the white matter increases with age, suggesting a
role for microglia in the general pathogenesis of normal brain aging (Sloane et al., 1999).
In aged human brain incidental white matter lesions are a common feature. Elevated
CD68 expression has been reported in these lesions along with numerous markers of hy-
poxia suggesting failure of normal adaptive mechanisms (Fernando et al., 2006). It has
been reported that immunisation leads to solubilisation of the brillar plaques into var-
ious soluble A species (Kokjohn and Roher, 2009). Although reduction in the plaque
level was observed in the immunised patients, recent studies of the AN1792 immunised
patients, showed that total brain A levels were not decreased. In fact, an increase
of amyloid species in the white matter compared to non-immunised AD patients was
reported (Kokjohn and Roher, 2009). It has been proposed that solubilised amyloid
peptides may no longer be restricted to the grey matter and can diuse into the white
matter too (Patton et al., 2006). However, microglial activity in the white matter and
the possible diusion rates of soluble A species within the brain are not well under-
stood. No correlation between the phagocytic activity of microglia in the white matter
and the cortical A42 levels was observed in either of the AD groups. The measurement
of the total levels of dierent A species in the grey and white matter of cAD and iAD
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Overall, the results from the CD68 immunostaining in Study 1 suggested that the
immunisation increased the phagocytic activity of microglia and that at least a subset
of microglial population in iAD was directed specically against A.
5.1.3 The eect of A42 immunisation on microglial HLA-DR
The assessment of HLA-DR showed no signicant immunisation-related changes, neither
in the areas aected by the AD pathology nor in the pons. HLA-DR is a cell surface
protein, the role of which in the periphery is to initiate the immune response by present-
ing antigens to T cells. Although its function in the central nervous system, where there
are few T cells, is unclear, it has been used extensively to identify microglial activation.
Microglia constitutively express HLA-DR (Gehrmann et al., 1993) and with ageing this
expression seems to increase (Overmyer et al., 1999; DiPatre and Gelman, 1997; Streit
and Sparks, 1997) . In AD brain, HLA-DR clustering around amyloid plaques has been
reported as opposed to a uniform distribution throughout grey and white matter in non-
AD cases (Perlmutter et al., 1992). In a transgenic mouse model of AD (Tg2576 + PS1)
MHC II expression was not observed until the full development of the A pathology
(Gordon et al., 2002). Immunotherapy in PDAPP transgenic mice has described MHC
II expression associated with reduction of the plaque burden (Schenk et al., 1999); how-
ever, the level and distribution of MHC II were not reported in that study. A degree of
clustering around the A plaques was noticed in the cAD cases, supporting previous ob-
servations (Perlmutter et al., 1992). In a double transgenic mouse model of AD (Tg2576
+ PS1), in which MHC II increases with age and A accumulation, the authors did not
nd any correlation between the amount of A and MHCII-positive cells (Gordon et al.,
2002), consistent with the ndings from the current project. Despite the absence of
correlation between the A42 load and the HLA-DR expression, there was a clear histo-
logical modication of HLA-DR expression with an increase of clustering around plaques
in the iAD cases, implying a redistribution of HLA-DR-expressing microglia rather than
a quantitative change in overall HLA-DR expression. A link between the duration of
the disease and the increase in HLA-DR was suggested by some AD studies as well as
signicant correlation between HLA-DR and the tau burden in AD patients (Overmyer
et al., 1999; DiPatre and Gelman, 1997). However, no relationship was found in iAD
cases between microglial markers (CD68 or HLA-DR) and the duration of dementia or
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Finally, observations of colocalisation of HLA-DR and CD68 by confocal microscopy
suggest a degree of overlap between the two microglial markers in iAD that is not
present in cAD cases. This implies that CD68 and HLA-DR proteins identify dierent,
but overlapping, subsets of microglia. This is consistent with the data suggesting that
microglia exist in dierent phenotypic and functional states (Perry et al., 2007, 2010;
Ransoho and Perry, 2009). Immunisation seems to induce a selective eect on certain
subsets of microglia, upregulating phagocytosis specically targeted at A plaques.
5.1.4 The eect of A42 immunotherapy on the perivascular macrophage
population
CD163 immunostaining was performed for the following reasons: to assess the level
of the perivascular macrophage (PVM) population in immunised vs control AD cases,
and to investigate whether this scavenger receptor was also expressed by parenchymal
microglia in AD.
The immunostaining was localised to blood vessels only, and no parenchymal CD163
expression was found in either control or immunised AD cases. CD163 is identied as
a PVM-specic haemoglobin-haptoglobin scavenger receptor, involved in signal trans-
duction pathway through production of cytokines (Fabriek et al., 2005). The current
nding is, therefore, in accordance with the reported specicity of the CD163 marker.
In the periphery, increase in the expression of CD163 occurs following an acute
inammatory reaction and during wound healing (Zwadlo et al., 1987). In the CNS,
PVMs are strategically positioned at the interface between the brain and the periphery.
They have been shown to interact with T lymphocytes, and to recognise, process and
present antigens to T cells (Fabriek et al., 2005; Galea et al., 2008). Their phagocytic
function has also been demonstrated (Galea et al., 2005).
One of the suggested routes for the clearance of A in AD brain is through the
perivascular drainage (Weller et al., 1998; Preston et al., 2003; Carare et al., 2008;
Weller et al., 2008). Increased A42 burden in the grey matter blood vessels of the
immunised AD cases has been reported suggesting the involvement of this route in the
immunisation-induced A clearance (Boche et al., 2008). A large dierence between the
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was observed, with signicantly higher expression in the grey matter. This observation
suggests that PVM population is higher in the A-loaded vessels. However, no dier-
ences in the level of the CD163 expression between the immunised and the control AD
groups in the grey as well as in the white matter was found, indicating that the A42
immunisation had no eect on the level of this cell population in vasculature of the
brain. Positive correlations observed in the PVM level between the grey and the white
matter, and lack of correlation between the cortical A42 level and the level of CD163
in the immunised and control AD cases further suggest that elimination of A from the
parenchyma of immunised cases (regardless of the route) does not seem to involve the
PVM population.
With respect to microglia, CD163 expression by these cells has been reported in
certain pathogen-induced inammatory disorders, such as HIV-associated encephalitis
(Roberts et al., 2004). The role of these microglia in such disorders is not clear. The
selective location of CD163 in the blood vessels in the current study groups indicates
that the integrity of the blood-brain barrier was not compromised in most of the AD
cases, and even in those with higher incidence of microhaemorrhages (cases 1, 6 and
9) (Boche et al., 2008) no inux of perivascular macrophages into the parenchyma or
expression of CD163 by microglia was observed.
Overall, the results from this study demonstrate that immunisation had a specic
anti-A42 eect only on a selective population of the CNS macrophage-like cells - phago-
cytic microglia.
5.1.5 Comments on the results of the CD68 and HLA-DR colocalisa-
tion experiment
A preliminary visual assessment of colocalisation images suggested a higher degree and
incidence of overlap between the markers of two types of the microglial activity in the
immunised compared to the control AD cases. However, the chosen quantitative ap-
proach to this question failed to support this initial observation. The overall strikingly
low degree of colocalisation (tM values far less than 1) even in the images that were
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limitations of the technique and of the chosen approaches to image capture and quan-
tication. Low number of cases assessed and brain area covered also contributed to the
lack of any conclusive observations in this respect.
The higher degree of variation in the overlap coecients within the immunised com-
pared to the control AD group is the only indicator of any apparent A42 immunisation-
induced eect. Among the immunised AD cases, the highest degree of overlap between
the two markers is observed in cases that also showed relatively high levels of CD68
and/or HLA-DR expression, and were within median range of A42 load (as assessed
separately using the DAB immunostaining and light microscopy) - cases 1, 2, 6 and 10.
This is particularly relevant to the HLA-DR marker. Although with limited condence,
it can be speculated that immunisation-induced individual (rather than group) increase
in antigen presentation activity of microglia appears to be in the same brain areas where
phagocytic activity (possibly A-specic phagocytosis) is observed. However, the low
number of cases does not allow to defend this point. The lack of correlation between the
data obtained on CD68 and HLA-DR individually (by light microscopy) also disregards
this speculation (data not shown).
Due to the time-demanding nature of the techniques used in the colocalisation ex-
periment, no further investigations into this question were carried out.
5.2 Study 2
The aims of this Study included immunophenotyping of microglia in human AD brain
with respect to the receptors involved in direct and antibody-mediated ligand recognition
and clearance, investigating the relation of these receptors to A and tau pathology, and
the eect of active A42 immunisation on these receptors. This work follows on from the
Study 1 attempting to provide a detailed microglial prole in AD and following A42
immunisation. Following the Study 1, it was recognised that while the number of the
immunised AD cases was limited, a larger cohort of control AD cases (at least double
that of the immunised) well-matched to the immunised cases for factors such as age,
gender, ApoE genotype, duration of dementia and Braak stage was necessary in order
to address the proposed hypothesis and to obtain statistically stronger data. Hence, a
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(Bristol). Another issue addressed in Study 2 was the identication of pitfalls of the
quantication method used in Study 1 and the development of a more consistent method
described in Section 3.3.1.2. The assessment of the protein load of each microglial marker
allowed comparing the two AD groups to reveal the eect of the immunisation treatment
on microglia. The investigation into the relationships between microglial markers and
the pathology features of the AD (A and phospho-tau), as well as the IgG and the
complement element C1q within cAD and iAD groups oered further insights into the
eect of the immunisation treatment relative to the pathology and microglia, as well
as provided valuable and detailed immunohistochemical account of microglia in a fully
established AD pathology.
5.2.1 Eect of immunisation on microglial receptors load, cell number
and distribution
The quantitative analysis of the microglial MSR-A, CD64, CD32, and CD68 revealed
signicantly lower levels of these markers in immunised AD cases, suggesting downregu-
lation of microglial activity after immunisation. These results were somewhat surprising
as the ndings from the Study 1 suggested either upregulation or no change in microglial
activity in fewer iAD cases compared to a smaller cAD group. If microglia were to be
involved in the observed reduced A load and some features of phospho-tau pathol-
ogy following the immunisation treatment, it was expected that their activity would
be upregulated. Yet, the ndings from the Study 2 point out towards overall reduced
microglial activity at least by the time of post-mortem examination. The results on each
marker are discussed below followed by an attempt to draw an overall microglial prole.
It is worth noting that human data on the detailed microglial prole in chronic neu-
rodegeneration and in response to stimulation of the immune system are scarce. In a rat
model, induction of an immune response through intrahippocampal injection of A1-
42 elevated levels of Iba-1 (Ryu et al., 2009). Transient increase in microglial markers
including Fc receptor II and scavenger receptor A (SR-A, the murine homologue of
human MSR-A) without any associated neuronal loss was observed in wild-type mice
after a single intrahippocampal injection of bacterial cell wall component lipopolysac-
charide (LPS) (Herber et al., 2006). Intracranial injection of LPS in the hAPP mice
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other receptors associated with reduced A burden (Herber et al., 2007). Similarly,
intracerebral LPS injection in the APP+PS1 mice increased expression of microglial
markers (including major histocompatibility complex II, Iba-1, and CD68), and reduced
hippocampal A (Malm et al., 2008). A immunisation (active or passive) in animal
models caused a reduction in A burden, associated with microglial activity (Schenk
et al., 1999; Wilcock et al., 2001, 2004). Although a detailed microglial prole was not
provided in these studies, Wilcock and colleagues reported that passive immunisation in
hAPPSw mice (a model of amyloid deposition without tau pathology or neuronal loss)
and active immunisation in hAPPSw/NOS2-/- mice (a model of amyloid deposition with
progression to tau pathology and neuronal loss) shifted the expression of inammatory
genes towards an overall classical pro-inammatory activation prole characterised by
elevated expression of TNF, IL1, and IL6 (Wilcock et al., 2011). Prior to immu-
nisation, hAPPSw mice displayed an alternative activation and acquired deactivation
proles, described as anti-inammatory and immunosuppressive, associated with res-
olution of inammation, extracellular matrix remodelling, and clearance of apoptotic
cells. The hAPPSw/NOS2-/- mice displayed a mix of all three immune proles. In sum-
mary, animal studies suggest that induction of an immune response in the brain leads to
acutely elevated levels of microglial receptors and alterations in an inammatory gene
prole towards classical activation associated with reduced brain A levels.
Fc receptors I and II - antibody-dependent phagocytosis
The Fc receptors I and II are involved in the antibody- and immune complex-mediated
activity of microglia, and might be expected to be involved in the CNS innate immune
response to immunotherapy. However, an overall 56% lower and 66% lower load of Fc
RI and Fc RII respectively was observed in the iAD compared to cAD brain. Fc
RI, II, and III immunoreactivity has been reported in senile plaques and on ramied
microglia throughout the cortex and white matter of normal and AD brains suggesting
that Fc receptors are involved in immune-related processes in normal and diseased
brain (Peress et al., 1993). These ndings are in accordance with the observed even
distribution of Fc receptors within the cAD brain. Although the load was lower in
iAD, the distribution was similar to cAD, i.e. no particular clustering around plaques
was noted. The perivascular immunostaining for Fc RII suggested presence of immune
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A and phospho-tau, and present a question for future research into the involvement of
Fc receptors in the AD pathology.
Macrophage scavenger receptor A - antibody-independent phagocytosis
The cell surface scavenger receptor MSR-A is involved in activation of microglia for
uptake of extracellular matter, including amyloid. In the immunised AD group, an 89%
lower MSR-A load and a 68% lower number of MSR-A-positive clusters were observed,
consistent with the degree of plaque removal seen in these cases.
Studies of primary cultures of mixed glial cells from newborn mice suggest that SR-
A, as well as Fc receptors, can be involved in the uptake of brillar A fragments
(non-opsonised or opsonised by IgG or complement protein C1q) (Brazil et al., 2000).
Other in vitro studies using murine microglial cells also showed that SR-A was the rst
receptor to engage in phagocytosis of A brils (El Khoury et al., 1996; Paresce et al.,
1996) resulting in immobilisation of microglia and release of neurotoxic cytokines and
reactive oxygen species (ROS) (El Khoury et al., 1996; Husemann et al., 2002). Similar
observations were made on cultured human microglia from AD and non-demented cases
(Lue and Walker, 2002). The strong clustering pattern of MSR-A-positive microglia
observed in cAD and iAD cases is in accordance with other studies that looked at
expression of macrophage scavenger receptors in Alzheimer's disease and non-demented
brains (Christie et al., 1996; Honda et al., 1998) suggesting that these clusters are related
to A plaques. Clustering and colocalisation of microglial markers HLA-DR and CD68
around A plaques were also evident from Study 1. No obvious A-related clustering
of cells expressing Fc receptors was noted, in keeping with observations of these cells
being distributed throughout the cortex and white matter of normal and Alzheimer's
disease brains by Peress et al. (Peress et al., 1993). The distinct distribution of MSR-A
immunostaining may be explained by the selective immobilisation of the MSR-A-positive
cells, when they encounter plaques, as mentioned above.
CD68 - the marker of phagocytosis
CD68 marker of microglial lysosomes is an important indicator of phagocytosis. The
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group. In order to conrm the immunisation-induced change on microglia in a larger
group of immunised AD cases compared to a larger and better matched cohort of non-
immunised AD controls, CD68 was also included in Study 2. Similar to MSR-A and
Fc receptors, this marker of intracellular microglial lysosomes was 60% lower in the
immunised group. The discrepancy from the results of the Study 1 could be the conse-
quence of two important dierences between Studies 1 and 2. Firstly, Study 2 used a
dierent group of control AD cases. The 28 cAD cases used in Study 2 were matched to
the iAD group for gender, age, Braak stage, duration of dementia and ApoE genotype,
and displayed large individual variability of CD68 immunostaining as demonstrated in
a scatter plot and a box and whiskers plot in Figure 4.52. The cAD cohort in Study
1 consisted of 8 cases, and therefore was less representative of Alzheimer's disease than
the 28-case cohort. Secondly, the quantication methods used for the analysis of the
immunostaining in the two studies were dierent. As outlined in Chapter 3, the method
used in Study 2 was more consistent as image processing stages prone to artifacts (sub-
traction of the background and enhancement of the contrast) were identied in Method
1 and then improved or omitted in Method 2. Section 3.3.1.2 particularly describes
how the Enhance Contrast function may lead to over-estimation of immunopositive area
in images that contain fewer objects of interest, and under-estimation of the results of
images that contain more objects of interest due to the pixel saturation quota. When
coupled with the Subtract Background function of ImageJ using rolling-ball algorithm,
the results may be aected by highly inconsistent errors. In order to validate the CD68
results from Study 1, the two methods were compared directly by re-analysing images
of the CD68 immunostaining (grey matter only) from Study 1 using Method 2. The
results of this analysis are presented in Appendix C, and show that using Method 2,
no evidence was found for the CD68 load to be dierent between the 9-case iAD and
the 8-case cAD groups. This nding indicates that the sample size in Study 1 was not
sucient to detect the dierence observed in Study 2 highlighting the importance of
using well-matched and large cohorts in human studies. The re-analysis of the Study 1
images using Method 2 also revealed that the median value of the CD68 load for iAD
group obtained from Study 1 matched that from Study 2 (0.02%), demonstrating that,
despite covering smaller cortex area, zigzag image sampling at magnication x20 (Study
2, 30 images per case, covering 20 mm2) was comparable to that at magnication x10
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Iba-1 - the marker of microglia independent of their activation state
While all of the above mentioned markers of microglial activation were lower in the
immunised than in the non-immunised cases, no evidence for the dierence in the Iba-1
load or the number of Iba-1-positive cells between the immunised and control Alzheimer's
disease groups was observed. Iba-1 antibody is reported to label all microglia, whether
resting or activated (Streit et al., 2009). In accordance with this, a higher Iba-1 load
than that of the other microglial markers was expected, but not observed in Study
2. Simard and colleagues showed that blood-derived monocytes can be recruited into
the brain of transgenic mice and dierentiate into microglia-like cells, which are more
ecient at clearing A plaques (Simard et al., 2006). The Iba-1 observations from the
Study 2 oered no evidence for the immunisation-induced recruitment of monocytes
from the periphery or in situ proliferation of microglia, and suggested no change in total
microglial number or calcium-binding protein expression after the immunisation.
Microglial prole based on the protein load of all microglial markers
Together, the data on the protein load of microglial receptors involved in antigen recogni-
tion and uptake suggested that, in the long term, immunotherapy had a downregulating
eect on the expression of these receptors, while keeping the overall number of microglia
unaltered. These ndings seem counter to the observations in animal models. It may be
relevant that animal models often simulate only particular aspects of a disease and that
the protocols for induction of an immune response in the animal studies diered from
those in the AN1792 human clinical trial. Active immunisation in elderly humans is also
likely to produce a variable immune response, and indeed large variation in antibody
response level was evident in the AN1792 cohort as shown in Table 3.1. Importantly, the
time-course also diered: in the experimental models the response was typically studied
after a matter of days, whereas the current study investigated the brains of Alzheimer's
disease patients almost all of whom were studied several years following immunisation.
The primary function of microglia is surveillance of the brain and migration to a site of
damage or infection. In Alzheimer's disease, microglia may react to abnormally accu-
mulated proteins (A or tau) and/or neuronal damage by expressing specic receptors
and migrating to the relevant site, e.g. A plaques, neurobrillary tangles or dystrophic
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their functional phenotypes has been demonstrated in vitro and in vivo (Stout et al.,
2005; Lunnon et al., 2011). The variability in the distribution of microglial markers
observed in this study suggested that microglia may be present in dierent functional
states in the same brain in Alzheimer's disease, for example adjacent to and remote from
plaques, with further alterations following A immunisation.
Correlations between all microglial markers
The observed multiple correlations between the microglial markers tested in Study 2
suggest a regulated communication between microglia inuenced by the expression of
multiple receptors involved in antigen recognition and clearance. Immunisation seems to
alter these relationships, although lack of correlations may be due to the lower expression
of most of the receptors following the immunisation treatment. The observed correlations
encourage further questions and investigations into inuence of the expression of one
microglial receptor onto another, as well as the order and cascade of events that occur
in the AD pathogenesis with respect to microglia.
5.2.2 Microglial markers and pathological features of Alzheimer's dis-
ease, A42 and tau
A42 and phospho-tau pathology in control and immunised AD
As in Study 1, the A42 load was quantied in the cAD and iAD groups in order
to investigate microglial relation to the AD pathology. In addition, phospho-tau load
and individual features of the pathology (NFTs and DNs) were also quantied as equally
important components of the AD pathology. Consistent with observations in Study 1 and
previous reports, a signicantly lower A42 load in the 11 immunised Alzheimer's disease
cases compared to the 28 non-immunised Alzheimer's disease controls was observed
(Nicoll et al., 2003; Ferrer et al., 2004; Masliah et al., 2005; Nicoll et al., 2006; Boche
et al., 2010; Serrano-Pozo et al., 2010). Similarly, the total phospho-tau load was reduced
in the iAD compared to cAD group in accordance with previously reported ndings
using 10 iAD cases and a dierent quantication method for phospho-tau load (Boche
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report. Marked reduction in the tau-containing dystrophic neurite clusters associated
with plaques was observed, but no changes in the number of neurobrillary tangles.
In both cAD and iAD groups the number of NFTs correlated with the total phospho-
tau load suggesting that NFTs may be the main contributors towards the phospho-tau
load and an important indicator of the extent of phospho-tau related neuronal damage.
It also may oer some explanation to the lack of improvement in the cognition of the
immunised patients, as although immunisation reduced the number of the DN clusters (in
addition to the A42 load), the NFT pathology remained unchanged. This observation
has an important point for the future research into AD pathology. Although it has
been previously suggested that phospho-tau features other than NFT (e.g. neuopil
threads) may be the main contributors to the tau immunoreactivity in brain samples
from individuals with and without cognitive impairments (Mitchell et al., 2000), the
same group later demonstrated that in patients with cognitive impairment the extent
of NFT pathology, but not the neuropil pathology, signicantly correlated with episodic
memory scores (Mitchell et al., 2002).
In the iAD group, it was also noted that the number of dystrophic neurite clus-
ters correlated with the A42 load, suggesting a link between the remaining dystrophic
neurites and plaque cores following the immunisation. Consistent with the recognised
distinct plaque sub-types in AD brain (McKenzie et al., 1992), in addition to neuritic
plaques, cAD cases often had large diuse A formations that lacked dystrophic neu-
rites associated with more dense-core plaques. In iAD, diuse A plaques were absent
and the only A that was observed comprised remaining plaque cores and A granules,
suggesting, perhaps not surprisingly, that a dense neuritic plaque presents a more chal-
lenging object for immunisation and while plaque core remains, so do the associated
dystrophic neurites, revealing a correlation between the two features of the AD pathol-
ogy. As mainly the cores of plaques were left in iAD, the observed correlation was only
obvious in this cohort.
As a reection of the alteration in the pathology following immunisation, marked
changes in correlations between the microglial receptors load and A42 or phospho-tau
features were observed in the iAD group. While the observed down-regulation of the
microglia markers supported the hypothesis that the microglial level of activation and
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related to the associated reduction in the AD pathology had a more exploratory nature.
This part of the study aimed to explore the relationship of microglia with A and tau
pathology as well as IgG and complement. Therefore, the current ndings should be
regarded as a base for further detailed investigations into the role of individual microglial
receptors in the development of AD pathology and their potential involvement in a
mechanism of future disease-modifying treatments.
Correlations between A42 and microglial markers
With respect to A42, inverse correlations were observed with Iba-1 load and Fc recep-
tor II load in the non-immunised group only. Iba-1 is a calcium adapter protein expressed
constitutively by microglia in the brain, with increased expression upon microglial acti-
vation (Imai et al., 1996; Imai and Kohsaka, 2002). It has been proposed that the role
of Iba-1 in microglial function is related to its cytoskeletal reorganisation, membrane
ruing and actin cross-linking, necessary for phagocytosis (Ohsawa et al., 2000; Sasaki
et al., 2001; Kanazawa et al., 2002). The Fc receptors are also expressed by microglia
and perivascular macrophages being important players in phagocytosis, transport and
clearance of antibodies and immune complexes from the brain, and antibody-dependent
cell-mediated cytotoxicity (Ulvestad et al., 1994; Deane et al., 2009). Fc receptor-
mediated immune responses show marked cellular heterogeneity, and the direct eect
of an antibody or an immune complex on the eector cell response is not well under-
stood. It has been suggested that activation of Fc receptors leads to increased levels of
intracellular Ca2+ (Ravetch and Kinet, 1991), possibly indicating a link between Iba-1
and Fc receptors. Spontaneously generated anti-A autoantibodies were detected in
the plasma of AD patients but did not confer protection against the development of de-
mentia (Hyman et al., 2001). The ability of anti-A antibodies to cross the blood-brain
barrier has been reported in animal models (Bard et al., 2000; Deane et al., 2005). One
explanation for the observations of inverse correlations between A and the microglial
Iba-1 and Fc receptor II may be that in Alzheimer's disease, the expression of these
receptors is limiting the accumulation of amyloid. Equally, the inverse relationship could
reect a mechanism whereby A aggregation and, presumably, A immune complexes,
down-regulate microglia as a means of minimising neuronal damage in the context of a
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and these receptors. This may contribute to a change in microglial function that facili-
tates A clearance, as suggested by the correlation between MSR-A-positive clusters and
A42 load in immunised Alzheimer's disease cases. The relationship between microglia
and amyloid plaques remains unclear as even in animal studies, microglia were demon-
strated to migrate towards and maintain their dynamic activity around amyloid plaques,
although near-total ablation of microglia had no eect on the amyloid load within the
same model (Bolmont et al., 2008; Grathwohl et al., 2009). These conicting ndings in
animals and the observed relationships in the current human study indicate the need for
further studies to investigate the role of Iba-1 and Fc receptors in Alzheimer's disease
pathogenesis and relationship to amyloid accumulation.
Overall, these ndings suggest that immunisation changed microglial functional pro-
le with respect to A, resulting in a reduced A load whilst downregulating microglial
receptors involved in antibody and antigen recognition and clearance, perhaps as a
physiological response to minimise non-specic bystander damage. As cytokine gene
expression analysis using the tissue samples available to this project was unsuccessful,
it is currently unclear how these ndings relate to the detection of a higher level of the
pro-inammatory cytokine TNF in grey matter homogenates from immunised than
non-immunised Alzheimer's disease control brains (Maarouf et al., 2010).
Correlation between phospho-tau load and microglial markers
In the non-immunised Alzheimer's disease cases, phospho-tau load correlated with those
of all of the microglial markers assessed in this study. These ndings suggest that mi-
croglial activation observed in Alzheimer's disease may be related to the pathological
changes other than A. There is evidence for a connection between microglial activation
and tau pathology in Alzheimer's disease and other neurodegenerative diseases (DiPatre
and Gelman, 1997; Kitazawa et al., 2004). Chronic microglial activation resulting in the
release of cytokines (e.g. IL-1, IL-1 and TNF) and other molecules (e.g. quinolinic
acid) may cause tau hyperphosphorylation (Iqbal and Grundke-Iqbal, 2002; Li et al.,
2003). Conversely, microglial activity may be a response to the synaptic loss associated
with tau pathology (Cunningham et al., 2005; Iqbal and Grundke-Iqbal, 2002). Neu-
ropathological assessment of human brain samples has also suggested that aging-related
microglial senescence and loss of their neuroprotective function contribute to the spread172 Chapter 5. Discussion
of tau pathology and the onset of AD (Streit et al., 2009). No relation between the tau
pathology and microglial markers in immunised Alzheimer's disease group were noted,
in keeping with a change in the microglial prole after A42 immunisation.
5.2.3 IgG
The amount of IgG in the tissue sections was assessed in order to estimate the extent
of opsonisation of A plaques prior to and following immunisation. The immunohisto-
chemical analysis of IgG showed no signicant dierence in the total load of IgG within
the cortex. This is despite the evidence that anti-A antibodies persist for many years
in the blood of patients immunised with AN1972 (Holmes et al., 2008). It should be
noted that no dierentiation between host-generated antibodies of dierent specicities
(e.g. anti-A) that might be present in the brain was performed as the methodology
detected all IgG. It is possible that an increase in A-specic antibody level and immune
complex formation within the brain takes place in Alzheimer's disease brain immediately
following the treatment, as observed in animal studies using passive immunisation (Bard
et al., 2000). If so, the observed lower levels of Fc receptors I and II in immunised cases
by the time of autopsy suggest an eective use of these receptors in clearance of A,
followed by their down-regulation.
A correlation between the IgG load and the phospho-tau load within the non-
immunised but not the immunised Alzheimer's disease group was noted. A link be-
tween the changes in the brain-blood barrier permeability in Alzheimer's disease and
inux and localisation of IgG within neurons, leading to reorganisation of the neuronal
micro-tubule structures has been suggested (Bouras et al., 2005). Increased parenchy-
mal IgG was reported in a mouse model of chronic neurodegeneration (ME7) (Lunnon
et al., 2011). The data from the current study suggest that in the context of human
Alzheimer's disease pathology, the level of brain IgG may in part depend on the extent
of the tau pathology. This is further supported by the strong correlations between the
amount of IgG and the levels of all microglial receptors, and between these receptors
and the phospho-tau load, as discussed above. Immunisation against A42 seems to
change these relationships, suggesting possible alteration in the type of IgG present in
the brain following the treatment. The trends toward correlations between IgG load andChapter 5. Discussion 173
microglial MSR-A, Fc receptors I and II in immunised cases suggest a continued rela-
tionship after immunisation; the fact that these did not reach the statistical signicance
may simply be due to the smaller size of the immunised group.
5.2.4 C1q
Complement system forms a part of the innate immunity and inammation reaction
signalling for recruitment of immune cells to the site of a pathogen invasion, an injury
or stress. The complement cascade involves multiple stages and elements, starting with
C1 and ultimately leading to the formation of the membrane attack complex C5b-9 on
a surface of a pathogen. Classical, alternative, and lectin pathways of the complement
system are recognised. The classical cascade is initiated by antibody-antigen complexes
through activation of C1 component. As with other immune reactions, damaging as
well as protective properties of the complement engagement have been proposed to
play a role in AD pathogenesis. Recent identication of a complement-related gene
encoding complement receptor 1 (CR1) being related to the risk of development of AD
has further conrmed the importance of this mechanism (Kirszbaum et al., 1992). The
eect is suggested to be through a coding variant of CR1 that inuences C1q-mediated
A particles clearance (Keenan et al., 2012).
C1q is an opsonin that by itself can promote neuronal survival and growth and is
involved in the removal of apoptotic/necrotic debris (Benoit and Tenner, 2011; Fraser
et al., 2010; Bensa et al., 1983; Ogden et al., 2001; Pisalyaput and Tenner, 2008; Bowness
et al., 1994). However, although the precise mechanism is not clear, C1q has been
suggested to play a role in AD pathogenesis as microglia derived from AD subjects
secreted higher levels of C1q than microglia derived from non-demented controls (Lue
et al., 2001). While amyloid brils were shown to directly activate classical complement
pathway (Tacnet-Delorme et al., 2001), low concentrations of A were also shown to
partially block the oxidative stress caused to neurons by incubations with C1q (Luo
et al., 2003).
The distribution of C1q immunostaining in the immunised and control AD groups
was similar to IgG, perhaps not surprisingly as C1q recognises and binds IgG complexes
in a classical activation pathway. As further support to this observation, C1q load
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The observed C1q immunostaining was mainly localised on amyloid plaques and
neurons with only occasional positive microglia and astrocytes - in accordance with
other studies suggesting that in AD C1q is likely to be expressed by neurons (Veerhuis
et al., 2003; Tooyama et al., 2001; Head et al., 2001; Afagh et al., 1996; Zanjani et al.,
2005; Fonseca et al., 2004; Fischer et al., 1995; Fan and Tenner, 2004). Similarly, blood-
vessel-associated C1q has also been previously reported in both normal and AD brain
(Afagh et al., 1996). Afagh and colleagues reported that in AD microglia were associated
with C1q positive brillar amyloid plaques and neurons, but were not themselves C1q-
positive (Afagh et al., 1996). However, in vitro studies have shown that microglia derived
from AD and normal brain express C1q (Veerhuis et al., 1999).
Although no change was observed in the total C1q load between the control and im-
munised AD groups, the dierences in correlations between C1q and microglial markers,
and C1q and A/tau load support the role for C1q in AD pathogenesis and immunisation-
related changes. Consistent with the suggested ability of C1q to activate microglial cells
(Veerhuis et al., 2003), C1q load correlated with the load of all microglial markers in
cAD group only. The eect of the immunisation treatment in this respect is demon-
strated by the lack of any correlation or even trends between C1q load and microglial
markers in the iAD group. While immunisation did not alter the total level of C1q,
the relationship between C1q and microglia observed in cAD was no longer apparent in
iAD. This could indicate a benecial eect of immunisation as overall downregulation
of microglia was observed in iAD group. Relationships between C1q and total phospho-
tau load, and C1q and the number of NFTs were observed in cAD group, but not in
iAD group, supporting a view that C1q is related to the degeneration of neurons in
AD (Fonseca et al., 2004; D'Andrea, 2005). In iAD, again, these relationships were no
longer present. Instead, an invert relationship between A42 load and C1q was noted,
suggesting a dierent role for C1q after immunisation, perhaps related to the clearance
of A. The literature with respect to C1q and A relationship is somewhat confusing.
Increased uptake of C1q-coated brillar A particles by mouse microglia in vitro has
been reported (Brazil et al., 2000). However, another in vitro study using cell cultures
derived from a rat model of plaque accumulation demonstrated inhibiting eect of C1q
on A uptake (Webster et al., 2000). Overall, the observations from the cAD and iAD
cases indicate that C1q is likely to be a mediator in the microglia-A-tau network in
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5.3 Microglial prole in AD and following A42 immuni-
sation - the overall picture
The immunohistochemical proling of microglia undertaken by the current study showed
that in AD multiple microglial receptors are engaged, most of which are markedly re-
duced after the immunisation.
The observations of correlations between microglia and tau and between microglia
and A, but not between tau and A in non-immunised Alzheimer's disease cases sug-
gest that microglia play a pivotal role in Alzheimer's disease. Figure 5.1 attempts to
schematically summarise the main ndings of the project.
Figure 5.1: Schematic summary of the microglial receptor prole, IgG and C1q rel-
ative to the A and phospho-tau pathology in cAD (left) and iAD (right) based on
the results from the current project. The reduced or unchanged load of microglial re-
ceptors, IgG and C1q is represented by the reduced or equal number and/or reduced
size of the respective symbols in iAD compared to cAD. The observed correlations are
demonstrated by double-headed arrows. The + or - sign above the arrows indicates pos-
itive or inverse correlations respectively. NFT - neurobrillary tangles, DN - dystrophic
neurites.
The inverse correlations between A42 load and microglial Iba-1 (load and number
of cells) and FcRII suggest a presence of a negative feedback mechanism between
A and microglia in AD. The inability to clear the expanding A deposits may be
accompanied by a signal (e.g. through formation of immune complexes) to downregulate
these receptors in an attempt to reduce neuronal damage caused by microglial activation.
It is also possible that these two receptors have a regulatory function aiming to confer
(although unsuccessfully) a certain resistance against expansion of A pathology.
The observed correlations between microglial receptors and phospho-tau load are
of particular interest. On the one hand this may indicate that phospho-tau pathology176 Chapter 5. Discussion
activates microglia, supporting the role of tau in the pathogenesis of AD. However, al-
though following the immunisation some of the tau-features (e.g. dystrophic neurites)
are reduced along with A load, the larger features of the tau pathology (NFTs) re-
main unchanged. Yet, microglia no longer correlate with the phospho-tau load in iAD
group. Therefore, microglia, activated by A and/or neuronal and synaptic changes,
may exacerbate the pathology by initiating and promoting tau dysfunction leading to
the formation of NFTs and dystrophic neurites. The involvement of antibodies and
complement system as revealed by the correlations of IgG and C1q load not only with
microglia, but also with tau in cAD group, further supports this view.
The role of systemic infections in the pathogenesis of AD has also become more
prominent in recent years (Perry et al., 2007; Holmes et al., 2009). A accumulation
may trigger an initial microglial response, but with inammation being tightly controlled
particularly in the brain, microglia may become \primed" rather than fully activated
(Combrinck et al., 2002). Any further stimulus (such as peripheral infection), may trigger
a much stronger immune response, leading to the neuronal damage through breakdown
of tau mechanism. Exacerbated by the continued accumulation of A, this progressive
sequence of repeated events is likely to lead to the fully developed AD.
It should be noted that dierent population of microglial cells may be involved in the
suggested events as supported by the observed variation in the distribution of microglial
markers. Equally, microglia may be able to switch between dierent proles depending
on the surrounding stimuli.
Although the events immediately following the immunisation treatment cannot be
deduced from the type of material used in this study, the overall comparison of non-
immunised and immunised AD groups indicated that immunisation focused microglial
activity on the removal of A, and once removed the activation level remained be-
low that of non-immunised AD. The prominent correlations between phoshpo-tau load
and microglial markers in the cAD group were no longer observed in iAD. Despite the
dramatic reduction in the MSR-A load, the number of the MSR-A-positive clusters cor-
related with the A42 load in the iAD group. Interestingly, the same was observed
for another feature of the AD pathology aected by the immunisation, the dystrophic
neurites, as their number also correlated with the number of MSR-A-positive clusters,
making this receptor a valid candidate for linking A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To summarise, the A42 immunisation treatment resulted not only in the reduced
A load, but also reduced phospho-tau load and downregulation of microglial receptors
involved in antigen recognition and uptake without aecting the number of microglial
cells. Importantly, the current study also presents a detailed immunohistochemical pro-
ling of microglia in human AD brain alongside the assessment of changes in the main
hallmarks of the AD pathology (A and tau), producing valuable supporting evidence
for the role of microglia in the pathogenesis of AD and in the events that follow the
anti-A treatment.Chapter 6
Conclusions, general comments
and future directions
6.1 Conclusions
The current study has demonstrated immunohistochemically that active A42 immuni-
sation inuenced the expression of several microglial antigens in the human Alzheimer's
disease brain. Consistent with the proposed hypothesis implying that the treatment
would aect microglial level of activation and prole, MSR-A, CD68, Fc receptors I
and II were reduced, with no evidence of a change in microglial numbers or expres-
sion of Iba-1 and HLA-DR. The observed downregulation may be a consequence of the
treatment itself or secondary to the long-term treatment-induced changes in A and tau
pathology. The response to immunisation changes with time, and the immunoprole
of microglia in post-mortem tissue, analysed some years after the event, may well dif-
fer from that immediately following immunisation. However, it is noteworthy that A
plaques persisted in some immunised Alzheimer's disease cases after many years and that
circulating anti-A antibodies were still present at a late stage (Holmes et al., 2008).
The continued presence of antigen and antigen-specic antibody might be expected to
cause persisting high levels of microglial activation but this seems not to be the case.
The current ndings provide no evidence of a broad-spectrum long-term increase in mi-
croglial activation after immunotherapy despite the enhanced microglial phagocytosis of
plaque-associated A.
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The study also explored the relationship between microglia, A and phospho-tau.
The results indicate that in AD microglia may be linked to both A and tau, sometimes
via the same receptors. However, the nature of their relationship to phospho-tau and
A is complex and requires further detailed investigations addressing the eect of each
receptor. Following the immunisation, the microglial relations with A and tau change,
as a likely reection of the alterations in microglial prole and supported further by the
observed reduction in A and some of the phospho-tau pathology. These observations
highlight the complex nature of microglial reactions and the importance of attempting
to assess not just the presence but also the functional state of microglia.
Based on the results obtained from the current project, it is suggested that dierent
populations of microglia are likely to be present in the Alzheimer's disease brain: some
are predominantly located in and around plaques (e.g. MSR-A-positive microglia) and
therefore presumably responding in a specic way to plaque components, whereas oth-
ers are diusely distributed through the cortex, perhaps responding or contributing to
neuronal and/or synaptic damage. This suggests that the concept of specic phenotypes
of microglia, with dierent functions as dened in animal studies (Perry et al., 2010),
also applies to human neurodegenerative disease.
6.2 General comments about the study and the techniques
used
All available techniques relevant to the aims of the study were assessed and optimised on
the basis of the accuracy, reproducibility and type of relevant information that could be
obtained, as well as the available time-scale. The most appropriate techniques were se-
lected. However, all scientic methods have their limitations, and these should be taken
into account when interpreting the results. Limitations and optimisation approaches
relevant to each technique were noted in Chapter 3.
The following assumptions that have been applied should also be taken into account:
 Microglial markers chosen for this project, to the best of the author's knowledge
(based on antibody specication, literature and previous experience), represented
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 Individual variability of immunostaining between the cases for a particular marker
was due to the treatment(A42 immunisation)/no treatment condition only, and
not due to the dierences in post-mortem delay, xation time or technique error.
Another limitation of the study is the number of available subjects (immunised and
control). In an attempt to overcome this limitation, a collaboration with South West
Dementia Brain Bank, Bristol, was established and a dierent set of non-immunised
(control) AD tissue was obtained for Study 2. The number of control cases was more
than double that of the immunised cases to allow more accurate and representative
baseline for the comparison to the immunised group. Equally, to narrow down any
non-specic (i.e. not related to the immunisation treatment) variation between the two
groups, all other variables, such as sex, age, duration of dementia, ApoE genotype,
Braak stage, tissue xation time, were matched.
Finally, despite the listed limitations, it should be emphasised that this study pre-
sented a unique investigation into the eect of the A42 immunisation on the pathology
of AD, including the role of microglia and inammation, in the human brain. The re-
sults from this study demonstrate the complexity of the overall picture of the pathology
modications in human brain, which can be compared and applied to the animal mod-
els for future investigations into individual interactions between microglia and the AD
pathology features and for the development of AD treatments with more predictable
outcomes.
6.3 Future directions
Immunotherapy remains actively researched topic and the most promising treatment
approach against AD. However, there is still a lack of clear understanding of the exact
sequence of events leading to AD that hinders the breakthrough to combat the dis-
ease. This is reected by the recent disappointing news of the halt of anti-A passive
immunisation Phase III clinical trial of Bapineuzumab IV, which did not show clini-
cal improvements in AD patients (Alzheimer's Research Forum News, 8 August 2012,
www.alzforum.org). The current movement towards early identication of pre-clinical
AD patients and introducing treatments at asymptomatic stages of the disease may
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but the approach needs to be systematic, detailed and taking into account A, tau, and
all the components of the immune system including microglia, astrocytes, cytokines,
complement system and the involvement of antibodies and T cells. Recent report of an-
tibody replacement approach of intravenous immunoglobulin (IVIg) therapy (Gammard,
Baxter) halting the progression of cognitive decline in a small cohort of AD patients (24
participants), once again support the involvement of immune system in the AD patho-
genesis (Shayan et al., 2012). Identication of dierent types of antibodies present in
the AD brain prior to and following a treatment would provide useful information in
this respect. The ability of microglia to co-express dierent receptors in AD should also
be explored by multiple labeling and confocal microscopy. Further insights could also
be gained from detailed investigations into the eect of each microglial receptor on the
neuronal and synaptic integrity.Appendix A
Publications
Journal articles published during the course of this project are listed below.
First-author publications
E. Zotova, J. A. R. Nicoll, R. Kalaria, C. Holmes, and D. Boche Inammation in
Alzheimer's disease: relevance to pathogenesis and therapy Alzheimer's Research and
Therapy, 2010 January 22; 2(1):1.
E. Zotova, C. Holmes, D. Johnston, J. W. Neal, J. A. R. Nicoll, and D. Boche Microglial
alterations in human Alzheimer's disease following A42 immunization Neuropathology
and Applied Neurobiology, 2011 August; 37(5):513-524. This publication was awarded
the 2011 Jean Corsan Prize by the Alzheimer's Research UK.
E. Zotova, V. Bharambe, C. Holmes, S. Harris, J. W. Neal, S. Love, J. A. R. Nicoll,
and D. Boche Microglial prole in human Alzheimer's disease following active A42
immunisation Acta Neuropathologica (in preparation)
Other publications from the A42 immunisation study
C. Holmes, D. Boche, D, Wilkinson, G. Yadegarfar, V. Hopkins, A. Bayer, R. W. Jones,
R. Bullock, S. Love, J. W. Neal, E. Zotova and J. A. Nicoll Long-term eects of A42 im-
munisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase
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I trial. Lancet, 2008 July 19; 372(9634):216-223.
D. Boche, E. Zotova, R.O.Weller, S. Love, J.W. Neal, R. M. Pickering, D.Wilkinson,
C. Holmes and J. A. R. Nicoll Consequence of A immunization on the vasculature of
human Alzheimer's disease brain. Brain, 2008 December; 131(12):3299-3310.
Additional studies
C. Holmes, C. Cunningham, E. Zotova, J. Woolford, C. Dean, S. Kerr, D. Culliford,
and V.H. Perry Systemic Inammation And Disease Progression In Alzheimers Disease
Neurology, 2009 September 8; 73:768-774.
C. Holmes, C. Cunningham, E. Zotova, D. Culliford, and V.H. Perry Proinamma-
tory cytokines, sickness behaviour, and Alzheimer's disease Neurology, 2011 July 19;
77(3):212-218
Conferences and meetings
Some of the results obtained during the course of this project have been presented by
the author (unless otherwise stated) at the following meetings and conferences:
 British Neuropathological Society meeting (London), 11-13 January 2012 (oral
presentation)
 Alzheimer's Association International Conference (Paris, France), 16-21 July 2011
(oral presentation)
 University of Southampton School of Medicine Postgraduate Conference, June
2011 (oral presentation)
 Jean Corsan award presentation at the 12th Annual Network Conference of Alzheimer's
Research UK (formerly Alzheimer's Research Trust)(Leeds), 15-17 March 2011
(oral presentation)
 10th International Congress of Neuroimmunology (Sitges, Spain), 26-30 October
2010 (poster presentation)Appendix A. Publications 185
 University of Southampton School of Medicine Postgraduate Conference, June
2010 (oral presentation)
 11th Annual Network Conference of Alzheimer's Research Trust (Southampton),
18-19 March 2010 (oral presentation)
 University of Southampton School of Medicine Postgraduate Conference, June
2009 (poster presentation)
 10th Annual Network Conference of Alzheimer's Research Trust (London), 19-20
March 2009 (poster presentation)
 9th International Congress of Neuroimmunology, 26-30 October 2008, Texas (oral
presentation by Dr. D. Boche)
 Young Neuroscientists' Day (Cardi), October 2008 (oral presentation)
 Alzheimer's Association International Conference on Alzheimer's Disease 2008,
26-31 July, Chicago (oral presentation by Dr. D. Boche)
 University of Southampton School of Medicine Postgraduate Conference, June
2008 (poster presentation - certicate of commendation)
 9th Annual Network Conference of Alzheimer's Research Trust (Bristol), 2008
(poster presentation)
 Young Neuroscientists' Day (Bristol), October 2007 (poster presentation)
The author also received the \Excellence with Impact" Early Career Researcher prize
from the Southampton Neuroscience Group (SoNG) for the research on \Following up
a clinical trial testing immunisation with A42 against Alzheimer's disease".Appendix B
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Table B.1: Primary antibodies that were tried but not included in the nal immuno-
histochemistry analysis in Study 2
Name/Antigen Proposed function
CD36, macrophage scavenger
receptor B
Involved in amyloid-related pro-inammatory sig-
nalling pathway through microglial activation (Coraci
et al., 2002; El Khoury et al., 2003; Moore et al., 2002;
Stewart et al., 2010).
Toll-like receptor 4 (TLR-4) Receptor primarily involved in bacterial recognition,
also has suggested function in A clearance and in-
ammation (Stewart et al., 2010).
CD14 Savenger receptor, co-receptor to TLR-4, acts as op-
sonising receptor, promoting phagocytosis, has been
suggested to contribute to A response and promote
inammation in AD (Fassbender et al., 2004).
CD11c, complement receptor
4
Commonly, a marker of dendritic-like cells, involved
in uptake of complement-coated particles. CD11c ex-
pression by microglia has been suggested to promote
eective antigen-presentation, A phagocytosis and
resistance to AD (Butovsky et al., 2006).
CD16, Fc RIII Low anity receptor for IgG, involved in antibody-
dependent responses.
CD11b, complement receptor
3
Downstream product of classic complement activation,
implicated in adhesive interactions of monocytes and
mediating uptake of complement-coated particles.
CD40 Amplier of inammatory responses, CD40-CD40L
complex in AD is linked to inammation prole (Buch-
have et al., 2009; Giunta et al., 2010; Volmar et al.,
2009).
CD200R Receptor for CD200. CD200-CD200R interaction is
linked to anti-inammatory prole and immune tol-
erance, and may be decient in AD (Walker et al.,
2009).Appendix C
Results of the image analysis of
CD68 immunostaining from
Study 1 using Method 2
The images of CD68 immunostaining in grey matter taken during Study 1 (Section
3.3.1.1) of 9 iAD cases (No. 1-4 and 6-10, Table 3.1) and 8 cAD cases (Table 3.2) were
re-analysed using Method 2 described in Section 3.3.1.2 in order to directly compare
the two image analysis methods. The maximum threshold value was set to 200, while
the minimum threshold value was 0. The results showed no evidence that the CD68
load was dierent between the cAD (0.03%) and iAD (0.02%) groups (Mann-Whitney
P=0.700 , Figure C.1).
Figure C.1: Scatter plots (left) and box and whiskers plots (right) of the CD68 load
in the cortex of 8 non-immunised AD cases (cAD) and 9 immunised AD cases (iAD)
from Study 1 summarising the results of image analysis using Method 2. No evidence
for the dierence in CD68 load between the iAD group (median value 0.02%) and cAD
group (median value 0.03%) was observed (Mann-Whitney P=0.700).
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